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Abstract
Cancer is a highly prevalent disease that places a significant economic burden upon soci-
ety. Radiotherapy is commonly utilised as a treatment for benign and malignant tumours.
A fundamental challenge in radiotherapy is delivering a sufficient dose of radiation to
eradicate a tumour while minimizing the dose deposited in surrounding healthy tissue.
Excessive radiation damage to these tissues can result in treatment toxicities that may
have adverse effects on patient quality of life.
Proton therapy offers the potential for increased sparing of normal tissue compared with
X-ray therapy, which is more commonly used in radiotherapy. However, the degree of this
sparing can be highly variable between patients. Furthermore, data from Phase III clinical
trials can quickly become outdated due to the long follow-up times that are required to
observe late effects, together with the rapid evolution of technology. The process of
deciding whether to refer a patient for proton therapy can be complex as a result. In
addition, proton therapy is significantly more expensive as a treatment compared with X-
ray therapy. This suggests that patients who are expected to receive the greatest benefit
should be prioritised. Computer models can offer a possible solution to this dilemma, by
predicting the clinical outcome that may be expected as a result of a given treatment.
In this work, a Markov simulation tool was developed which is capable of producing
such predictions and comparing proton and X-ray radiotherapy treatment plans on an
individual patient basis. The radiobiological effect of a given treatment plan is estimated
in terms of the probabilities of tumour control, radiation-induced injuries and radiation-
induced second cancers. These are combined in the Markov model to efficiently estimate
the clinical outcome resulting from a given treatment plan. This outcome is quantified
in terms of the quality adjusted life expectancy (QALE), or number of quality adjusted
life years (QALYs), which is an adjustment of the raw life expectancy to account for the
effect of time spent with injury or disease. The result is a model that uses several input
parameters to produce a single quantitative output, indicative of the relative quality of a
treatment plan.
The predictions of the model can be affected by uncertainties in the radiobiological model
parameters and uncertainties in dose delivery. The latter can arise as a result of changes
in the target volume relative to the radiation field over the course of treatment. A
consideration of these effects was incorporated into the model, as they have the potential
to influence whether a patient is selected to receive proton therapy.
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The cost-effectiveness of a treatment is of particular importance in the current resource
limited healthcare environment. The Markov model was developed to include treatment
costs, including treatment of radiation therapy side effects. An application of the model
to a cohort of base of skull chordoma patients revealed that all patients could be treated
with proton therapy cost-effectively due to the potential for sparing of critical structures.
Base of skull chordoma is typically regarded as a standard indication for proton therapy.
In contrast, in a study of a cohort of left-sided breast cancer patients, it was found that
the majority of patients could not be treated cost-effectively with proton therapy. This
was likely due to the cardiac toxicity rate being particularly low with the deep inspiration
breath hold X-ray treatment technique used for the patients in this cohort, resulting in
no significant advantage from proton therapy.
The developed model has the potential to form the basis of a clinically viable patient
selection tool. However, the model requires external validation before being suitable for
clinical implementation. Due to the limited availability of proton therapy, such a model
may prove useful as Australia prepares to begin treating cancer patients with proton
therapy.
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In 2011, cancer was the leading cause of disease burden in Australia [1]. In 2017 it was
estimated that more than 130,000 Australians were diagnosed with cancer, corresponding
to an average of 367 diagnoses per day [1]. It is likely that this will increase given the
ageing population. Therefore, it is important to ensure access to high quality treatments.
There are several treatment options available for cancer, including surgery, radiation
therapy, chemotherapy and immunotherapy.
1.1 Radiation Therapy
Radiation therapy utilises ionising radiation to damage the DNA in tumour cells, hence
facilitating the eradication of the tumour. High energy X-rays are typically used for this
purpose. Radiotherapy treatments can be broadly classified as either external beam ra-
diotherapy or brachytherapy [2]. These differ in the location of the source of radiation
with respect to the target within the patient. External beam radiotherapy involves a
source at a distance from the patient. Brachytherapy involves placing the source within
the patient, or immediately abutting the patient for skin treatments. It has been es-
timated that 48% of Australian cancer patients should receive external beam radiation
therapy at least once during their treatment [3].
1
Chapter 1. Introduction 2
The primary goal of radiotherapy is to deliver a maximum dose of radiation to the tumour
volume, while minimising the dose to surrounding healthy tissue. A major limiting factor
on the maximum dose that can be delivered to the tumour, and consequently the chance
of a successful treatment, is the tolerance of normal tissue. Depending on the magnitude
and location of the radiation dose received by normal tissue, any damage may be sufficient
to result in treatment side effects. These can have a significant impact on the quality of
life of the patient. Therefore, many techniques are employed in radiotherapy clinics to
minimise the amount of radiation received by normal tissue. This is a rapidly evolving
area of research. For example, newer treatment technologies such as intensity modulated
radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) allow an escalated
dose to be delivered to the tumour volume without increasing the dose received by sur-
rounding healthy tissue. The use of charged particles, such as protons or carbon ions,
rather than photons can also yield superior dose distributions in certain cases.
Prior to receiving a course of radiotherapy, a computed tomography (CT) scan of the
patient is normally used by a treatment planner to develop a treatment plan. While
the primary purpose of this is to determine optimal treatment strategy, it also allows
estimates of the dose that would be deposited in the tumour and in normal tissue to be
obtained.
1.2 Proton therapy
With technological advances, IMRT and VMAT have become the most common treatment
modalities in radiation oncology. However, the use of proton therapy has been becoming
increasingly available in recent years. Proton therapy has the advantage of being able
to significantly reduce the radiation dose that is deposited in tissues outside the tumour
volume. Protons have been used for therapeutic purposes since the mid-1950s [4].
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1.2.1 Physics of proton therapy
A description of the basic physics of proton therapy is given by Khan [5]. Proton therapy
involves a beam of high energy protons that have been accelerated using either a cyclotron
or synchrotron. The more favourable dose distribution of proton therapy compared with
photons can be explained by the difference in the way in which protons interact with
matter. The rate of energy loss of a particle per unit path length in a medium is repre-
sented by the stopping power. The dose absorbed in the medium is related to this energy
loss. The stopping power increases as the particle velocity decreases, with the energy loss
reaching a maximum near the end of the particle range. For protons, the sharp increase
in the deposited dose near the end of the particle range is known as the Bragg peak
(Figure 1.2).
The characteristically narrow Bragg peak is not clinically useful for irradiating tumours
which typically have a much larger physical extent. A spread-out Bragg peak (SOBP) can
be obtained through the superposition of several beams of different energies, as depicted
in Figure 1.2. The energy range is chosen such that the range of the particles in the
highest energy beam is sufficient to reach the distal edge of the target volume, and this
is superimposed on beams of decreasing energy. The result is a more uniform dose over
the tumour region compared with a single beam.
A beam delivery system is necessary to spread the narrow beam to the required field
size for treatment. This system can be either of two types: passive scattering or pencil
beam scanning, which are described by Khan [6]. Passive scattering is where the beam is
scattered using thin foils. For these systems, range modulator wheels are utilised to obtain
a range of energies resulting in the SOBP, however the longitudinal width of the SOBP
is also constant across the field which results in larger doses outside of the target volume
(see Figure 1.1). Range compensators are required for the isodose lines to conform to the
distal edge of the target volume. The range compensators and modulators increase the
number of interactions that the beam undergoes outside of the patient, which increases
the neutron contamination.
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Figure 1.1: Comparison of passive scattering and active (pencil beam) scanning beam
delivery systems. Passive scattering systems result in larger doses outside of the target
volume. Source: [7].
Scanning involves scanning the thin pencil beam over the target volume with magnets.
In this system, range modulation is achieved with energy degraders (objects of variable
thickness which are placed in the path of the beam) at the exit of the accelerator or
using variable energy accelerators. The use of pencil beam scanning is becoming more
common, due to the superior dose distributions achievable compared to passive scattering
[8]. In addition, the flexibility of scanning makes it an ideal technique for the delivery
of intensity modulated proton therapy (IMPT). However, a disadvantage is the greater
sensitivity of scanning to organ motion due to respiration. This effect, known as the
interplay effect, can result in the delivery of a suboptimal dose. Techniques have been
developed to reduce this effect, such as the isolayered rescanning approach of Karder et
al. [9] which involves simulating the effect of motion so it can be accounted for.
Figure 1.2 illustrates the superior dose distribution of a proton beam with a SOBP formed
by several proton beams, compared with a single X-ray beam. In contrast to protons,
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photons are attenuated exponentially in matter resulting in an exponential decrease in
deposited dose with depth. The physical dose deposition properties of protons result in a
conformal tumour dose and close to zero exit dose compared with photons. This makes
it possible to increase tumour dose without increasing dose to normal tissue.
Figure 1.2: Percentage depth dose (PDD) for a 210 MeV proton beam (green), and
several proton beams of different energies resulting in a SOBP (blue). The dose deposi-
tion for a photon beam is also shown for comparison (red). Reproduced with permission
from Michael Douglass.
1.2.2 Radiobiology
The relative biological effectiveness (RBE) of any radiation is the ratio of the dose from
250 kV X-rays required to produce a given biological effect to the dose from the radiation
of interest to produce the same biological effect. While there is uncertainty regarding
the RBE of protons, most clinics adopt a value of 1.1 [10]. Therefore, a 10% greater
physical dose from photons is required to produce the same biological effect as for protons.
This value has been determined through extensive studies and serves only as a rough
approximation for all tissues. It can also vary with the depth of the protons, with higher
values in the distal part of the SOBP [11]. The uncertainty in the RBE is particularly
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problematic considering magnitude of the end of range dose [12]. A misplaced Bragg peak
could result in considerable dose to healthy tissue.
Secondary radiation arising from nuclear interactions both inside and outside of the pa-
tient is also an important consideration in the biological effect of protons [13]. For ex-
ample, neutrons that are produced in these interactions can carry energy a significant
distance from the interaction site. These neutrons have a high RBE and neutrons gener-
ated outside of the patient increase the integral dose.
1.2.3 Availability and cost
While proton therapy can potentially offer a superior dose distribution compared with X-
ray therapy, it is also a more expensive form of treatment with limited availability. This
is particularly true in Australia, where there are currently no proton therapy treatment
facilities and patients must be sent overseas for proton therapy (although as of 2018
several facilities were in the early stages of planning).
The cost of proton therapy is typically estimated to be approximately 2.5 times that of
X-ray therapy [14]. However, it is likely that this ratio will decrease over time. Goitein
and Jermann [15] estimated that the ratio could decrease to 1.7. In some situations, it
may be possible to justify the expense of proton therapy if it is anticipated that it will
lead to a lower cost of treating radiation-induced complications than photon radiotherapy.
1.3 Clinical trials of proton therapy
Clinical trials are an important component of research of cancer treatments. An intro-
duction to the concept of clinical trials of ion beam therapy is given by Cox [16]. Clinical
trials in radiation oncology can be classified as follows:
 Phase I: the safety of a new treatment is tested on a small cohort of patients.
 Phase II: the efficacy of the treatment is tested on a larger cohort of patients.
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 Phase III: randomised control trials (RCTs). The efficacy of the newer treatment
is compared with a standard treatment. These trials are considered the “gold
standard” as valid conclusions can be drawn.
While proton therapy can result in a more favourable dose distribution in a patient com-
pared with X-ray therapy, there is uncertainty as to whether this distribution corresponds
to a significant difference in clinical outcome. There is evidence of improved quality of
life and patient reported outcomes for selected cancers after receiving proton treatment
[17]. However, at the end of 2018 no Phase III clinical trials were able to show the benefit
of protons. However, a number were being conducted that are detailed by Mishra et al.
[18].
Concern has been raised regarding the lack of positive Phase III clinical trials of proton
therapy, recommending that they should be required before proton therapy is adopted
as standard treatment [19–22]. However, others have argued that positive Phase III
clinical trials of proton therapy should not be a requirement [23, 24]. For example, Suit
et al. [23] note that if it were not for the larger cost, then proton therapy would be
adopted as a standard treatment. It has been well established that protons can deliver
an equal or more favourable dose distribution compared with X-rays and hence the only
disadvantage of proton therapy is treatment cost. However, Suit et al. [23] and Goitein
and Cox [24] argue that cost-effectiveness alone is insufficient grounds to justify the need
for an RCT, especially when the expensive treatment will also likely produce the better
outcome. Furthermore, in order for a clinical trial to be morally justifiable, there must
be uncertainty regarding the relative benefit of the two arms of the trial [25], also known
as equipoise. An equivalent or superior dose distribution can be expected from proton
therapy compared to X-ray therapy, and hence it is not possible to ethically assign patients
to arms of a trial. In the opinion of Suit et al. [23], resources would be better allocated
to improving proton therapy treatment.
Dahl [26] has also noted that in the past other technologies in radiation oncology such as
cobalt units and IMRT have not required positive Phase III clinical trials to be adopted
as part of routine clinical practice. Instead, cobalt units were adopted based on improved
modelled dose distributions.
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There are other reasons why RCTs may not be suitable for investigating and quantifying
the relative clinical benefit of protons. A significant challenge for Phase III clinical trials is
that the treatment techniques being compared evolve rapidly and can change significantly
over the time period required to conduct clinical trials. Furthermore, some radiation-
induced injuries take several years to develop. For example, heart disease often occurs 5
years after treatment and can occur up to 20 years later [27]. The development of second
malignancies can have a greater latency period. It is not practical to conduct clinical
trials over time periods of this magnitude as once the results are obtained, they will not
be relevant to the current technology.
Enrolment of patients in these trials is another issue, particularly if health insurance is
a limiting factor. Study biases can result if selected groups of patients are not enrolled
in the proton arm of the trial due to lack of insurance coverage. In addition, Glimelius
and Montelius [22] noted that it is possible that proton therapy can benefit more rare
types of cancers which would make it difficult to recruit sufficient members for a trial in
a reasonable time frame.
It is apparent that Phase III clinical trials may not be appropriate for determining whether
the superior dose distribution of proton therapy translates to a clinical benefit. Further-
more, the magnitude of any clinical benefit is likely to be highly variable between patients.
In addition, the limited availability of the treatment suggests that it should be prescribed
preferentially to patients who are expected to receive the greatest benefit compared with
X-ray therapy. The result is oncologists being presented with a challenge when deciding
whether to refer a patient for proton therapy.
1.4 Model-based patient selection for proton therapy
As discussed in Section 1.3, deciding which patients to treat based on the results of
Phase III clinical trials of proton therapy may not be the best approach. An alternative
approach is to use evidence-based mathematical models to provide predictions of clinical
outcomes. The concept of model-based patient selection was proposed by Langendijk et
al. [28]. The approach aims to select patients to receive proton therapy based on the
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predicted clinical outcome relative to the clinical outcome of X-ray therapy. Specifically,
the clinical benefit is estimated in terms of the normal tissue complication probability
(NTCP), that is, the probability of radiation-induced injury. The method was proposed
as a means of introducing proton therapy into the Dutch health care system, in lieu of
evidence in the form of RCTs. The model is discussed in more detail in Section 2.1.1.
The limitations of the approach are that there is no consideration of treatment failure or
of radiation induced secondary malignancies.
1.5 Motivation and thesis structure
1.5.1 Motivation
Compared with X-ray therapy, proton therapy has the potential to reduce radiation treat-
ment complication rates in selected groups of patients. However, it is also significantly
more expensive and has limited availability. Therefore, it is important to identify pa-
tients who are likely to experience an improved clinical outcome if treated with proton
therapy. For the reasons discussed in Section 1.3, randomised clinical trials have not
been conducted until recently. This leads to a more challenging treatment referral pro-
cess. Modelling studies may provide an alternative approach to assessing proton therapy
outcomes. As personalized medicine becomes increasingly important, it is advantageous
to quantify the clinical benefit of proton therapy compared with X-ray therapy on an
individual patient basis.
A proton therapy patient selection model has been developed [28] to address the issue of
the limited availability of the treatment in the Netherlands where it has recently become
available. However, there remains potential for alternative, more refined approaches. The
model does not consider the possibility of treatment failure or the induction of radiation-
induced malignancies. The latter is a particularly important consideration given the
expected difference in integral dose between a proton and photon treatment. Furthermore,
it is important to account for the effect of radiation-induced malignancies on the clinical
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outcome of younger patients, as they have a greater remaining lifetime over which to
develop such a cancer.
While proton therapy was unavailable in Australia at the time of writing (early 2019),
construction of a treatment facility in Adelaide was close to commencement. Facilities
in other cities were also in the early stages of planning. In the coming years, Australia
will continue to face the issue of limited availability of this lifesaving treatment. An
evidence-based proton therapy patient selection model can aid in this respect.
1.5.2 Aims of current work
The aim of the current work was to develop a toolkit with the ability to predict the
clinical outcome of a given radiotherapy treatment on an individual patient basis. This
prediction may then be used to assess the optimal radiotherapy treatment strategy for
an individual patient.
The toolkit is based on a Markov model which is a type of stochastic model. These have
been utilised in radiotherapy to predict patient outcomes and are described in more detail
in Section 2.2. The model input is the dose-volume histogram (DVH) data correspond-
ing to a particular patient’s treatment plans, one for proton therapy and one for X-ray
therapy. This data specifies the amount of radiation the tumour volume and each of the
organs at risk receives. The patient age and gender are also necessary inputs.
For a given treatment plan, radiobiological models are used to determine the probabilities
of tumour control, radiation-induced injuries and radiation-induced second cancers. These
are combined in the Markov model into a single metric which is output by the model,
the quality-adjusted life expectancy (QALE). This is an adjustment of the predicted life
expectancy for the effect of treatment complications and is a more holistic representation
of the treatment outcome than simply the NTCP. The difference in QALE between two
treatment plans (one proton, one photon) provides a quantitative estimate of the relative
benefit a patient can expect if treated with proton therapy.
The intended usage of the model is to select patients to receive proton therapy based on
a comparison of predicted QALEs for their proton and X-ray radiotherapy plans. The
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strength of the toolkit is its ability to combine several competing treatment factors (such
as tumour control and complication risk) into a single metric that is indicative of the
quality of a treatment plan. In addition, the toolkit is able to consider any treatment site
and any number of radiation-induced injuries when determining the QALE. While it was
developed to compare proton therapy with X-ray therapy, the toolkit has the flexibility
to compare any two radiation treatment techniques provided a treatment plan can be
provided for each.
In addition to developing the Markov toolkit to select patients to receive proton therapy,
the aims of the current work were to:
1. Incorporate the effect of treatment and model parameter uncertainties on the output
of the tool;
2. Incorporate an analysis of treatment cost-effectiveness into the tool;
3. Given a cohort of base of skull chordoma patients, determine whether this indication
can be treated with proton therapy cost-effectively; and
4. Investigate which patients, if any, would be selected to receive proton therapy from
a cohort of left-sided breast cancer patients.
1.5.3 Thesis outline
This thesis includes several publications, which form the basis of some chapters. Other
chapters have a conventional format.
Chapter 2 provides a review of patient selection methods in proton therapy, Markov
models and radiobiological models. Necessary background information is also provided.
Chapter 3 outlines the first model that was developed, which is based on a Monte Carlo
simulation. The methodology of the development of the model is presented, along with
a demonstration of the output with an example patient. The publication P1 forms the
basis of this chapter.
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Chapter 4 outlines the second model that was developed, where the solution is calculated
analytically, thus providing the exact solution. This approach also results in a significantly
reduced computation time, while producing results that are equivalent to the first model
(for a sufficiently large number of Monte Carlo iterations).
Chapter 5 details the methodology of including treatment and model parameter uncer-
tainties in the model predictions. These uncertainties can potentially impact whether a
patient is selected for proton therapy. The magnitude of these uncertainties are assessed
and the output is demonstrated with an example patient. The publication P2 forms the
basis of this chapter.
Chapter 6 details the incorporation of treatment cost-effectiveness analysis into the tool.
Cost is often used to justify the need for more expensive treatments. The updated model is
applied in a retrospective study to a cohort of base of skull chordoma patients to determine
the cost-effectiveness of treating this indication with proton therapy. This cancer type is
generally regarded as a standard indication for proton therapy. The publication P3 forms
the basis of this chapter.
Chapter 7 describes the application of the toolkit to a cohort of left-sided breast cancer
patients who had proton plans created retrospectively. Breast cancer is not generally
considered as a standard indication for proton therapy. The aim was to determine which
patients, if any, would be selected for proton therapy. The publication P4 forms the basis
of this chapter.
Chapter 8 provides a conclusion of the thesis with a summary of the outcomes of the
research. Directions for future work are recommended.
Chapter 2
Background and Literature Review
2.1 Decision making in radiation oncology
As discussed in Section 1.3, deciding on the best course of treatment for a cancer patient
can be challenging. This is particularly true due to the limitation of data on the late
effects of newer radiotherapy treatments. In addition, there are a number of factors that
must be considered including treatment availability, quality of life and patient preferences
[29]. While it is possible to assess and compare radiotherapy treatment plans visually, it
is difficult to predict the degree to which a difference in dose distribution will affect the
clinical outcome of a patient in terms of disease-free survival. Decision support systems
based on mathematical models can assist in predicting the most likely patient outcome.
In a review of predictive models in radiation oncology, Lambin et al. [29] discussed
the increasing importance of individualised medicine in the current healthcare landscape.
They noted that an important challenge is quantitatively integrating clinical, imaging and
molecular data, and that many current prediction models lack assessments of robustness,
reproducibility and clinical utility.
An example of a clinical decision support tool was created by Brodin et al. [30] for
radiotherapy plan comparison for Hodgkin lymphoma. Volumetric modulated arc therapy
(VMAT) plans and 3D conformal plans were compared based on the risk of developing
complications. As the disease can be spread through the body, normal tissue complication
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probability (NTCP) models were included for multiple sites, weighted based on their
reliability and applicability. Another decision aid has been developed by Smith et al.
[31]. This tool was based on a Bayesian network and a Markov model and was used to
compare different IMRT treatment plans for prostate cancer. In addition to complication
risks, the tumour control probability (TCP) was also considered in this method.
Demand modelling can also inform clinical decision making in radiotherapy as well as
assist in planning of radiotherapy services. An example was described by Delaney et al.
[32], where the proportion of cancer cases eligible for radiotherapy was estimated using
an optimal radiotherapy utilisation tree based on clinical guidelines and epidemiological
data. It was found that in Australia, there were fewer patients who received radiotherapy
than patients who would have received a benefit from the treatment.
2.1.1 Patient selection strategies for proton therapy
The importance of prioritising patients for proton therapy is discussed in Chapter 1.
Ideally, those who will likely receive the most improved clinical outcome if treated with
proton therapy compared with X-ray therapy should be selected. However, quantitatively
defining clinical outcomes can be challenging. In a review of mathematical modelling for
patient selection in proton therapy, Mee et al. [33] summarised a range of models that
have been developed for this purpose. There are a variety of methods employed, including
discrete event simulations, Markov models and NTCP-based models.
The concept of in silico clinical trials proposed by Langendijk et al. [28] has been intro-
duced in Section 1.4. The aim of the approach is to provide evidence-based medicine in
the absence of data from clinical trials. The approach involves generating a photon plan
and a proton plan for a given patient. The dose to critical structures is calculated from
each treatment plan and, together with validated NTCP models (see Section 2.3.2), is
used to predict the likelihood of toxicity after each treatment. Hence, the difference in
the dose distribution is translated to a difference in clinical outcome, as demonstrated in
Figure 2.1 [28]. If the difference in the expected NTCP exceeds a defined threshold, then
the patient is selected to receive proton therapy.
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Figure 2.1: Demonstration of the translation of the difference in dose between a proton
and photon treatment plan to a difference in normal tissue complication probability
(NTCP), in this case xerostomia. Two examples are presented and it is apparent
that the NTCP difference depends on both the dose difference and the dose region.
Source: [28].
Proton therapy treatments began in the Netherlands in 2018 and this approach of patient
selection has been adopted by Dutch health authorities. In addition, patient participation
in follow-up programs is compulsory, which allows the compilation of valuable research
data on patient outcomes after receiving proton therapy. This is particularly important
to facilitate the validation and refinement of the NTCP models.
The question of whether or not proton therapy should be adopted with the absence of
evidence from Phase III clinical trials has been discussed in Section 1.3. If it is adopted
without such supporting evidence, then the risk is investing considerably in a treatment
that may not improve clinical outcomes. Alternatively, if the introduction of proton
therapy is delayed, then patients may receive sub-optimal treatment. Grutters et al. [34]
analysed this trade-off using the method of real options analysis. This approach can assist
in determining whether a treatment should be adopted, or whether a trial is required.
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The optimal design of a trial can also be indicated in terms of sample size and follow-
up time. For the case of proton therapy, the three options are to adopt the treatment
without trial, adopt with a trial, or delay with a trial. Grutters et al. [34] have found
the benefits of conducting trials to be sufficient to outweigh the costs when comparing
proton therapy with stereotactic body radiotherapy in the treatment of stage I non-small
cell lung cancer. Furthermore, they found that the expected net gain of adopting proton
therapy is greater than that of not adopting it.
Langendijk et al. [28] and Widder et al. [35] also proposed that model-based approaches
can be used for designing clinical trials of proton therapy, in addition to selecting patients
to receive the treatment. Sequential prospective observation cohort studies are suggested
as an alternative to traditional randomised control trials. The procedure of these cohort
studies is as follows:
1. A historical control group is created. Each patient treated before protons were
available (and therefore were treated with photons) has a proton plan created ret-
rospectively. The difference in NTCP between each plan is calculated for each
patient. The historical control group consists of the patients that would have been
selected for proton therapy had it been available.
2. The treatment group consists of the patients selected to receive protons once the
treatment is available using the same comparative planning procedure. The only
difference is that the proton treatment plans are created before the treatment is
delivered.
3. The outcomes of the two groups are compared using analysis procedures similar to
those of traditional clinical trials.
The advantage of this approach is that the issue of ethically assigning patients to different
arms of a clinical trial is removed (this issue is discussed in Section 1.3). All patients
receive a proton treatment course if: (i) a proton treatment is available and (ii) they are
expected to experience an improved clinical outcome compared with the photon treat-
ment. Another advantage is that groups with similar characteristics are defined and biases
are removed. If the groups were not defined carefully in this manner, then the treatment
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group would be compared to all patients who did not receive protons. It is likely that
many of these patients would not experience an enhanced clinical outcome from a proton
treatment and this would skew the results. In this case, a positive result would mean
that patients who would experience no benefit from receiving proton therapy would be
selected to do so, while a negative result would mean that eligible patients would not be
selected. However, the disadvantage of designing a clinical trial using this approach is
that selection criteria may change over time, making it more difficult to compare current
cohorts with historical cohorts.
The Proton Priority System developed by Bekelman et al. [36] aims to compare patients
and select those who would likely receive the greatest benefit if treated with proton
therapy. In this system, each patient is assigned a score which is a weighted sum of
7 domains. These include diagnosis, anatomic site, stage, co-morbidities, age, urgency,
and clinical protocol. There are factors in each of these domains that are assigned a
score between 0 and 10. Higher scores are assigned where a greater benefit from proton
therapy is expected. For example, sites including the base of skull and spine are assigned
10 points, while the brain is assigned 5 points. Higher scores are also assigned to younger
patients and more urgent cases. Proton therapy is more likely to benefit patients with
localised cancers rather than metastatic cancer. The scores and weights were decided by
the Proton Priority Oversight and Advisory Board established by the Roberts Proton
Therapy Centre at the University of Pennsylvania. The board consists of oncologists, a
nurse, a patient representative and a medical ethicist. The best available evidence and
expert opinion are utilised in determining scores and weights. The framework also has
the flexibility to evolve as new evidence and experience emerges.
An important principle of the Proton Priority System [36] is equity. Therefore, a patient’s
score should not be affected by sex, race, geography or insurance status. Bekelman et
al. [36] investigated the association between score and receipt of proton therapy with
insurance status, gender, race and geography. It was found that allocation depended
on insurance status. Furthermore, the disadvantage of this approach is that it is more
qualitative than quantitative compared with the approach proposed by Langendijk et al.
[28].
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As an alternative to individualised patient selection for proton therapy, Jakobi et al.
[37] attempted to identify a subgroup of head and neck patients that would receive a
significantly reduced NTCP if treated with proton therapy rather than X-ray therapy. In
their study, patient-specific NTCPs were predicted using proton and photon treatment
plans for each patient. Subgroups were defined based on primary tumour location. This
allowed groups that would experience a greater NTCP reduction to be identified. The
implication is that comparative planning would not be required for all patients in clinics
with more limited resources.
2.1.2 Cost-effectiveness of proton therapy
Health care represents a significant portion of government expenditure in many coun-
tries. This corresponds to an important investment as the burden of disease is costly for
society. Understanding the cost-effectiveness of treatments is vital to ensuring the most
appropriate and efficient allocation of limited resources. Proton therapy has the poten-
tial to improve quality of life and may even be lifesaving for some patients. However,
as discussed in Section 1.2, it has been estimated that proton therapy is 2.5 times more
expensive than X-ray therapy. In many instances, this cost may be justified if quality
of life can be improved, the cost of treating side effects is reduced, or if the patient is
more productive in society as a result of being disease free. Therefore, it is important to
consider cost-effectiveness when selecting patients for proton therapy. Cost-effectiveness
studies typically involve comparing the costs and outcomes or benefits of two treatments.
Verma et al. [38] identified factors that affect the cost-effectiveness of proton therapy.
These include patient age, risk of toxicity, and tumour characteristics. Proton therapy
is likely to be increasingly cost-effective where tumours are located in close proximity to
dose-limiting organs at risk. Alternatively, it may not be cost-effective to treat tumours
that have poor prognoses with proton therapy as it is unlikely that patients will live long
enough to experience lower toxicity, unless potential side effects will impact significantly
on quality of life or mortality risks. Verma et al. [39] concluded proton therapy to be cost-
effective for paediatric brain tumours, selected breast cancers, locoregionally advanced
non-small cell lung cancer and high risk head and neck cancers. However, it was not
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demonstrated that prostate cancer or early stage non-small cell lung cancer can be treated
with proton therapy cost-effectively in the review.
Lundkvist et al. [40–42] investigated the cost-effectiveness of treating various cancers with
proton therapy. They employed a Markov model to estimate patient outcomes, which
are commonly used in cost-effectiveness studies with medical applications (discussed in
more detail in Section 2.2). The findings of this cost-effectiveness research suggest that
proton therapy can be cost-effective and cost-saving if appropriate patients are selected
to receive the treatment. Childhood medulloblastoma may be treated cost-effectively,
particularly as a result of costs associated with hormone replacement therapy and with
lost productivity due to IQ reduction. Lundkvist et al. [41] recommended that only the
cases where there is a higher risk of growth hormone deficiency and IQ loss with X-ray
therapy would be cost-effective proton treatments, highlighting a need for individualised
patient selection strategies.
Mailhot Vega et al. [43] also developed a Markov model to evaluate the cost-effectiveness
of treating childhood brain tumours with proton therapy with regard to risk of growth
hormone deficiency, and of childhood medulloblastoma specifically [44]. Proton therapy
was found to be a cost-effective treatment for medulloblastoma where there were a wide
range of potential toxicities including coronary artery disease, congestive heart failure,
ototoxicity, gonadotropin deficiency, growth hormone deficiency, hypothyroidism, adreno-
corticotropic hormone deficiency, secondary malignancy, relapse and death. In this study,
the risk of growth hormone deficiency was found to be the most influential factor in de-
termining the cost-effectiveness of a proton treatment. It was subsequently concluded
[43] that patients who have the greatest potential for sparing of the hypothalamus with
proton therapy would be the best candidates to receive the treatment in terms of cost-
effectiveness. Proton therapy could also be cost-saving with increased sparing of this
tissue.
While paediatric and brain cancers are typically regarded as standard indications for
proton therapy, this is not the case for breast cancer. Treating left-sided breast cancer
with proton therapy has been found to be cost-effective but only for selected patients
with a high risk of developing cardiac disease [40]. The Markov model developed by
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Mailhot Vega et al. [45] produced similar predictions to Lundkvist et al. [40] in that
proton therapy was found to be cost-effective for patients who had an elevated risk of
cardiac problems. In addition, it was found that patients with these risk factors who
would receive a mean heart dose of greater than 5 Gy when treated with photons could
be treated with proton therapy cost-effectively, and should therefore be prioritised. The
cost-effectiveness of proton therapy may also increase as a wider range of indications are
identified [42].
Ramaekers et al. [46] analysed the cost-effectiveness of treating head and neck cancers
with swallowing sparing photon and proton therapy. Swallowing sparing treatments for
head and neck cancer were compared considering risks of dysphagia (swallowing difficulty)
and xerostomia (reduced saliva production). If equal survival between the two modalities
is assumed, then proton therapy would be cost-effective for selected patients only.
2.1.3 Summary
Decision making in radiation oncology is an important and complex task. Several factors
must be considered, including patient quality of life and treatment cost-effectiveness.
In the absence of data from Phase III clinical trials of proton therapy, model-based
approaches have been proposed to provide evidence as to the most appropriate use of the
treatment. The limitation of the Proton Priority System [36] is that only clinical variables
are included and there is no consideration of patient-specific dosimetry. The patient
selection strategy employed in the Netherlands [28] and the system proposed by Mailhot
Vega et al. [43] are based on a limited number of NTCP models and provide a quantitative
comparison of treatment plans. These models incorporate effects of individual patient
dosimetry and clinical variables. However, there is no consideration of the effects of
treatment failure or radiation-induced cancers on patient quality of life. Furthermore,
cost-effectiveness, which can be important where a treatment has limited availability and
is provided with public funding, is not typically included in patient selection systems
(with the exception of Mailhot Vega et al. [43]). Cost-effectiveness studies have indicated
that selected patients could be treated cost-effectively. However, many of these studies
have relied on cohort-based estimates of toxicity risks and do not consider the dosimetry
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that is unique to the treatment plans of an individual patient. As a result, there remains
potential for more detailed modelling approaches.
In this thesis, models are developed that include the effects of treatment failure and sec-
ond primary cancer induction on patient quality of life, as well as a range of toxicity
risks. These effects are assessed using patient-specific dosimetry and, collectively, facil-
itate a more complete representation of treatment outcomes. Furthermore, treatment
cost-effectiveness is incorporated into this work to allow the potential benefit of a treat-
ment to be evaluated from an economic perspective. This is particularly important in
the context of healthcare delivery, where resources are often limited. As an additional
enhancement, individualised cost-effectiveness predictions are possible, which are based
on the patient-specific dosimetry resulting from a given radiation treatment plan.
2.2 Markov models
A Markov model, or Markov chain, is a type of mathematical model used to model
randomly-varying systems. A theoretical background of these models is provided by
Grimmett and Stirzaker [47]. An important property of Markov models is the memo-
ryless Markov property whereby future events depend on current events only, and are
independent of past history. The variable of time can be either continuous or discrete.
Discrete-time Markov chains are considered here. At each time point, an event may or
may not occur, based on a given probability.
2.2.1 Theoretical background
Let {Xi}i∈N, where N is the set of natural numbers, be a sequence of discrete random
variables that take values from the finite set S, which is known as the state space of the
chain. Each value of S may be thought of as a state of a randomly changing system. If
x0, x1, ..., xn−1, s ∈ S, then the Markov property can be written as:
Pr(Xn = s|X0 = x0, X1 = x1, ..., Xn−1 = xn−1) = Pr(Xn = s|Xn−1 = xn−1), (2.1)
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for all n ≥ 1. The evolution of a chain with time is determined by transition probabilities,
Pr(Xn+1 = j|Xn = i). These are the probabilities of the system transitioning from being
in state i at a given time to state j at the subsequent time point, for i, j ∈ S. A chain is
said to be homogeneous if:
Pr(Xn+1 = j|Xn = i) = Pr(X1 = j|X0 = i), (2.2)
for all n ≥ 0, that is, the probability of transitioning in one step between two given states
is constant with time. If the transition probabilities are time variable, then the chain is
inhomogeneous.
All transition probabilities may be represented by a |S| × |S| matrix, P, where |S| is the
number of Markov states and each (i, j) element of P is defined as
pij = Pr(Xn+1 = j|Xn = i). (2.3)
Each row of the transition matrix must sum to 1. The values of P change at each time
point for an inhomogeneous chain.
2.2.2 Markov models in radiotherapy
Markov models have been applied in the discipline of radiation oncology [48, 49]. They
may be used to approximate disease progression over a period of time, particularly af-
ter a choice of disease management strategy. Decision support systems are often based
on Markov models. The Assessment of New Radiation Oncology Technology and Treat-
ment (ANROTAT) Project [50] (undertaken by the Tasman Radiation Oncology Group
(TROG)) has developed a framework Markov model to aid the assessment of which
new technologies should be funded by Medicare. The Markov model allows the cost-
effectiveness of technologies to be evaluated, and hence technologies are selected based
on their potential to maximise overall societal benefit.
Sonnenberg and Beck [51] provided a detailed description of the theoretical basis of
Markov models applied to medical decision making. At any given time, a patient is
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assumed to exist in one of a finite number of discrete states. Each state in the state
space describes the health status of the patient. For example, if the patient is disease
free, then they are in the Well state. If pneumonia was present, for example, then they
would occupy the Pneumonia state.
The time period of interest is a portion of the patient’s lifetime. The cycle length is the
period of time between consecutive discrete time points. In medical applications, the
cycle length is typically one year. At the end of each cycle, it is possible for the patient to
transition to another health state. Figure 2.2 shows an example of this process. The series
of these transitions can be modelled using a Markov chain. Due to the Markov property,
the probability of the patient transitioning to another state depends only on their current
state and not on the time spent in any previous states. Markov state transition diagrams
are used to represent the possible transitions between states. A simple state transition
diagram is given in Figure 2.3.
The Dead, or Deceased, state is particularly important as it is the absorbing state. The
patient cannot leave this state and this allows the Markov chain to terminate. The
time horizon is the maximum possible value that the time variable can take. The chain
terminates at this point if the absorbing state has not been reached prior. In this work,
a time horizon of 100 years is used.
An example of a Markov model utilised in radiation oncology is the decision aid devel-
oped by Smith et al. [31] (discussed in Section 2.1), which is based on both a Markov
model and Bayesian network. Another example of a Markov model was developed by
Punglia et al. [49] to simulate the progression of ductal carcinoma in situ after radia-
tion therapy. Two treatment strategies, excision and radiotherapy and excision alone,
were evaluated with the model. The analysis considered local recurrence, breast cancer
mortality and mastectomy risks. The model predicted that radiation therapy resulted in
a slight improvement of disease-free and overall survival compared with excision alone.
However, radiation therapy was also associated with higher probability of mastectomy.
This highlights the importance of including patient preferences in decision tools.
Markov models are also often utilised in cost-effectiveness studies (see Section 2.1.2).
Lundkvist et al. [40] developed such a model to assess the cost-effectiveness treating
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Figure 2.2: State transitions made by a person in a Markov chain until the Dead
state is reached in cycle 6. Source: [51].
Figure 2.3: A simple Markov state transition diagram. There are three states repre-
sented by circles. Allowed transitions are represented by arrows. Where an arrow leads
from a state to itself again, a patient is allowed to remain in that state in consecutive
cycles. Note that recovery from disability is not possible in this example. Source: [51].
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Figure 2.4: A simple decision tree diagram. The decision node is found at the centre.
The outcome nodes are found at the end of the branches representing each strategy.
left-sided breast cancer with proton therapy. Ramaekers et al. [46] (introduced in 2.1.2)
also utilised Markov modelling to investigate proton therapy cost-effectiveness for the
treatment of head and neck cancer.
2.2.2.1 Comparison with other prognosis modelling approaches
Decision tree models consist of three components as illustrated by Figure 2.4 [52]: (i) the
decision node which is the point in time when a choice is made between two treatment
strategies; (ii) the decision strategies which correspond to the branches of the tree; and
(iii) the outcome nodes which are the outcomes of the strategies. For the simple tree in
Figure 2.4, it is not possible to specify when events occur, or for events to occur more
than once. While additional trees could be added to outcome nodes to address this, the
result would be an unacceptably high number of branches. Markov models offer a much
more convenient means of tracking the timing of events, which is particularly important
for estimating prognoses [51].
Discrete-event simulations (DES) differ from Markov models in that they are event ori-
ented rather than state oriented [53]. DES can have the advantage of being able to more
simply model patient histories and competing risks [54]. The time between events is not
necessarily constant in DES. Events may be instantaneous and are not mutually exclusive.
The memoryless property of Markov models means that it is not possible to easily include
patient history without significantly increasing the number of Markov states. However,
the disadvantage of DES is that large datasets are often required which may not always
be available.
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2.2.3 Quality of life concept and utilities
A Markov process can be used to model the life expectancy of a patient by counting the
number of cycles that pass before the Deceased state is reached. However, the quality of a
patient’s life may also be of interest, and this is affected by cancer or injuries arising from
treatment complications. The quality-adjusted life expectancy (QALE) is an adjustment
of the raw life expectancy to account for these factors. To calculate the QALE, each state
is assigned a quality of life (QoL) utility (also known as a QoL weight). The QALE is
given by (2.4), where ti is the total number of cycles the patient spends in the i
th state,





The QALE may also be thought of as the number of quality-adjusted life years (QALYs)
lived until death. The advantage of the model that has been developed in this work is that
the probabilities of tumour control and of developing complications are incorporated into
a single metric, the QALE, which is used to compare treatment plans. By incorporating
both these factors into the analysis, a more informed comparison can be made between
two treatment plans.
The value of the utility depends only on the associated state and not history of health
state occupation. The Well state has u = 1, Dead has u = 0, and the other states
have a value in (0, 1) [55]. A variety of methods may be used to assign utilities to the
remaining states. For example, Kharroubi et al. [56] used Bayesian Markov chain Monte
Carlo methods and clinical data to estimate utilities that describe a patient’s quality of
life. The Bayesian models also provide uncertainty distributions associated with these
values. The utilities estimated were intended for use in cost-effectiveness analyses [56].
Sonnenberg and Beck [51] also noted that it is possible to enhance Markov models using
time-dependent utility values.
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2.2.4 Summary
Markov models provide a framework for modelling disease progression and patient quality
of life. While they have limitations, these models have advantages compared with other
methods that are applied in prognosis modelling. For example, they may prove useful
where data availability is limited. Markov approaches have been utilised for investigating
clinical outcomes of various radiation treatments, including proton therapy. The results
of these investigations highlight the need to select appropriate patients to receive proton
therapy. Therefore, Markov models may also prove useful when implemented as part of
proton therapy patient selection strategies.
2.3 Radiobiological models
Ionising radiation has the potential to cause damage to biological tissue, specifically
through damaging DNA. A variety of mathematical models exist that relate the radiation
dose to a clinical endpoint. Several of these radiobiological models were incorporated into
this work as dose-dependent transition probabilities in the Markov model. The endpoints
considered included tumour control, normal tissue complications and second malignancies
(radiation-induced). The radiobiological models employed to calculate the probabilities
of these endpoints occurring are introduced and discussed in this section.
Other studies have utilised alternative methods to determine Markov transition probabil-
ities. The transition probabilities in the Markov model utilised by Lundkvist et al. [40]
were estimated based on toxicity and mortality rates available in the literature, rather
than based on patient-specific doses. Smith et al. [31] derived transition probabilities
from a Bayesian network.
Radiobiological models have also been used to compare treatment plans directly, without
using them as input to a Markov model. The proton therapy patient selection approach
proposed by Langendijk et al. [28] involved calculating the NTCP using the dose to a
given organ resulting from a treatment plan, along with other clinical variables. The
NTCP resulting from a photon plan is compared with the NTCP expected with a proton
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plan. Hence, the NTCP is used to quantify the clinical outcome. The disadvantage
of this approach is that this quantification does not consider other factors such as the
induction of second cancers. The advantage of Markov models is that several factors may
be combined to give a single metric that can indicate the quality of a plan.
2.3.1 TCP
In this work, the tumour control probability (TCP) is used in the model to determine
whether a radiotherapy treatment is successful. As a result, it is an important parameter
as it determines the state that a patient begins the Markov simulation in (either Well for
a successful treatment or Cancer for an unsuccessful treatment). The TCP is based on
the linear quadratic (LQ) model [57],
S(D) = exp(−αD − βD2), (2.5)
which gives the fractional number of surviving cells after being irradiated by a certain
dose, D, where α and β are the linear and quadratic coefficients of the LQ model, respec-
tively. In general, TCP models assume that the number of surviving tumour cells follows
a Poisson distribution and that a single surviving clonogen (cancerous cell) is required for
tumour regrowth. Hence tumour control corresponds to all cells being killed. The total















where there are a total of ` voxels, with each having a fractional volume (of the total
tumour) vi that receives dose Di as part of a treatment delivered in n fractions. The
parameter γ = D dTCP
dD
is the normalised dose-response gradient evaluated at D = D50,
the treatment dose D at which 50% of tumours are controlled.
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2.3.2 NTCP modelling
The normal tissue complication probability (NTCP) represents the probability of devel-
oping a radiation-induced injury as a result of treatment. NTCP models are also based
on the dose received by volume fractions of a particular organ. Depending on the prop-
erties of a given organ, it may respond as a serial or parallel organ. However, there is a
spectrum of organ behaviour, with purely serial and purely parallel organs representing
opposite ends of the spectrum. The response of a purely parallel organ, the lung for
example, has a greater dependency on the irradiated volume. For example, if a larger
volume is irradiated, then there will be a greater impact on organ function. In contrast,
response of a purely serial organ, the spinal cord for example, has a greater dependency
on the magnitude of the dose rather than the irradiated volume. The functioning of these
organs can be impaired by irradiation of a small volume. Therefore, NTCP models should
incorporate the effect of organ volume dependency.
2.3.2.1 LKB model























where TD50 is the uniform dose given to the entire organ that results in 50% complication
risk, m is an organ specific parameter that is related to dNTCP
dD
, n is a parameter that
characterises the volume dependence of the organ’s response to radiation, Deff is the
effective dose, and ` is the number of voxels. For a purely parallel organ, n = 1 and for
a purely serial organ, n = 0.
The parameters in the model are complication-specific. Ideally, these are clinically
founded. An advantage of the LKB model is that there are many published parame-
ters for a wide range of endpoints [62–64]. The Quantitative Analysis of Normal Tissue
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Effects in the Clinic (QUANTEC) data is an important resource for these parameters
[65].
However, a limitation of the LKB model is that patient-specific clinical variables such as
disease history and concurrent chemotherapy are not included. These variables can have
have a significant influence on complication rates.
2.3.2.2 Other NTCP models










where s = 1 for a purely serial organ, s = 0 for a purely parallel organ, Di, vi and `
have the same meaning as for the LKB model, and P (Di) is given by (2.7). The relative
seriality model is very similar in principle to the LKB model; however, the definition of
the parameters varies slightly.
NTCP models have been developed that depend on both dose and clinical variables
(such as tumour stage, patient age and sex, concurrent chemotherapy). Several such
models have been developed in the Netherlands for several endpoints including xerosto-
mia [66, 67], swallowing dysfunction [68] and tube feeding dependency [69]. These have
been developed through the method of logistic regression to identify which variables con-
tributed to the value of the NTCP. Many of these models have been implemented as part
of the proton therapy patient selection system that has been adopted in the Netherlands
[28].
External validation is important to ensure the reliability of these models. This process
involves comparing the predictions of the model with observed outcomes of a treatment
cohort that is independent of the cohort utilised to develop the model. Several NTCP
models exist have been subjected to this rigorous testing process [70–72].
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2.3.3 Second cancer risk
The second primary cancer induction probability (SPCIP) is the probability of developing
a cancer as a result of the treatment radiation. This is distinct from recurrence or
metastasis of the primary treated cancer, which is referred to as secondary cancer in this
work. This is a particularly important consideration for paediatric patients as radiation-
induced cancers can take several years, even decades, to develop [73]. Therefore, it is more
likely that older patients would be less concerned by the threat posed by these cancers,
while younger patients have a longer remaining life-time over which to develop second
cancers. In addition, younger patients have a greater proportion of proliferating cells,
which are more likely to be in a radiosensitive (more susceptible to radiation damage)
stage of the cell cycle [74]. Younger patients are also more likely to be affected by rare
tumours that are typically close to critical structures in the central nervous system [75].
Therefore, proton therapy is often more appropriate for younger patients than photon
treatments. As a consequence, it is important to consider the effect of second cancers on
patient quality of life when selecting patients for proton therapy.
Comparative planning studies have indicated that proton therapy is associated with a sig-
nificantly reduced risk of second cancers. Examples include patients with liver metastases
receiving proton beam radiosurgery or photon beam radiosurgery [76], and medulloblas-
toma patients receiving spinal irradiations with IMPT (lifetime risk of 4%) or IMRT
(lifetime risk of 30%) [77]. The latter could be explained by the greater risk of second
malignancies associated with IMRT compared with conventional X-ray treatments [78],
[79]. In contrast, observations of second malignancy incidences after proton therapy indi-
cate that the treatment is not associated with a significantly increased risk of secondary
malignancies compared with photon therapy [80]. However, these observations were over
a relatively short follow-up period (median 6.7 years) compared with the time periods
over which these cancers can often develop [73].
Malignant transformation of cells is a stochastic process and usually occurs in the lower
dose region whereas cell death (leading to injury) occurs in the higher dose region. There-
fore, radiation that has been scattered during the treatment delivery is more likely to
result in a second cancer due to the lower dose it delivers [73]. While proton therapy
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reduces the integral dose to a patient, thus reducing the probability of cancer induction
[81], the out-of-field doses are not negligible. This further highlights the need to consider
the risk of second cancers when comparing proton and photon therapies [82].
Timlin et al. [83] developed a model to predict malignant induction probabilities for a
given dose to an individual patient, while considering varying responses of different tissue
types. They proposed that their model could be used for comparing radiation treatment
plans, but noted that validation is required to allow meaningful comparisons.
In this work, the SPICP is based on the model of Schneider et al. [84]. Here, the volumes
that receive a given dose are used to calculate the excess absolute risk (EAR) of cancer
induction for each year after exposure. Note that this is a cumulative probability and
differential probabilities were defined for this work as the difference in EAR between
adjacent years. The EAR for a particular organ at a particular time after treatment due







Here, ageX is the age of the patient at the time of treatment (the time of exposure to
radiation), age is the age of the patient after treatment at the year of interest, VT is the
total volume of the organ, βEAR is the initial slope of the dose-response curve, ` is the
total number of voxels, and
µ(ageX, age) = exp
[





with γe and γa being the age modifying parameters. The EAR model parameters assume
an age at exposure of 30 years and the age modifying parameters account for this. The
function RED(D) is the risk equivalent dose (RED) mechanistic model which accounts
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where R is the repopulation/repair parameter, α′ is given by




and DT and dT represent the prescribed dose to the target volume and the corresponding
dose per fraction, respectively.
The advantage of this model is that it combines data from the low dose region (A-bomb
survivors) with data from the higher dose region (Hodgkin’s Disease patients) to produce
a more reliable prediction in dose regions relevant to radiotherapy patients. In addition,
the effect of radiation treatment fractionation (where the treatment dose is delivered in
small, regular fractions) is incorporated. The limitation is the lack of clinical validation,
which can be difficult due to the long follow-up period required.
2.3.4 Summary
Radiobiological models have the power to quantify the complex relationship between radi-
ation dose and biological effect. Several models have been developed to quantify a variety
of endpoints. However, it is not advisable to implement these models clinically without
proper validation, otherwise a large degree of uncertainty exists regarding the accuracy of
their predictions. Radiation-induced malignancies are a particularly important consider-
ation when comparing photon and proton treatments at the level of individual patients.
Validation of these models can be practically challenging due to the long follow-up pe-
riods required. These uncertainties and limitations will be discussed in the publications
that form the body of this thesis.
Chapter 3
Monte Carlo Evaluation
The publication P1 forms the basis of this chapter.
Austin, A.M., Douglass, M.J.J., Nguyen, G.T. & Penfold, SN. A radiobiological Markov
simulation tool for aiding decision making in proton therapy referral. Physica Medica.
2017; 44:72–82.
3.1 Introduction and motivation
In this chapter, the development of the first patient selection model is described. The
distinguishing feature of this model is that it is based on a Monte Carlo simulation. This
preliminary model served as the basis for future patient selection models. However, this
model is complete and is able to predict the clinical outcome of an individual patient
from a given treatment plan.
The aims of this publication were to introduce the toolkit and to demonstrate the output
with an example patient, thus quantitatively determining whether the patient in question
would benefit from proton therapy.
Technical details relating to the development of this model are also presented in this
chapter, along with the results of the model verification. This verification was carried out
to ensure that the model was behaving as expected.
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3.2 Statement of contribution
3.2.1 Conception
The idea to use a Markov model as a tool for patient selection for proton therapy was
first conceptualised by Scott Penfold. All authors contributed to the development of ideas
and methods.
3.2.2 Realisation
The writing of the code and analysis was performed by Annabelle Austin, with advice
provided by Scott Penfold, Michael Douglass and Giang Nguyen.
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A B S T R A C T
Purpose: Proton therapy can be a highly effective strategy for the treatment of tumours. However, compared
with X-ray therapy it is more expensive and has limited availability. In addition, it is not always clear whether it
will benefit an individual patient more than a course of traditional X-ray therapy. Basing a treatment decision on
outcomes of clinical trials can be difficult due to a shortage of data. Predictive modelling studies are becoming an
attractive alternative to supplement clinical decisions. The aim of the current work is to present a Markov
framework that compares clinical outcomes for proton and X-ray therapy.
Methods: A Markov model has been developed which estimates the radiobiological effect of a given treatment
plan. This radiobiological effect is estimated using the tumour control probability (TCP), normal tissue com-
plication probability (NTCP) and second primary cancer induction probability (SPCIP). These metrics are used as
transition probabilities in the Markov chain. The clinical outcome is quantified by the quality adjusted life
expectancy. To demonstrate functionality, the model was applied to a 6-year-old patient presenting with skull
base chordoma.
Results: The model was successfully developed to compare clinical outcomes for proton and X-ray treatment
plans. For the example patient considered, it was predicted that proton therapy would offer a significant ad-
vantage compared with volumetric modulated arc therapy in terms of survival and mitigating injuries.
Conclusions: The functionality of the model was demonstrated using the example patient. The proposed Markov
method may be a useful tool for deciding on a treatment strategy for individual patients.
1. Introduction
The use of intensity modulated proton therapy (IMPT) for the
treatment of cancer has become increasingly common in recent years.
The primary advantage of IMPT over intensity modulated radiation
therapy with X-rays (IMRT) lies in reduction of integral dose deposited
in the patient while delivering an equivalent dose to the tumour volume
[1,2]. The disadvantage of proton therapy is that it is a more expensive
form of treatment with limited availability.
The issue of limited availability suggests that proton therapy should
be prescribed for those patients who will benefit most when compared
to treatment with conventional X-ray therapy. However, it is often
difficult to base a treatment decision for a given patient on the results of
randomised Phase III clinical trial data comparing novel and standard
treatments. One of the main issues is the long follow-up times required
for these clinical trials in an environment of rapidly evolving
radiotherapy technology, with results potentially becoming obsolete
shortly after they are gathered.
The concept of in silico clinical trials for proton therapy was pro-
posed by Langendijk et al. [3] to address this issue. Langendijk et al. [3]
suggest the use of normal tissue complication probabilities (NTCPs) as a
discriminator for when a patient should receive proton therapy. Using
validated, evidence-based parameters for the calculation of a given
NTCP, a comparison of values for proton therapy and X-ray therapy is
made. If the NTCP is reduced by a certain threshold value in the proton
plan relative to the X-ray plan, the patient is eligible to receive proton
therapy. A key assumption of this model is that the tumour control
probability (TCP) is equal for both treatments and second primary
cancer induction probabilities (SPCIPs) are neglected. Considering the
difference in integral dose one can expect when comparing an X-ray
treatment plan with a proton treatment plan, the latter assumption
warrants further investigation. This is particularly true for paediatric
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cancers where the patient may potentially live for many years after
treatment. A review of the potential use of radiation-induced cancer
risk predictive models was presented by Stokkevaåg et al. [4]. Another
example of work comparing X-ray and proton therapy (specifically
IMRT and spot-scanning proton therapy), based on NTCP modelling
only was presented by Yoshimura et al. [5].
In the current work we propose an in silico clinical trial model which
accounts for NTCP as well as TCP and SPCIP. To achieve this, a Markov
simulation framework was developed which aims to combine the do-
simetric data from all contoured structures to provide an estimate of the
quality adjusted life expectancy (QALE) resulting from a given treat-
ment plan. A Markov model is a type of stochastic model that is com-
monly applied in medical decision making [6–8]. The International
Society for Pharmacoeconomics and Outcomes Research Modelling
Good Research Practices Task Force has prepared a report outlining
best practices for developing and implementing Markov models in
medical applications [9]. The core quantitative output of the Markov
model presented in the current work is the QALE, which is an adjust-
ment of the raw life expectancy to account for the effect of poor health
on the quality of life of the patient. Therefore, estimating the QALE with
a Markov model can allow a quantitative comparison of treatment plans
at the level of clinical outcome. An example of a Markov model applied
to proton therapy was presented by Ramaekers et al. [10], who de-
veloped a tool for comparing proton and photon treatments for head
and neck cancers based on NTCP models. Xerostomia and dysphagia
were the only two toxicities considered which were assumed to be ir-
reversible after the first six months.
The novelty of the Markov framework presented in the current work
lies in the inclusion of a wide range of NTCPs and also the effects of TCP
and SPCIP on a patient’s quality of life. The induction of second cancers
is an important consideration for the younger patients often treated
with proton therapy. Separate NTCPs and SPCIPs were considered for
various organs at risk (OARs) to allow for a more realistic model, by
distinguishing between the effects of different treatment complications.
Several potential toxicities were included in addition to xerostomia and
dysphagia. As a further enhancement of the work of Ramaekers et al.
[10], all transition probabilities are time-variable in the proposed
model.
As a demonstrative test case, the model was used to estimate the
outcomes for a paediatric base of skull chordoma (BOSCh) patient after
receiving an IMPT and a volumetric modulated arc therapy (VMAT)
treatment. BOSCh is a very rare form of bone tumour that is difficult to
treat with radiotherapy due to the proximity of the spinal chord. In
addition, this type of tumour typically affects younger patients who
have a both a heightened sensitivity to radiation-induced cancer and
longer remaining lifetime over which to potentially develop one. Proton
therapy is seen as an advantageous treatment for this disease as it de-
livers a much smaller integral dose to the body compared with IMRT
[11]. The intention of this test was to demonstrate the capabilities of
the model rather than compare the efficacy of IMRT and IMPT for the
treatment of BOSCh.
In summary, the aim of this work was to develop and present a
Markov framework that included TCP and SPCIP in addition to NTCP
models to estimate the clinical outcome of a proton or X-ray treatment
plan on an individual patient basis. The technical details of the model
are presented in Section 2 with a description of the Markov states,
transition probabilities and model verification. The clinical example
and results are described in detail in Section 3 and a discussion and
conclusion is given in Sections 4 and 5.
2. The Markov model
With a discrete-time inhomogeneous (time-dependent) Markov
chain, the response of a patient to a particular treatment is modelled by
approximating the remainder of the patient’s life as a series of transi-
tions between a finite number of discrete states. The patient can occupy
only a single state at a given time. These states describe the health
status of a patient and include Well, Deceased and the Diseased group of
states (Section 2.1). The course of radiation therapy (either proton or
photon) is the strategy that is evaluated by the model and hence re-
presents a one-time intervention at the beginning of the Markov chain.
There are no subsequent interventions (additional treatments for ex-
ample) in this model.
In a Markov chain, the time period of interest (the patient’s lifetime
in this case) is divided into equal increments, or cycles. The cycle length
for this Markov chain was chosen to be one year as this provided
computational efficiency while allowing the Markov chain to have a
large number of cycles. This is particularly important in the context of
radiotherapy where complications can arise several years after treat-
ment. The model assumes that the patient remains in a particular state
for the duration of a cycle. At the end of each cycle, it is possible for the
patient to transition to another state. An important property of a
Markov process is memorylessness, which in this context implies that
the probability of the patient transitioning to another state depends
only on their current state and not on any previous states. The transi-
tion probabilities can vary with time and may be different for distinct
transitions between state pairs. The patient response is quantified by
the QALE, which is the primary metric used to evaluate and compare
treatment plans. Kaplan-Meier plots also provide a useful visual sum-
mary of the clinical outcome. In order to obtain statistical results, the
Markov process is simulated many times with each simulation re-
presenting a member of a hypothetical patient cohort. All tables re-
ferred to in this section can be found in the Appendix.
2.1. Markov states
Fig. 1 shows the Markov states for the simple case where there is
only one OAR being considered. In general however, the model can
consider any number of OARs. Each state is represented by a node in
Fig. 1. In medical applications of Markov models, the Well state cor-
responds to perfect health and the Deceased state represents patient
death. The other states represent various cases of poor health. In this
work, the Diseased group contains states that represent varying num-
bers and forms of diseases arising as a result of treatment. These states
include the cases in which a patient:
• still has their initial primary cancer due to unsuccessful treatment
(Diseased (primary cancer)), represented by the Cancer node
• develops one or more normal tissue complications as a result of
treatment (Diseased (injury)), represented by the Inj node
• develops one or more second primary cancers (SPCs) as a result of
treatment (Diseased (second cancer)), represented by the SPC node
There are also other states representing every possible combination
Fig. 1. The Markov state transition diagram showing the allowed transitions between
states. For simplicity, this describes the case where there is only one injury and one SPC
being considered in the model. “Well” represents perfect health. “Cancer” represents the
situation where the patient still has the initial primary cancer and “Inj” represents an
injury state.
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of the above:
• Diseased (primary cancer and injury), Cancer & Inj node
• Diseased (primary and second cancer), Cancer & SPC node
• Diseased (second cancer and injury), Inj & SPC node
• Diseased (primary and second cancer and injury), Cancer & Inj &
SPC node
The number of Markov states in the Diseased group is a variable
which depends on the number of second primary cancers (SPCs) and
injuries that are being considered in the model. A state exists for every
possible combination of SPCs and injuries that could affect a patient at a
given time. In addition, there is also a state for every possible combi-
nation of SPCs and injuries for the case where the primary cancer re-
mains as a result of unsuccessful treatment. Fig. 1 shows the allowed
transitions between states for the case where there is only one injury
and one SPC being considered. Depending on the value of the TCP, the
patient can begin the Markov process in either the Well state or the
Diseased (primary cancer) state (see Section 2.4.1 for an explanation).
Therefore, once the Markov process has begun, it is not possible to
transition between these two states, as depicted in Fig. 1. Section 2.4
describes how the probabilities of transitioning between these states are
derived.
2.2. Quality adjusted life expectancy
The Deceased state is particularly important as it is the absorbing
state of the Markov model. The patient cannot leave this state, which
allows the Markov process to terminate. The process will also terminate
if the patient reaches 100 years of age. This age represents the time
horizon of the Markov model. It was assigned a value of 100 years due
to the high probability of a patient deceasing before this age. The model
can estimate the life expectancy of a patient by counting the number of
cycles that pass before the Deceased state is reached, which is equiva-
lent to the number of years until death. However, the quality of a pa-
tient’s life is also of interest and this is affected by cancer or injuries
arising from complications from treatment. The quality adjusted life
expectancy (QALE) is an adjustment of the raw life expectancy to ac-
count for these factors. The QALE is the most indicative parameter of
the quality of a patient plan. To calculate the QALE, each state was
assigned a quality of life (QoL) utility. These values represent the
quality of life associated with the state relative to perfect health. By
default, the Well state is assigned the maximum QoL utility of 1 and the
Deceased state is assigned the minimum QoL utility of 0. All other states









where ti is the total number of cycles the patient spends in state i u, i is
the QoL utility for state i and n is the total number possible states. As
the utilities each have a value on the interval [0,1], the QALE cannot be
greater than the raw life expectancy. The advantage of this model is
that the probabilities of tumour control and of developing complica-
tions are incorporated into a single metric, the QALE, which is used to
evaluate treatment plans. Balancing these two factors leads to a more
effective comparison.
2.3. The Monte Carlo method
In order to accurately model the likely response of a patient to a
course of treatment, it is necessary to employ statistical methods. The
Monte Carlo approach to Markov modelling makes use of random
numbers and repeated sampling from probability distributions to obtain
numerical results.
Initially, a single hypothetical patient, also referred to as a Sim, is
considered in the model with an initial age equal to the patient’s age at
the time of treatment. At the beginning of each cycle, a pseudo-random
number η is generated and compared to the transition probabilities
between different possible states to determine whether a transition will
be made. This process involves considering all allowed transitions from
the current state. For example, it is not possible to transition from a
Diseased (cancer) state to the Well state. All relevant transition prob-
abilities are normalised to yield relative probabilities and then con-
verted to cumulative probabilities, such that the interval [0,1] is divided
into n regions representing the relative magnitude of each probability,
…R R R R[ , , , , ]n1 2 3 , where n is the number of allowed transitions and =R 1n .
If the normalised probability of transitioning to state k is P k( ) for ex-
ample, then +R R[ , ]k k 1 represents the region within the interval [0,1]
corresponding to that transition, where = −+P k R R( ) k k1 . If
< ⩽ +R η Rk k 1 then the Sim moves to state k, where the value of η is
constrained by < ⩽η0 1. The age and state variables are updated and
another cycle occurs. Once this Sim reaches the absorbing Deceased
state, or if the Sim reaches the age of 100, the process terminates and
the QALE (along with other metrics) is stored. This process is repeated
for a large hypothetical cohort of these Sims, with each Sim being an
identical copy of the individual patient under consideration. The re-
lative uncertainty is proportional to N1/ where N is the cohort size. A
large cohort is therefore required to maximise the precision of the re-
sults.
2.4. State transition probabilities
The probabilities of a Sim transitioning between particular states
were derived from radiobiological models. These models all require the
dose-volume data which is the primary input for the Markov model as a
whole. The choice of radiobiological model that is applied depends on
the pair of states between which a transition is being made.
2.4.1. Tumour control probability
The tumour control probability (TCP) is a single probability used in
the model to determine whether the treatment successfully controlled
the tumour. It is an important parameter as it determines the state in
which a Sim begins the Markov simulation, either Well for a successful
treatment or Diseased (primary cancer only) otherwise. If the calculated
TCP is less than a pseudo-random number, then the Sim begins the
Markov process in the Well state. If it is greater than or equal to the
pseudo-random number, then the Sim begins the process in the
Diseased (primary cancer only) state. Once the simulation has begun, it
is not possible for the Sim to transition between these two states.
The TCP is based on the linear quadratic (LQ) model which gives the
fractional number of surviving cells after being irradiated by a certain
dose [12]. In general, TCP models assume that the number of surviving
tumour cells follows a Poisson distribution, and that a single surviving
clonogen (cancerous cell) is required for tumour regrowth. Hence, tu-
mour control corresponds to all clonogenic cells being killed. The total
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where there are a total of M voxels, each having a fractional volume vi
(of the total tumour) that receives dose Di as part of a treatment de-
livered in n fractions n( )frac , and α and β are the linear and quadratic
coefficients of the LQ model, respectively. The parameter γ is the nor-
malised dose-response gradient evaluated at =D D50, the dose at which
50% of tumours are controlled.
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The particular values used for these parameters in the example
patient calculation are listed in Table 4 (Appendix A), along with an
explanation of their derivation. The sources of these parameters as-
sumed 2 Gy fractions, and hence the input dose was converted to the

















before being used as Di values to calculate the TCP with (2).
2.4.2. Normal tissue complication probabilities
The normal tissue complication probability (NTCP) represents the
probability of developing an injury as a result of treatment. In this si-
mulation tool, there is a separate NTCP for each injury being con-
sidered. For example, when treating BOSCh, necrosis of the brainstem,
cataracts of the eye lens, and spinal cord myelitis are some of the
possible complications that can arise after the commencement of
radiotherapy. Distinguishing between different injuries is important as
they may have varying effects on a patient’s quality of life. The NTCP
for a particular injury corresponds to a transition to the Diseased state
representing that injury.
The Lyman-Kutcher-Burman NTCP formalism is given by (5) and (6)
[12–14],




























where TD50 is the uniform dose given to the entire organ that results in
50% complication risk, m is an organ-specific parameter that represents
the gradient of the dose-response curve (analogous to γ), and n is a
parameter that characterises the volume dependence of the organ’s
response to radiation. Using the same method outlined in Section 2.4.1,
the Di values were obtained by converting the raw dose values to
equivalent doses in 2 Gy fractions. The NTCP calculation requires
clinically founded organ-specific parameters (listed in Table 5).
Unlike the TCP which is a single number, the NTCP is a time-de-
pendent probability and hence is given by an array of probabilities (one
value for each year after treatment). The all-time NTCP is given by (5).
The NTCP for each year after treatment is calculated based on a normal
distribution. This process involves several steps:
1. A time interval between two years x1 and x2 is selected.
2. The probability density function of the normal distribution is in-
tegrated using the trapezoidal rule,
∫ ∑≈ + + +
=
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to give the probability of developing an injury in a particular year
between years x1 and x2, where = −s x x N( )/2 1 is the step size, N is the
number of integration steps and the normal density function with
mean μ and standard deviation σ is given by
= −
−
f x μ σ
σ π










The parameters μ and σ are estimates of the mean and standard
deviation of time taken after treatment for the particular injury to
develop (listed in Table 6). An important source of these parameters
is the Quantitative Analysis of Normal Tissue Effects in the Clinic
(QUANTEC) data [15]. This is a large and comprehensive review of
available dose-response data for a variety of normal tissue end-
points. An alternative is the publication ALERT – Adverse Late Ef-
fects of Cancer Treatment [16]. Similarly to QUANTEC, it provides a
review of organ specific complications that can arise from treat-
ment, as well as organ specific dose-volume relationships.
3. The probability of developing the injury in a particular year is then
scaled so that the total area beneath the normal distribution over the
remaining possible life time of the patient (the difference between
100 and the initial age of the patient in years) is equal to the all-time
NTCP calculated from (5) for that injury. This calculation is re-
peated for each injury and the result is an NTCP for each possible
injury for each year after treatment. The total all-time NTCPs for
each injury are listed in Table 11.
2.4.3. Second primary cancer induction probabilities
The second primary cancer induction probability (SPCIP) represents
the probability of developing a second primary cancer as a result of
treatment. Similarly to the NTCP, there is a separate SPCIP for each
tissue where an SPC could form, which is used in the Markov model as
the probability of transitioning to a Diseased state representing that
particular SPC. In addition, the SPCIP is a time-dependent probability
and has a different value for each year after treatment.
The excess absolute risk (EAR) of developing a cancer in a particular
organ at a particular time after treatment due to radiation exposure is
given by (9) and was taken as an estimate of the SPCIP [17,18]
∑=EAR age
V
v D β RED D μ ageX age( ) 1 ( ) ( ) ( , ).org
T i
i i EAR i
(9)
Here, ageX is the age of the patient at the time of treatment (the time of
exposure to radiation), age is the age of the patient after treatment at
the year of interest,VT is the total volume of the organ, βEAR is the initial
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with γe and γa being the age modifying parameters.
Eq. (11) gives the risk equivalent dose (RED) mechanistic model
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where R is the repopulation/repair parameter, ′α is given by





and DT and dT represent the prescribed dose to the target volume and
the corresponding dose per fraction, respectively. The values used for
these parameters are listed in Table 7.
The probability of cancer induction for each year after exposure is
given by EARorg. Hence it is necessary to convert the probabilities from
cumulative to differential.
2.4.4. Transitions between diseased states
In reality, it is possible for more than one injury or SPC to affect a
patient at a given time which will in turn affect their quality of life. It is
therefore important to account for this in the model. As mentioned in
Section 2.1, there is a separate Markov state for every possible combi-
nation of injuries and SPCs that can affect a patient at a given time. To
transition between any two states that are within the Diseased group, at
least one of three possible events E must occur:
• development of an SPC, ESPCD,
• development of an NTC, ENTCD,
• recovery from an NTC, ENTCR.
These events were modelled as independent events, and thus it is
possible for more than one injury or SPC to develop in a given cycle. For
example, the probability of developing injury 1 E( )1 and injury 2 E( )2 in
the same cycle is given by
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∩ = ×P E E NTCP NTCP( ) .1 2 1 2 (13)
Note that while it is possible to recover from an injury and develop
another in the same cycle, it is not possible to develop and recover from
a given injury in the same cycle.
Injuries and SPCs also develop independently of whether the tumour
was successfully treated in this model. As a result, the presence or ab-
sence of the initial primary cancer was treated as a constant factor and
was modelled separately to the transitions between the Diseased states.
For example, the probability of transitioning to a Diseased state is the
same regardless of whether the treatment was successful.
2.4.5. Death probabilities
The probabilities of a Sim transitioning to the Deceased state are not
based on radiobiological models. In this model, there are three ways in
which a Sim can transition to the Deceased state:
• Death from the initial primary cancer. This transition probability is
time-dependent with a different probability for each year after
treatment. The complementary probability, the probability of sur-
viving cancer, was calculated before converting to death prob-
ability. It was assumed that cancer survival followed an exponential
distribution. The survival probability was calculated by integrating
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with a clinically derived decay parameter λ (listed in Table 8). The
function is scaled such that the total time integrated probability of
dying of cancer is equal to the area beneath the curve. The trape-
zoidal rule method as described in Section 2.4.2 was used to in-
tegrate the function between two particular years x1 and x2 to give a
probability of dying from cancer in a particular year.
• Death from injury or second primary cancer. This is also time-de-
pendent and derived using the same method as the primary cancer
death probability. Relevant parameters are listed in Table 8. These
probabilities are distinct from initial primary cancer death
Fig. 2. The CT scan of the patient with the isodose contours for each treatment plan.
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probabilities as the time of injury or second cancer onset is variable.
Therefore, the probability of dying from an injury or second cancer
depends on how long it has been affecting a patient. Implementing
these presents a practical challenge due to the ‘memoryless’ prop-
erty of Markov models where the probability of transitioning to a
particular state only depends on the current state and not on any
previous states. To address this challenge, a different state was used
to represent each of the possible time periods that an injury or
second cancer had been affecting the patient. For example, for a
given injury, there is a separate state for the cases where the injury
had been present for one year, for two years, for three years and so
on. The appropriate death probability was assigned to each of these
states.
• Death from unrelated causes. This probability is based on data from
life tables obtained from the Australian Bureau of Statistics (ABS)
[19]. The life tables give the probability that a person will die for
any given year in their life and hence this is a time-dependent
probability. Including the effect of unrelated death results in a more
realistic estimate for the life expectancy of the patient.
The model has the ability to distinguish between these different
causes of death. Each living state is associated with a probability of
dying from each of the various causes listed above. These probabilities
are added to the list of possible transitions that can be made from that
state. Section 2.3 describes how pseudo-random numbers are used to
determine the new state at the end of a cycle given the state at the
beginning of the cycle.
2.4.6. Recovery probabilities
The possibility of recovery from an injury once developed is in-
cluded in the model. The probability of recovering from a given injury
is calculated from a normal distribution in a similar fashion to the
cancer and injury death probabilities. This normal distribution requires
estimates of the mean and standard deviation of the recovery times,
along with an overall recovery probability.
3. Clinical example
A 6-year-old male presenting with base of skull chordoma was
considered for the purposes of testing the simulation tool. Treatment
plans for the delivery of 78 Gy in 39 fractions to the tumour with IMPT
(Fig. 2a) and with VMAT (Fig. 2b) were retrospectively generated by
using the patient computed tomography (CT) scans and MRI images as
input to the research release of Philips Pinnacle3 (Amsterdam, Neth-
erlands) treatment planning software. The treatment plans underwent
robust optimisation. In each treatment plan for this patient, each cri-
tical structure (healthy tissue) and the target volume corresponding to
the tumour were contoured by a clinician. A differential DVH was
generated for each of these regions. There was also a DVH for the total
volume of normal tissue. The injuries considered are listed in Appendix
A. Several injuries were considered for some structures. The TCPs,
NTCPs and SPCIPs that were calculated for each treatment plan for this
patient are listed in Appendix Tables 10–12, respectively.
3.1. Results
The model predicted the treatment response for a hypothetical co-
hort of patients, with each being a copy of the patient under con-
sideration. The cohort size was chosen to be 5·105, as this gave a stan-
dard error of less than 1%. The model returned the median life
expectancy of all the Sims along with the median QALE. The results for
this clinical example are listed in Table 1. The estimates of the life
expectancy (LE) are equal for both treatments but the QALE is greater
for the IMPT case.
The life expectancy is related to the cause of death. For the cohort
representing this patient, most deaths were not due to the cancer or
treatment. The proportions of the cohort who died as a result of other
causes are listed in Table 2.
The Kaplan-Meier survival curves are given in Fig. 3 where the
standard deviation used to estimate the 95% confidence intervals
SD(1.96 ) was calculated using Greenwood’s formula (15) [20],
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where ̂S j( ) is the survival fraction estimate at year j, yk is the number of
deaths that occurred in year k, and nk is number surviving at year k.
Kaplan-Meier survival curves were also generated for the QALE, and
are given in Fig. 4. A consistent difference in the treatments is apparent.
The proportions of Sims suffering an injury or second cancer are
listed in Table 3. The model predicted that there would be a small
probability of developing a second cancer for both treatments. There is
a larger probability that the patient would suffer a radiation induced
injury if treated with VMAT, most likely due to the proximity of the
tumour to the critical structures.
Table 1
The estimates of the median raw life expectancies (LE) and the median QALEs in years for
each treatment modality.
IMPT VMAT
Raw LE (years) 77.5 77.5
QALE (years) 76.5 74.9
Table 2
The proportions of the hypothetical cohort who died as a result of various causes for each
treatment modality. Injuries were not considered to be life threatening in this example.
Note that the simulation ceases when a Sim reaches 100 years of age.
Cause of death IMPT VMAT
Primary cancer 5.98% 8.21%
Second primary cancer 1.36% 1.55%
Unrelated death 91.5% 89.0%
Reached 100 (did not die during the simulation) 1.31% 1.20%
Fig. 3. Kaplan-Meier raw survival curves. A greater survival rate is predicted for IMPT in
the earlier years after treatment. The raw data has been binned yearly as it has integer
values. The 95% confidence intervals are indicated by shaded areas but are small in
magnitude.
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3.2. Significance testing
A log-rank test [20] was used to determine the statistical sig-
nificance of the results. This test allows a non-parametric two-sample
comparison of survival data, which is appropriate in this case as not all
Sims necessarily reach the Deceased state before they reach an age of
100. The null hypothesis of the log-rank test is that the hazard rate h at
a particular year i is equal for two treatments A and B,
=H i h h( ): Ai Bi0 (16)
where the hazard rate is defined by =h y n/i i i, with yi being the number
of deaths and ni being the number at risk (the number alive at the
beginning of year i). Under the null hypothesis, yi has mean Ei and
variance Vi as given by the hypogeometric distribution,
=
= −
E n n n
V n n n n n n
/
/[ ( 1)],
i Ai di i
i Ai Bi di si i i
2 (17)
where ndi, nsi and ni are the total number of deaths in year i, the total
number surviving at the end of year i, and total number at risk at the
beginning of year i, respectively, between the two treatments. The log-





















By the Central Limit Theorem, under the null hypothesis Z follows a
standard normal distribution. A two-tailed log-rank test was used to
compare the IMPT and VMAT raw Kaplan-Meier survival curves, as well
as the QALE Kaplan-Meier survival curves. A statistically significant
difference (p-value <0.05) between the treatments was detected for both
the raw and quality adjusted survival curves.
4. Discussion
A Markov model that predicts the clinical outcome after radio-
therapy has been developed and tested with two alternative treatment
plans for an example patient. The results of this demonstration suggest
that both the overall survival probability and the quality adjusted
survival would be significantly improved with the use of IMPT rather
than VMAT. This can be explained by the greater TCP associated with
the IMPT plan. In addition, many of the NTCPs associated with the
IMPT plan are an order of magnitude smaller than those associated with
the VMAT plan (Appendix C). Therefore, this patient could expect to
live both longer and with an enhanced quality of life with a reduced
probability of suffering a radiation induced injury or second cancer.
This is particularly true in the later years after treatment.
The strength of this Markov model is that it allows clear visualisa-
tion of the likely patient outcome in terms of not only survival, but also
complication risks. Furthermore, it has the ability to distinguish be-
tween alternative causes of high injury rates. For example, both treat-
ment plans used in the current example could result in complications
related to the parotids due to the elevated dose in this region. These
features could be a valuable aid for a clinician faced with the task of
prescribing an optimal treatment for a tumour. If the treatment plans
used for the demonstration were to be compared using the model of
Langendijk et al. [3] which compares NTCPs only, then the result would
most likely be similar, as the collective NTCP for VMAT was greater
than IMPT. However, the model presented in the current work also
accounts for a difference in TCP between treatment plans (see Table 2).
The presented model has several limitations which may have re-
duced the accuracy of its predictions. The results are predominantly
determined by the TCP, NTCP and SPCIP radiobiological models. While
efforts were made to include clinically founded parameters in these
models and the calculations of other transition probabilities, it was not
always possible to obtain relevant estimates in the literature. In addi-
tion, while the QALE is an important metric estimated by the model, its
value depends strongly on the QoL utilities assigned to each state which
were not clinically founded in all cases. In such instances, estimates
were used (see Appendix B). In other cases, it was not possible to source
entirely appropriate parameters. For example, the probabilities of dying
from a radiation induced brainstem glioma was based on adult patient
data, yet the model was applied to a paediatric patient in this work. It
was also not possible to source a quality of life utility for spinal cord
myelitis, and a utility for spinal stenosis was taken as an approximation.
However, these values are easily modified in a situation were new
studies come to light. Indeed, following the suggestions of Langendijk
et al. [3], the input database of model parameters should be continually
updated with follow-up data acquired as part of a the referral program.
NTCP model and dose uncertainties are known to have a significant
impact on the accuracy of model-based patient selection [21]. These
parameter uncertainties are distinct from the stochastic uncertainty that
has been considered in this work. Future development of this model will
account for the uncertainties associated with the DVH and radio-
biological parameters, allowing for representation of the overall un-
certainties in the final results.
The radiobiological models themselves also have limitations. The
advantage of the Lyman-Kutcher-Burman NTCP formalism is that it is
commonly employed in modelling studies and parameters are therefore
widely available. However, only severe radiation induced injuries were
considered in this work due to the difficulty in finding parameters for
less severe injuries. These types of injuries will be considered in future
applications of the model. The SPCIP was based on the Schneider model
of radiation-induced cancer[17] which has been developed for dose
ranges relevant in radiotherapy. However, that model has limitations.
For example, the dose delivered to the whole body can result from a
variety of dose distributions in the organs.
Another limitation of the model was that the course of the patient’s
disease was greatly simplified. For example, the possibility of metastasis
of the initial primary cancer or second primary cancers was omitted. A
constant quality of life was assumed for these cancer states.
Furthermore, it was assumed that if complete control was achieved,
there was no possibility of recurrence which also represents a deviation
Fig. 4. Kaplan-Meier QALE survival curves. The raw data has been binned yearly. The
95% confidence intervals are indicated by shaded areas but are small in magnitude.
Table 3
The proportion of the cohort that suffered a second cancer or injury.
IMPT VMAT
Proportion suffered injury 1.87% 10.3%
Proportion suffered cancer 5.68% 6.04%
A.M. Austin et al. Physica Medica 44 (2017) 72–82
78
from reality. These simplifications were made as the treatments used for
the initial primary cancer alone were the subjects of comparison.
Likewise, any treatments for subsequent injuries or second cancers that
would normally be carried out routinely were not considered directly in
the model. However, the effects of disease progression and metastasis
are important factors in determining both life expectancy and quality of
life. For more reliable estimates of these values, disease progression
would need to be considered in future versions of the model.
Proton therapy is known to be a significantly more expensive
treatment compared with X-ray therapy. As a result, cost-effectiveness
can be an important consideration in proton therapy referral. Cost-ef-
fectiveness for left-sided breast cancer has been evaluated by Lundkvist
et al. [22]. Due to the variability of both treatment costs and healthcare
system economics between countries, cost can be a challenging factor to
consider. As such, cost-effectiveness has not been considered in the
presented model. However, it may be considered in future develop-
ments within this framework.
Although the presented model has strengths, its inevitable limita-
tions may reduce its validity. Thorough internal model validation has
been carried out where components of the code where checked for
consistency. However, performing external model validation were
model results are compared with real-world results is a stronger form of
validation [23]. Such analysis will be conducted in future studies to
ensure the reliability of the model predictions.
5. Conclusion
A radiobiological-based Markov model for aiding the decision
making in proton therapy referral has been presented with the cap-
abilities being demonstrated with a test case. The Markov model allows
comparisons to be made between IMPT and X-ray therapy on an in-
dividual patient basis. The model suggests that the BOSCh demonstra-
tion patient considered in this work would likely receive a significant
benefit if treated with IMPT rather than VMAT in terms of a reduced
risk of injury. The accuracy of the model is reliant on the quality of the
input calculation parameters. The concept of in silico clinical trials could
be used to gradually refine the accuracy of the input data over time.
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Appendix A. Model parameters
A.1. Tumour control probability
Several studies have been conducted to determine the 5-year local control rate of chordoma for a given median dose using X-ray or proton
therapy (without chemotherapy) [24–32]. This data was used to plot a TCP curve. D50 was then varied to obtain γ within a 90% confidence interval.
The optimum value was yielded by minimising the width of this confidence interval. The results are listed in Table 4 along with the α β/ value that
was obtained from the literature.
A.2. Normal tissue complication probabilities
The parameters used in the NTCP calculations are listed in Tables 5 and 6.
Some data listed in Table 6 was derived from histogram data of injury incidences. A normal distribution was fitted to the data once plotted and
the best fit mean and standard deviation parameters of the distribution were taken as the estimates listed in Table 6.
Table 4
Parameters used in the tumour control probability (TCP) calculation with (2).
D50 (Gy) α β/ (Gy) α (Gy−1) γ
60.0 2.45 [33] 0.053 2.06
Table 5
Parameters used for the calculation of the all-time NTCP for each injury using the LKB model. Burman et al. was used as the source of the parameters unless otherwise stated.
Tissue α β/ (Gy) Injury/Endpoint n m TD50 (Gy)
Brainstem 2.5 [34] Necrosis 0.16 0.14 65
Spinal cord 0.87 [35] Myelitis 0.05 0.175 66.5




Optic nerves and chiasm 3.01 Blindness 0.25 0.14 65
Parotids 3.01 Xerostomia 0.70 0.18 46
Lens 3.01 Cataract 0.30 0.27 18
1 Assumed as the default 3.0 for late responding tissue.
A.M. Austin et al. Physica Medica 44 (2017) 72–82
79
A.3. Second primary cancer induction probabilities
The parameters used for the SPCIP calculation are listed in Table 7 [17].
A.4. Death probabilities
The parameters used for the calculation of the death probabilities are listed in Table 8. Where estimates of the mean were given by a source, the
decay parameter λ was assumed to be the inverse. Where estimates of the median m were given, it was assumed =λ mln(2)/ . Estimates do not
assume that any particular treatment is undertaken, although most studies will involve treatment of the patients. The impact on the quality of life of
these treatments is not considered in the Markov model.
Table 6
Estimates of the mean x( ) and standard deviations σ( )x of the time taken for each injury to develop after treatment. Where it was not possible to find an estimate of the standard deviation,
it was assumed to be 6months.
Tissue Injury x (months) σx (months) Source
Brainstem Necrosis 17 6∗ [36]
Spinal cord Myelitis 13.6 3.9 [37]
Ear Acute serous otitis 12∗ 6∗ –
Chronic serous otitis 12∗ 6∗ –
Optic nerves and chiasm Blindness 18 6∗ [16]
Parotids Xerostomia 0.25 6∗ [38]
Lens Cataract 30 6 [16]
∗ Not clinically founded.
Table 7
Parameters used for the calculation of the SPCIP for each year after treatment for each cancer site considered. The same parameters were used for all sites within the brain and central
nervous system.
Tissue βEAR α R γe γa
Brain/CNS 0.70 0.018 0.93 −0.024 2.38
Normal tissue 74 0.089 0.17 −0.024 2.38
Parotids 0.73 0.087 0.23 −0.024 2.38
Table 8
Estimates of the decay parameter, λ, and the total probability of surviving the cancer altogether, Psurvive, that were used to calculate the yearly probabilities of death as a result of cancer.
Tissue λ years−1 Psurvive Source Comments
Base of skull chordoma 0.9617 0.10 [39] Derived from 3 and 5 year survival rates after relapse
Brainstem (glioma) 0.154 0.45 (at five years) [40] Data for adult giloma
Spinal cord 1.39 0.21 [41] Survival after surgery for malignant astrocytoma (the most common spinal cord tumour [42] which are
themselves generally rare).
Ear 1.0∗ 0.61 [43] Carcinoma of external auditory canal and middle ear
Optic nerves and chiasm 0.0526 0.44 [44] Chiasmal glioma only considered
Parotids 0.438 0.45 [45] Overall survival probability including cases where there is and is not local-regional control
Normal tissue 1.0∗ 0.1∗ –
∗ Not clinically founded.
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Appendix B. State QoL utilities
The quality of life utilities applied in the Markov model are listed in Table 9. For Diseased states where there is more than one injury or second
cancer, the assigned utility is a multiplication of the utilities of the states where there is only one of each injury or second cancer.
The states representing the cases of second primary cancers were all assigned a value of 0.8 in accordance with the Eastern Cooperative Oncology
Group (ECOG) performance status [47] as grade 1 (with utility 0.8) gave the most accurate description of these states. With similar reasoning,
injuries were assigned a default value of 0.6.
Appendix C. Calculated transition probabilities
The transition probabilities that were derived from radiobiological models are listed in Tables 10–12.
The SPCIP calculation returns a probability for each year after treatment and these values are used as input for the Markov model. They are listed
here as combined probabilities for each tissue which were calculated by integrating the function that represents the probability of developing a
second cancer for each year after treatment. The combined probabilities are listed in Table 12 for each structure.
Table 9
Estimates for the QoL utilities for states in the Markov model. The states representing a second primary cancer have default utilities of 0.8. Where it was not possible to
find an appropriate QoL utility for a particular injury, a default value of 0.6 was assigned.




Brainstem necrosis 0.6 Not clinically founded
Spinal cord myelitis 0.7 [46] Utility for spinal stenosis (confined to manual wheelchair) taken as an
approximation for myelitis




Blindness 0.33 [46] Complete blindness
Xerostomia 0.826 [10]
Cataracts 0.6 [46] Advanced lens opacity
Table 10
The values for the TCP that were calculated and used as input for the Markov




The values for the all-time NTCP (combined NTCPs over all years from treatment to the maximum possible age of 100) that were calculated for each injury using
(5) for each treatment modality.
Injury Tissue IMPT VMAT
Brainstem necrosis Brainstem −7.97·10 5 −4.36·10 6
Acute serous otitis Cochlea −1.11·10 5 −1.52·10 6
Chronic serous otitis Cochlea −1.67·10 16 < −10 16
Cataracts Lens −1.08·10 4 −1.86·10 4
Blindness Optic nerves and chiasm −5.20·10 13 −1.03·10 12
Xerostomia Parotids −1.18·10 2 0.10
Spinal cord myelitis Spinal cord −7.14·10 3 −4.81·10 3
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3.3 Markov model details
In this section the details of the Markov model are described, with a focus on technical
aspects that were considered too detailed for the publication. The code is written in
the C programming language, which allows for an improved computation time compared
with higher-level programming languages such as Python or MATLAB. The program has
been written in general terms and, as a result, its strength is its ability to consider any
cancer site, with an arbitrary number of treatments and injuries.
The Markov model consists of several phases. These are:
1. Determining the number of Markov states based on the model input,
2. Calculating the transition probabilities using the patient data,
3. Constructing the transition matrix using the transition probabilities,
4. Evaluating the Markov model using a Monte Carlo simulation,
5. Analysing the results.
Each of these stages is explained in more detail in this section.
3.3.1 Determining the number of Markov states
In reality, it is possible for more than one injury (or normal tissue complication (NTC))
or second primary cancer (SPC) to affect a patient at a given time, which will in turn
affect their quality of life. It is therefore important to account for this in the model. To
model this accurately, a Markov state was allocated for every possible combination of
injuries and cancers (including SPCs and the initial primary cancer) that can affect a
patient at a given time. The number of Markov states in the Unwell group is a variable
which depends on the number of second primary cancers (SPCs), N , and of injuries, M ,
that are being considered in the model. Therefore, the total number of states, n, is given
by
n = 2M+N+1 +M +N + 2, (3.1)
where addition of 1 in the exponent represents the initial primary cancer (the presence of
this is independent of the development of injuries and SPCs). It is possible to die from
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each injury and cancer (including the initial primary) as well as background death. The
additional states signified by the sum (M +N + 2) represent the Deceased states. While
it is possible to model death with only one Deceased state, having one for each possible
cause of death allows the cause of death to be tracked by the model.
3.3.2 Transition probability calculation
The transition probabilities in the Markov model can be broadly classified as dose-
dependent and dose-independent. The dose-dependent transition probabilities are cal-
culated using input dose-volume histograms (DVHs) for each organ being considered.
These histograms give the volume of an organ that receives a given dose and hence are
unique to a given patient. The dose-dependent transition probabilities include the tu-
mour control probability (TCP), normal tissue complication probabilities (NTCP) and
second primary cancer induction probabilities (SPCIP). The dose-independent transition
probabilities include death and injury recovery, and are assumed to be representative of
all patients. Another assumption of the Markov model is that it is not possible to recover
from a cancer (including both the initial primary cancer and any second cancers). In this
section, additional details are provided on select groups of transition probabilities.
3.3.2.1 Normal tissue complication probability (NTCP)
The model has the flexibility to incorporate any number of injuries in the analysis. The
NTCP is calculated for each injury and for each potential year after treatment using the
methods described in the publication P1, Section 2.4.2. To complete the construction
of the normal distribution, which has a user-defined mean and standard deviation, the
NTCP for each year is scaled such that the accumulated NTCP from the treatment
time to the time at which the patient is 100 years of age is equal to the all-time NTCP
calculated with the LKB model [60, 61]. This is done by a recursive adjustment of a linear
scaling parameter, as the total response to such a change is non-linear and cannot easily
be determined analytically. At each iteration, the all-time NTCP calculated with the
LKB is compared with the all-time NTCP corresponding to the normal distribution with
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the given mean and standard deviation. Each time point in the distribution is adjusted
at each iteration to achieve closer agreement with the NTCP calculated with the LKB
model. This process is repeated for each injury, resulting in an NTCP for each possible
injury for each year after treatment.
3.3.2.2 Second primary cancer induction probability (SPCIP)
The calculation of the SPCIPs are similar to the NTCPs, in that there is a probability for
each year and for each tissue. The difference is that these time-dependent probabilities
do not follow a normal distribution, as detailed in the publication P1, Section 2.4.3. In
addition, the units of EARorg are per 104 person-years and hence EARorg must be divided
by 104.
3.3.2.3 Cancer and injury death
A key feature of first-order Markov models is the memoryless property, whereby the
transition probabilities depend only on the current state and not on any previous states.
It was assumed that in reality the death probability changes depending on if and when a
cancer or injury develops, which can be represented as a Markov model of arbitrary order.
Injury death (and also injury recovery) was assumed to follow a normal distribution, with
injury-specific parameters specified by the user. Cancer death was assumed to follow an
exponential distribution (Section 2.4.5 of the publication P1). Background death, which
is not discussed in this section, depends on the age of the patient at a given time.
It is possible to accurately implement a time-dependent death probability using a first-
order Markov chain, by having a separate state for each time period that an injury or
cancer could be affecting a patient, and assigning the probability of dying depending
on which state the patient is in. The disadvantage of this approach is that the number
of Markov states becomes very large, also known as “state explosion”, which decreases
computational efficiency as this is a function of the number of Markov states.
To avoid state explosion, an alternative method for modelling time dependence is used
in the code. An array is used to track the year in which a particular injury or second
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cancer develops. In subsequent years, the death probability that is applied corresponds
to the year since it was developed. Injury recovery is also treated in a similar manner,
with the yearly recovery probability being applied rather than the death probability. It
is assumed that the initial primary cancer, if present, has been present since the initial
Markov cycle and hence it is not necessary to track the time since its development.
A flag is also used to track whether an injury has been recovered from. If the flag evaluates
to TRUE, the relevant NTCP is set to zero for all subsequent years to prevent the injury
from redeveloping.
3.3.2.4 Scaling of death probabilities
For a given state, the true probability of death can be difficult to determine exactly, as
it is possible for a patient to die as result of multiple different causes. For example, if a
patient is in the Well state, then it is possible to die as a result of unrelated causes only.
However, if the patient is in a state representing a cancer, then it is possible to die from
either that cancer or unrelated causes. Dying as a result of the cancer or from unrelated
causes are not independent events as it is not possible to die from both. Furthermore,
the possibility of both a cancer and an injury also exists in this model, and in this case,
there would be three possible ways to move to the Deceased state.
In this example, let the event of dying from cancer be DieC and the event of background
death be DieB, and assume that it is not possible to die from an injury. As these two
events are disjoint and exhaustive, the probability of not dying is 1−Pr(DieB)−Pr(DieC).
Ideally, studies would report the fraction of their study population that died of various
causes, which would allow true probabilities to be known, as Pr(DieB) and Pr(DieC)
would be derived from the same source. However, mortality rates due to various causes
are often convoluted in a single reported mortality. This situation becomes increasingly
complex with an increasing number of injuries and cancers. As a result, it was necessary
in this work to source probabilities from different studies, with the consequence being that
the sum of individual death probabilities can exceed 1, which should not be possible. It is
not a reasonable approximation in this case to truncate the combined death probability
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to 1 and hence assume that death occurs with certainty. Hence, a challenge exists in
combining probabilities from multiple sources in a meaningful way in the Markov model.
As an alternative, it was assumed that the probability of moving from a given state to




where Pr(Diei) is the input probability of dying due to cause i. Clearly, if an injury or
cancer is not present in a given state, then it is not possible to die as a result of it.
In order to maintain a distinction between alternative causes of death, all death proba-
bilities are scaled such that their sum is equal to the maximum death probability (before
scaling), as given by (3.2). To achieve this, each unscaled death probability is divided by






The limitation of this approach is that the true estimates are not preserved. Furthermore,
a patient with one potentially fatal injury would have the same probability of dying as a
patient with two potentially fatal injuries. However, this is a reasonable assumption to
make as often there is a single dominant death probability. This is particularly true when
the patient is older and the background death probability becomes large. Alternatively,
there is a higher probability of dying in the years immediately after treatment if the treat-
ment was unsuccessful. For the example presented in the publication P1, an alternative
method was used that involved scaling all values of the row of the transition matrix such
that all values summed to 1, rather than scaling the death probabilities separately. If
the scaling method outlined in this section is applied instead, then the estimates of the
QALEs are 77.0 for protons and 76.0 for photons. This represents a small difference of
0.5 and 1.1 years, respectively. Therefore, implementing this method of scaling has a
small impact on the results, while being more mathematically correct in that transition
probabilities to non-deceased states are preserved.
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It is also worth noting that the death probabilities are dose-independent and are in-
cluded to allow for a more realistic estimation of the life expectancy resulting from a
given treatment plan. In contrast to the dose-dependent transition probabilities that will
differ between the treatment plans being compared, the death probabilities are constant
between treatment plans.
3.3.3 The transition matrix
The development of the transition matrix is a complex process due to the large number of
states involved. The transition matrix P has dimensions of n× n where n is the number
of Markov states. Each element pij, i = 1, ..., n, j = 1, ..., n, represents the probability of
transitioning from state i to state j.
To transition between any of the states that are within the Unwell group (all Markov
states excluding Well and Deceased), at least one of three possible events must occur:
development of an SPC, development of an injury, or recovery from an injury. In addition,
death must not occur if a transition is made from one Unwell state to another. Injuries
and SPCs develop independently of whether the tumour was successfully treated in this
model. As a result, the presence or absence of the initial primary cancer was treated as a
constant factor and was modelled separately to the transitions between the Unwell states.
Depending on the number of iterations chosen (the number of Sims) and the number of
organs at risk (which determines the number of states, see Section 3.3.1), the Monte Carlo
model can have a significant computation time. However, as each Sim (as defined in the
publication P1, Section 2.3) in the hypothetical cohort is considered separately, it is only
necessary to calculate the row of the transition matrix corresponding to the starting state
of the Sim at a given cycle. The process of constructing each row of the matrix includes:
1. Efficiently representing the states.
2. Determining which injuries or second cancers contribute to a given transition prob-
ability.
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3. Multiplying the probabilities of independent events together that all must occur for
a given transition.
3.3.3.1 Representing states
Consider the situation where there are M possible injuries and N possible SPCs that could
affect the Sim at any given time. When constructing the transition matrix, it is important
to be able to efficiently determine which of the states correspond to injured states or cancer
states. A method was developed to ensure all combinations were accounted for and that
the meaning of each state could be easily specified to allow appropriate quality of life
utilities to be applied. A Boolean vector Si with M + N elements was used to track
which injuries and SPCs are affecting the Sim at the beginning of a particular Markov





1 if Sim has NTC/SPC `,
0 otherwise.
(3.4)
Therefore, Si represents the state being transitioned from in a particular cycle. Another
Boolean vector, Sj with M + N elements, is used to track which injuries and SPCs are
affecting the Sim at the end of a Markov cycle in the state that is transitioned to. The
first M elements of Si or of Sj correspond to the injuries and the remaining elements
represent the SPCs.
For example, if M = 3 and N = 2, then the state where the Sim has injury 1, injury 3,
and SPC 2 is represented by S = [1 0 1 0 1]. In the Well state, there are no injuries or
cancers present and therefore it is represented by S = [0 0 0 0 0]. A vector is not required
to represent Deceased states as there is no possibility of leaving absorbing states, and it
is also unnecessary to multiply the death probabilities to obtain the final probability of
moving to a deceased state, as explained later in Section 3.3.3.2.
It is not necessary to consider the states where both injuries/second cancers and primary
cancer are present, as the presence or absence of the primary cancer does not directly affect
the transition probabilities between Unwell states. A separate flag is used to track the
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presence or absence of the primary cancer, which is constant throughout the simulation.
This flag allows the correct probabilities and utilities to be applied at the appropriate
year. Hence, the state representing the situation where only the initial primary cancer is
present is also represented by S = [0 0 0 0 0] if M +N = 5.
3.3.3.2 Calculation of transition probabilities
The probability of transitioning to the Deceased state for a given starting state is de-
termined using the method outlined in Section 3.3.2.4. To transition between all other
Markov states, one or more events must occur. For example, one or more injuries may
develop while others do not and others are recovered from. The development of, and
recovery from, different injuries and SPCs were modelled as independent events. The
development of a second cancer and an injury in the same tissue were also assumed to be
independent events, as there are very different cellular processes involved. In this model,
it is therefore possible for more than one injury or SPC to develop in a given cycle. As
these events are assumed to be independent, the probability of multiple events occurring
is given by the multiplication of the probabilities of the events occurring individually. It
should be noted that while it is possible to recover from an injury and develop another in
the same cycle, it is not possible to develop and recover from the same injury in a given
cycle.
There is an event E` for each second cancer and injury `, ` = 1, ...,M +N , that is being
considered for a given patient (recall that it is not possible to develop or recover from the
initial primary cancer once the Markov process has begun and hence it is not necessary
to account for this). Therefore, the probability of transitioning from state i to state j at
year x after treatment is given by:
pij(x) = (1−Pr(Die, i, x))
M+N∏
`=1
Pr(E`, i, j, x); i = 1, ..., n−nd, j = 1, ..., n−nd, (3.5)
where nd = M −N − 2 is the number of Deceased states, Pr(E`, i, j, x) is the probability
of event E` occurring in year x in the transition from state i to state j, and Pr(Die, i, x)
is the probability of transitioning from state i to the Deceased state. The probabilities
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Pr(E`, i, j, x) are determined by comparing the Boolean vector, Si, representing the state
being transitioned from, i, to the vector, Sj, representing the state being transitioned
to, j. The values of each of the ` elements of Si and Sj are determined by the events
E` that occur in the transition. The events include injury development, second cancer
development, or injury recovery. The probability of not developing an injury or cancer, or
not recovering from an injury is given by the complement of the respective development
or recovery probabilities. The event probabilities are given by:




NTCP`(x) if Si,` = 0, Sj,` = 1, ` ≤M,
SPCIP`−M(x) if Si,` = 0, Sj,` = 1, M < ` ≤M +N,
1− NTCP`(x) if Si,` = 0, Sj,` = 0, ` ≤M,
1− SPCIP`−M(x) if Si,` = 0, Sj,` = 0, M < ` ≤M +N,
Pr(IR`, x) if Si,` = 1, Sj,` = 0, ` ≤M,
1− Pr(IR`, x) if Si,` = 1, Sj,` = 1, ` ≤M,
0 if Si,` = 1, Sj,` = 0, M < ` ≤M +N,
1 if Si,` = 1, Sj,` = 1, M < ` ≤M +N.
(3.6)
where Pr(IR`, x) is the recovery probability for injury ` at year x. As the first M elements
of S correspond to injuries, it is necessary to subtract M from the SPCIP index to ensure
that the correct probability is applied. For example, if M = 2, N = 3 and ` = 3, then
the relevant SPCIP is SPCIP1, even though ` = 3. Note that it is not possible to recover
from second cancers. It is necessary to multiply all transition probabilities between living
states by the complement of the death probability as it is assumed that death must not
occur for a transition to be made to a living state.
The elements pij, where 1 ≤ i ≤ n − nd and n − nd < j ≤ n, correspond to the death
probabilities, which include the probabilities of dying as a result of each injury (j = n−
nd+1, ..., n−nd+M), followed by each second cancer (j = n−nd+M+1, ..., n−nd+M+N),
the primary cancer, pi,n−1, and the probability of dying due to unrelated causes, pin. If
an injury or cancer is not present in the state being considered, then the corresponding
death probability is set to zero.
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The elements pij, where n− nd < i ≤ n and 1 ≤ j ≤ n− nd, are all zero, as each of these
represent the probability of returning from the dead. Furthermore, for i > n − nd and
j > n − nd, if i 6= j, then pij = 0 (the probability of moving between deceased states),
and if i = j then pij = 1 (the probability of remaining in a Deceased state).
In this model, not all rows of the transition matrix are defined simultaneously. Only the
row that represents the state at the beginning of a given cycle is defined. However, to
demonstrate (3.6), an example transition matrix for a given year is provided below for the
case where there are two injuries only. The states are ordered from left to right (and top
to bottom) as follows: Well, Injury 1, Injury 2, Injury 1 and 2, Deceased (due to Injury
1), Deceased (due to Injury 2), and Deceased (due to unrelated causes). Each death
probability is scaled using the method described in Section 3.3.2.4, to give the scaled
probability of death due to unrelated causes, Pr(Db) (denoted by Db), and the scaled
probability of death due to injuries 1 and 2, Pr(Di1) and Pr(Di2), respectively, such that
Pr(Db) + Pr(Di1) + Pr(Di2) = α, the maximum of all the possible death probabilities.
The event NTCPx is denoted by Ix for simplicity. The recovery probability is denoted




p11 I1(1− I2)(1− α) I2(1− I1)(1− α) I1I2(1− α) 0 0 Db
R1(1− I2)(1− α) p22 R1I2(1− α) I2(1−R1)(1− α) Di1 0 Db
R2(1− I1)(1− α) I1R2(1− α) p33 I1(1−R2)(1− α) 0 Di2 Db
R1R2(1− α) R2(1−R1)(1− α) R1(1−R2)(1− α) p44 Di1 Di2 Db
0 0 0 0 1 0 0
0 0 0 0 0 1 0








p11 = (1− I1)(1− I2)(1− α),
p22 = (1−R1)(1− I2)(1− α),
p33 = (1− I1)(1−R2)(1− α),
p44 = (1−R1)(1−R2)(1− α).
(3.7)
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All possible transitions are both mutually exclusive and collectively exhaustive. In other
words, either a single transition is made in a given Markov cycle or the patient stays in
the same state, with the state at the beginning of the cycle being the same as the state
at the end of the cycle. The implication is that each row of the transition matrix will
sum to 1.
3.3.4 Monte Carlo simulation
The Monte Carlo simulation involves using random numbers to determine which transi-
tions are made in the Markov model. A random number η ∈ [0, 1] can be used for this
purpose. If this interval is partitioned into subintervals that represent the magnitude
of each of the transition probabilities, then the most likely transition will be the one
with the largest magnitude. The interval [0, 1] is partitioned by converting the transition
probabilities in a given row of the transition matrix from absolute to cumulative. The
result is that [0, 1] contains n subintervals where n is the number of states. This process
is demonstrated by Figure 3.1 with three states considered for simplicity.
Figure 3.1: Demonstration of the conversion of the transition probabilities from ab-
solute to cumulative. The interval [0, 1] is partitioned to represent the magnitudes of
each probability.
In the example depicted in Figure 3.1, the row of the transition matrix is Pi = [0.2, 0.45, 0.35],





pij, for1 ≤ k ≤ n. (3.8)
Thus, Ci(n) = 1. If a particular transition is not allowed, for example to state k, then it
will have zero width on the interval [0, 1] and Ci(k) = Ci(k − 1).
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As explained in the publication P1, Section 2.3, if Ci(k) < η ≤ Ci(k + 1) then the Sim
moves to state k. If η ≤ Ci(1), which is the probability of being in the Well state at the
end of the cycle (see the definition of P in Section 3.3.3.2), then the Sim transitions to
the Well state.
Once a transition from state i to state j has been made, each Si,` is reset to the values of
Sj,` for all `, and the process of recalculating the transition probabilities to the allowed
states is repeated in the subsequent cycle of the Markov model.
For each cycle, the age and state variables are updated. When a Deceased state is reached,
the simulation is terminated.
3.3.5 Analysis of model output
Once the Markov chain has been simulated for each Sim in the cohort, with the life
expectancy and QALE determined for each, it is possible to obtain mean life expectancies
and QALEs. The mean QALE in particular represents the most important output of the
model.
There is a notable technicality in the code, in that the counter for the loop that iterates
through each year of the Sim’s life starts at zero and hence its value is zero during the
first year of the Markov cycle. However, if a Sim were to die in the first year then their
life expectancy is 1.
Kaplan-Meier curves, both raw and quality-adjusted are also produced using the data
for each Sim. Examples of these are shown in Figures 3 and 4 of the publication P1.
Log-rank tests were used to determine the statistical significance of the difference in the
survival curves between protons and photons. The results are presented in Table 3.1. A
statistically significant difference was found for both the raw and quality-adjusted survival
curves.
Along with the survival curves, the fraction of the cohort with any injury or second cancer
for each year after treatment is also stored.




Table 3.1: Results of the two-tailed log-rank tests comparing raw and quality-adjusted
Kaplan-Meier survival curves. The Z-statistic and corresponding p-values are shown.
3.4 Model verification
Once the model had been developed, tests were carried out to ensure that it was behaving
as expected. These tests included modelling situations in which a patient receives zero
dose for the cases with and without an initial tumour present. The tests were used to
confirm that the cancer death model and life table data were being processed correctly
in the Markov framework. A cohort size of 105 was chosen for the purposes of testing the
model, as this gave a statistical standard error of less than 1%. The proton treatment
plan data used for the publication P1 was used as input for the verification. For the
purposes of this testing, the cohort membership was counted at the beginning of each
cycle.
3.4.1 Zero dose, tumour absent case
For the case where the tumour was absent, and no dose is received, the expected fraction





where Pri is the probability of a healthy individual dying in the i
th year of their life as
given by the life table data. Note that Death is not possible at t = 0, the beginning of
the first Markov cycle, and hence Pr0 = 0 which gives F0 = 1. The results are given in
Figure 3.2.
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Figure 3.2: The surviving fraction of the cohort for each year after treatment, where
there is no dose received by any organs and a tumour was absent. As a result, the
only enabled death possibility was background death. A good agreement between the
output and expectations is apparent.
3.4.2 Zero dose, tumour present case
The expected surviving fraction was also calculated for the case where the tumour was
present using (3.9), with Pri instead being the time-dependent probability of dying from
the primary cancer during a given year i after the treatment. The effect of background
death was omitted for the purposes of testing this component of the model. The results
of this test are summarised in Figure 3.3.
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Figure 3.3: The surviving fraction of the cohort for each year after treatment, where
there is no dose received by any organs and a tumour was present (TCP manually
overridden and set to 0). The integral death probability was set to 0.9 and the decay
constant needed for the calculation of yearly death probabilities was set to 0.96. Back-
ground death was also disabled. OARs outside of the tumour volume received no dose
for this test. A good agreement between the output and expectations is apparent.
3.4.3 Uniform dose, tumour absent case
The radiobiological components of the model were also verified. The NTCP and SPCIP
components were tested for the case where a tissue received a uniform dose of 50 Gy in
30 fractions, which resulted in a 21% injury occurrence rate.
Figure 3.4 shows a comparison of the expected fraction of the cohort with the injury and
fraction predicted by the model. The expected fraction with an injury at the beginning
of year t was estimated with:
It = 1− [(1− It−1)(1−NTCPt−1) + (PrIR)t−1It−1] , for 1 ≤ t < 100, (3.10)
where PrIR represents the probability of injury recovery. The sum on the right-hand-side
of (3.10) calculates the fraction without an injury, with the first summand calculating the
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fraction without an injury who do not develop one in that cycle and the second calculating
the fraction with an injury who recover during the cycle. It is not possible to develop an
injury at the beginning of the first cycle.
The injury death model was also tested. The results are presented in Figure 3.5. The
expected fraction with an injury at the beginning of year t was estimated using (3.9) with
Pi being set to the injury death probability for year i. In this test, the probability of
death was set as a constant of 0.01 for all years. Note that Death is not possible at t = 0,
the beginning of the first Markov cycle, and hence P0 = 0 which gives S0 = 1.
Figure 3.4: The fraction of the cohort with an injury, for each year after treatment.
The NCTP was set to 0.21 (as a result of a uniform dose delivered to an OAR) for the
first year after treatment and 0 for all subsequent years and the probability of injury
recovery was set to 0.05. The possibility of death from all causes was disabled for the
purposes of this test. A good agreement between the expectations and the output is
apparent.
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Figure 3.5: The surviving fraction for each year after treatment, where an OAR
received a uniform dose (resulting in an NTCP of 1.0 for the first year after treatment).
The possibility of injury recovery was disabled for the purposes of this test. The injury
death probability was set to 0.01, and all other death possibilities were disabled. A
good agreement between the expectations and the output is apparent.
3.4.4 Statistical significance
To determine whether the observed differences in the distributions in Figures 3.2-3.5 were
statistically significant, Pearson’s chi-squared tests were conducted. The null hypothesis
(H0) was that the observed distribution as output by the model was drawn from the
expected distribution:
H0 : The distribution of deceased/injured Sims as estimated by the Markov model
was drawn from the expected distribution;
H1 : The distribution of deceased/injured Sims as estimated by the Markov model
was NOT drawn from the expected distribution.
The test statistics and p-values for the chi-squared tests that were conducted for each
of the three cases are summarised in Table 3.2. The high p-values indicated that the
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Case KS test statistic p-value H0 rejected
Tumour absent, zero dose 21.9 0.99 No
Tumour present, zero dose 5.2 1.0 No
Tumour absent, uniform dose 49.0 0.55 No
Table 3.2: Summary of the Chi-squared test statistics. For these tests, the number
of degrees of freedom was set at 51 as there were 52 bins in total (the example patient
was initially aged 48, with 52 years remaining until they reached 100).
observed and expected distributions agreed in each case, and that the model was behaving
as expected.
3.5 Discussion
The toolkit has been presented and output demonstrated in the publication. Verification
of the model has also been carried out, with the result being that the model performed
as intended. However, it must be stressed that this method is distinct from validation
whereby the results are compared with outcomes of real patients. This step is vital before
the model is able to be implemented clinically.
The technical aspects that were not presented in the publication also have limitations.
Monte Carlo methods are inherently slow as a large number of iterations are required for
accurate results. Although this process may be easily parallelised using packages such as
OpenMP (OpenMP Architecture Review Board; www.openmp.org), the efficiency will be
limited by the number of available processors. The model is currently only a prototype,
but the intention is that it will be implemented clinically in the future. It is likely
that many clinics will be publicly funded and may not have access to high performance
computing resources that offer a larger number of processors.
The uncertainty associated with the model output is statistical uncertainty due to the
Monte Carlo simulation being based on random sampling. There is no consideration of
uncertainties in the model parameters or in the dose delivered to the tumour and organs
at risk. These uncertainties have the potential to influence the predicted benefit (or lack
thereof) of treating a patient with proton therapy.
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Another limitation of this model is the assumption that the death probabilities (as a
result of cancers and injuries) are dependent on time. However, it is more likely that the
probability of death would depend on stage of cancer or grade of injury. The quality of
life associated with an Unwell state would also depend on the grade or stage.
While the importance of validation has been addressed in the Discussion of the publication
P1, it would likely be difficult to validate some aspects of the model. For example, it
difficult to know exactly what causes a second cancer as it is a biologically stochastic
process.
3.6 Conclusion
The initial model has been developed successfully to consistently predict a clinical out-
come given a radiotherapy treatment plan using a Monte Carlo approach. Although the
model has incorporated numerous technical details, there are limitations that are ad-
dressed in a later model (see Chapter 4). However, if computational efficiency were not





The initial model developed as part of this work was presented in Chapter 3. This model,
referred to in this chapter as the Monte Carlo Evaluated (MCE) model, had limitations
which were discussed. A notable limitation was the large computation time. In addition,
there was no consideration of uncertainties associated with the input parameters or dose
data used to calculate the state transition probabilities. It was concluded that the most
efficient way to include these uncertainties was to evaluate the Markov model analytically
instead of with a Monte Carlo simulation. Hence, the model presented in this chapter
was developed to facilitate the inclusion of non-statistical uncertainties in the model
estimates. These uncertainties, which can potentially impact on whether a patient is
selected for proton therapy, are considered in a later version (see Chapter 5).
In this chapter, an updated model is presented and evaluated analytically, producing
results consistent with the results of the model outlined in Chapter 3 (provided a suffi-
ciently large number of Monte Carlo iterations). This model, referred to in this chapter as
the Analytically Evaluated (AE) model, involves considering simultaneously the entirety
of a hypothetical cohort of Sims (each being an identical copy of an individual patient
under consideration), rather than each Sim in the cohort individually with each being a
Monte Carlo simulation. For this reason, it is possible to obtain results with significantly
68
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reduced computation time compared with the MCE model. However, a disadvantage is
a greater memory usage requirement. At any given time, only the distribution of Sims
among the Markov states is known, and it is not possible to track individual Sims in the
AE model. Therefore, alternative methods must be employed to obtain results that are
equivalent to the MCE model and to ensure efficient usage of memory. Both models were
written in the C programming language.
The development of the AE model involved implementing several alterations in the Monte
Carlo code, predominantly to increase computation efficiency and to provide a more
realistic model output. Details of these are outlined in Section 4.2, where key differences
in the Markov states and transition probabilities are described. Next, the method of
evaluating the AE model is presented in Sections 4.3 and 4.4. The output is described
in Section 4.5 and the results and computational efficiency are compared with the MCE
model in Section 4.6. Finally, a discussion of the strengths and limitations of the AE
model is provided in Section 4.7, with several points also being applicable to the MCE
model.
4.2 Description of the AE model
While the two models are largely equivalent, there are key differences which are sum-
marised in this section. More realistic predictions are facilitated in the AE model by
incorporating the effects of differing injury grades and cancer stages on the quality of life
of the patient. This allows for a more accurate estimate of the quality of life of a patient.
Grades specify the severity of an injury, with higher grades corresponding to more severe
injuries, which have a larger impact on quality of life. Different grades may also have
different death and recovery probabilities (see Section 4.2.3). The staging of cancers is
explained in Section 4.2.1. For each cancer, a state was allocated to each possible stage,
and for each injury, a state was allocated to each possible grade. As a result, the number
of Markov states in the AE model is significantly greater than that of the MCE model
(see Section 4.2.6). The increased computational efficiency that could be achieved with
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an analytic approach compared with a Monte Carlo simulation allowed for the inclusion
of these additional states.
However, while the analytic evaluation is computationally more efficient compared with
the Monte Carlo simulation (see Section 4.4), the computation speed is still a function
of the number of Markov states. To further increase computational efficiency, techniques
were employed to remove unnecessary Markov states. These included the removal of neg-
ligible probabilities, removing negligible injury grades, and combining all second cancer
states into a single second cancer state.
4.2.1 Cancer staging
Cancers can be classified based on the likely prognosis [85]. Factors including tumour
extent, lymph node involvement and the extent of metastasis affect the classification.
The cancer classification groups are known as stages which are described as follows:
 Stage 0: Carcinoma in situ with no metastatic potential,
 Stage I: Smaller and less invasive cancers with negative nodes,
 Stages II and III: Increasing tumour or nodal extent,
 Stage IV: Distant metastasis.
A state was allocated to each possible stage of cancer. It was assumed that there were
three stages in the model, as Stage 0 was not considered to impact quality of life. However,
this assumption can be easily modified if necessary.
As prognosis is represented by the stage, it was concluded that death probability should
depend on the stage for a given cancer, rather than the time since treatment. Therefore,
each stage has a unique death probability. This is discussed in more detail in Section 4.2.3.
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4.2.2 Inclusion of higher injury grades
Unlike the transitions from the Well state to states with higher cancer stages, it is pos-
sible to transition to states with higher injury grades directly from the Well state. The
probability of this transition is given by the NTCP for each grade of injury. The events
of developing different grades of the same injury are mutually exclusive, that is, it is not
possible to be simultaneously affected by two grades of the same injury at the same time.
Therefore, there are no Markov states where two grades of the same injury co-exist. It is
also impossible to develop a grade of an injury once another has been recovered from (see
Section 4.3.1). Note that there is a single Deceased state for each injury: death due to
differing grades of the same injury will result in a transition to the same Deceased state.
If a member of the cohort does not have a given injury ` at a given time, then the
probability of not developing that injury, Prc(`, x), is the complement of the probability
of developing any grade of that injury at year x, given by




where NTCPi(x) denotes the probability of developing grade i of the injury, and Ng
denotes the total number of grades of the injury. This probability is implemented when
calculating the transition probabilities with (3.5) and (3.6), which combine the probabil-
ities of various events that constitute a transition. For example, consider the case where
there are two possible injuries that could affect a patient, with Injury 1 having one grade
and Injury 2 having two grades, a and b. For simplicity, death is not possible in this
example. The probability of staying in the Well state (with row i = 1 and column j = 1)
at year x is the probability of not developing any grades of any injury,
p11(x) = (1− NTCP1(x))(1− NTCP2a(x)− NTCP2b(x)). (4.2)
It is also assumed that any time spent in lower grades of the same injury while recovering
from a higher grade is negligible. Therefore, it is not possible to transition between
different grades of the same injury.
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If a constant number of grades is assumed for all injuries, then the result is a larger number
of Markov states, corresponding to an increased computation time. As an alternative,
the number of grades for each injury was defined as a variable that depends on the injury,
as specified by the user. For example, Injury 1 may have a single grade while Injury 2
may have two.
Once the injury grades were incorporated into the model, the output was tested under a
variety of conditions to ensure that the model was behaving as expected. These included
varying the number of injuries and the number of grades for each. Death and injury
recovery were also included. Example results are provided in Figures 4.1 and 4.2. It is
evident that the model is behaving as expected after the inclusion of injury grades.
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Figure 4.1: A comparison of the model output with expectations for each year after
treatment and a variety of scenarios: (a) the surviving fraction with background death
being the only possible cause of death (with a non-zero SPCIP and NTCP and a varying
number of injuries and grades, which allows the transitions between these states to be
checked); (b) the same as (a) with the only cause of death being the initial primary
cancer (with probability 0.9 and a TCP = 1); (c) the same as (a) with the only cause of
death being second cancer (with probability 0.5); (d) the fraction with a second cancer.
In (d) all possible causes of death were disabled to allow this specific component of the
model to be tested. A perfect agreement with expectations is apparent.
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Figure 4.2: A comparison of the model output with expectations for each year after
treatment and two injury related scenarios: (a) The fraction surviving with the only
cause of death being injury related (with probability 0.5); (b) The fraction of the cohort
with an injury where death is not possible and recovery occurs with a yearly probability
of 0.05. Several tests were carried out for each scenario with varying grades of injuries.
A perfect agreement with expectations is apparent.
4.2.3 Grade/stage dependence of death probabilities
A key difference between the two models is that the recovery and death probabilities
were assumed to be time-independent in the AE model, with the exception being the
probability of unrelated death. This is time-dependent in both models, as it is not
realistic to assume a constant unrelated background death probability for all ages.
Instead of being time-dependent, the cancer and injury death probabilities are grade-
or stage-dependent in the AE model. This is a realistic assumption, as explained in
Section 4.2.1. For the case of cancer, it could be argued that the cancer stage and the
duration for which it has been present are correlated, but it was concluded that the stage
of a cancer is a more appropriate determinant of death probability as the prognosis is
represented by the stage.
Besides injury grades and cancer stages being more realistic determinants of the patient’s
treatment outcome than time, they also allow for a much smaller number of Markov
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states. Recall, from Section 3.3.2.3, that the memoryless property of Markov models
would mean that each state would be required to include the length of time a given
injury or cancer has been present to allow the correct time-dependent probability to be
applied. This would lead to an impractically large number of Markov states.
The death probabilities can be specified by the user. It is also possible to transition to
higher stages of cancer from lower stages, with these probabilities also being user-defined.
It is assumed that if a cancer develops as specified by the SPCIP, then the lowest possible
stage of cancer develops and that the patient moves to the corresponding state. Refer to
Section 4.2.2 for an explanation of the relationship between states representing different
grades of injury.
4.2.4 Removal of negligible probabilities
The computation time and memory usage both increase rapidly with the number of OARs
that are considered in the model. To increase efficiency, OARs that received a particularly
small dose of radiation were not considered. For simplicity, this section will focus on the
NTCP but similar methods were applied to the SPCIPs.
The all-time NTCPs are firstly calculated for each OAR. If the NTCP is less than a
user-defined threshold, then the OAR is removed from the list of injuries. The removal,
if required, is carried out before the time-dependent NTCPs are calculated using the
method described in Section 2.4.2 of the publication P1. Ideally, the optimum threshold
for probability exclusion would be determined through a sensitivity analysis to ensure
that the accuracy of the output is not compromised by the removal of organs with small
NTCPs.
4.2.5 Combining individual organ SPCIPs
Although it is important to consider the effect of a radiation-induced second cancer in the
model, injuries typically have a greater effect on the quality of life of a patient as SPCs
typically occur much later than injuries. It is therefore reasonable to assume that all
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SPCs have an equal impact on the quality of life of a patient. As a result, a simplification
was made by having only one Markov state to represent all of the SPCs that could
potentially develop within the patient, rather than a separate state for each organ. This
simplification results in a greatly reduced number of Markov states and a corresponding
decrease in computation time. Note that a state still exists for the cases where a SPC is
present in addition to every possible combination of injuries as well as the initial primary
cancer.
The probability of transitioning to the combined second cancer state is given by the
combined yearly SPCIP for each cancer site under consideration. The formula used to
combine the probabilities is given by






which gives the probability of developing a second cancer in tissue i (event Ei) at any
year after treatment. Here, Pr(Ei) is the SPCIP for tissue i for a particular year, N is
the total number of tissues being considered as potential cancer sites, and Eci denotes the
complement of Ei. It was assumed that the SPCIPs for each tissue were independent.
This calculation is repeated for each year after treatment.
A single quality of life utility is assigned to this state and there is also a fixed (user-defined)
probability of transitioning to higher grades of the cancer. This allows a reduced quality
of life to be applied to a higher grade and for an increased death probability. Recovery
from cancer remains impossible in the model. The exception is that it is possible to
recover from the primary cancer immediately after treatment and before the beginning
of the first Markov cycle.
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4.2.6 Number of Markov states
There is a state for every possible combination of injury grade and cancer stage. The
total number of states, without any minimisation techniques, is given by
n = (u+ 2)M(v + 1)N+1 +M +N + 2, (4.4)
where M is the total number of injuries, u is the number of grades of each injury, N is
the number of second cancer sites being considered and v is the number of cancer stages.
The first summand on the right hand side of (4.4) represents the number of living states
which is equivalent to the number of permutations, where the order matters. Each cancer
and injury can take a particular ‘value’, depending on whether it is present in a given
state, and which grade or stage if present. The combination of all these values in a given
state corresponds to a particular permutation. The order matters as it is important that
the grade/stage of a particular injury or cancer is known (rather than simply knowing
that a certain number of injuries were of a given grade).
For a given state, each injury can have u + 2 possible ‘values’, one for each grade, one
for the case where the injury is not present, and one for the case where the injury is not
present but there is a history of the injury in the time since radiation treatment. This
is explained in more detail in Section 4.3.1. Hence there are u + 2 values to select from,
and M are selected. Similar reasoning applies to the cancers, however it is not possible
to recover from cancers and hence there are only v+ 1 values, and N + 1 are selected (N
second cancers plus the initial primary cancer).
The addition of M + N + 2 represents the dead states, one for death from each second
cancer and injury, one from the initial primary cancer and one from background death.
If the number of injury grades is variable for each injury (Section 4.2.2) and all possible
second cancer sites are combined into a single site (Section 4.2.5), then the number of
Markov states becomes
n = (v + 1)2
M∏
`=1
(u` + 2) +M + 3, (4.5)
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where u` is the number of injury grades for injury `. Here, N has been replaced with the
value 1.
4.3 Evaluation
For the AE model, the transition matrix P for a given year after treatment is constructed
which stores the transition probabilities for each state pair at a particular year. A differ-
ence to the MCE model is that the entirety of the transition matrix must be evaluated
at a given year, rather than a single row.
The row vector πi represents the fraction of the cohort in each state at the end of year i
and has n elements, one for each state. The first two elements represent the fraction of
the cohort that are well and the fraction with the initial primary cancer only, respectively
(see (4.8)). All other elements are zero at this point. At year i,
πi = πi−1Pi. (4.6)





where π0 is given by
π0 =
[
TCP (1− TCP ) 0 · · · 0
]
. (4.8)
4.3.1 Preventing redevelopment of injuries
Including the possibility of recovery from an injury allows for a more accurate estimate of
the quality of life of a patient. Biologically, it is impossible to develop a radiation-induced
injury after it has been recovered from. It is therefore important to distinguish between
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situations where a patient is well without a history of the injury (since treatment), and
where he/she is well but has developed and recovered from an injury since the treatment.
In the MCE model, flags were used to determine which injuries had been recovered from
and therefore which NTCPs should be zero in subsequent years (see Section 3.3.2.3). This
is not possible in the AE model, however, as it is not possible to track individual Sims. In
the AE model, an extra state was created to represent the situation where an injury had
been recovered from to track the injury history. Transition probabilities from recovered
states to injured states (associated with the same injury) are zero. For the case where
multiple injuries could possibly affect the patient, an extra Markov state was created for
every possible combination of injuries that could have been recovered from. An example
of this is provided in the publication P2, which forms the basis of Chapter 5.
The possibility of redevelopment of cancers is not considered, as it is assumed that it is
not possible to recover from cancers in this model.
4.3.2 Representing states
As with the MCE model, efficiently constructing the transition matrix for the AE model
is a complex task. The reason for this complexity is that not only is there a state for
every possible combination of cancer and injury that could be present, but also every
possible combination of injury grades and cancer stages, which corresponds to a much
larger number of states.
A similar method to the MCE model was employed to address this issue. A vector
S was used to represent each Markov state, with each element being an integer value.
The combination of element values is unique to each state (see Section 3.3.3.1). There
is an element to represent the presence or absence of each injury or cancer in a given
state. The format of S can be explained as follows: The first M elements represent the
injuries, the second to last element represents the SPC and the final element represents the
initial primary cancer. For example, if M = 3 and the initial primary cancer was treated
successfully, then the state where the patient has grade 1 of injury 1, does not have injury
2, has grade 2 of injury 3, and has stage 2 SPC, is represented by S = [1 0 2 2 0].
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In the AE model, the form of S has two key differences compared with the form in the
MCE model:
1. The number of elements.
(a) All second cancers are combined into a single state (see Section 4.2.5), and
hence there is only one element in S to represent the presence or absence of
second cancers.
(b) An element is also added to represent the initial primary cancer. In the MCE
model, each Sim is tracked separately and hence it is possible to simply use a
flag to mark the presence or absence of a successful treatment. However, this
is not possible in the AE model as the cohort is considered simultaneously,
and it is therefore necessary to track the status of the initial primary cancer
using other means. Consequently, there are M + 2 elements in each vector S.
For example, if M = 3 and N = 2, in the MCE model
S = [s1 s2 s3 s4 s5 ], (4.9)
and in the AE model
S = [s1 s2 s3 s4 s5 ], (4.10)
where the positions of the elements representing second primary cancer states
are highlighted in pink and the initial primary cancer in yellow.
2. The possible values for the elements. In the MCE model, if an injury or cancer is
present, then the value of its corresponding element is 1. Otherwise, it is 0. In the





r if patient has grade/stage r of injury/SPC `,
−1 if patient has a history of injury `,
0 otherwise.
(4.11)
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The state at the end of the cycle is represented by Sj, which has each element `
defined in the same manner:
(a) Integers greater than 1 are used to account for states where there are higher
grades of injury or stages of cancer present. For example, if the lowest grade/stage
is present, then the element representing the corresponding injury/cancer is
assigned a value of 1. If grade/stage 2 is present, it is assigned a value of 2
and so on.
(b) Recovered states. Additional states, called recovered states, were assigned to
represent situations where there has been a history of a particular injury (see
Section 4.3.1). States where an injury is absent but has been present in the
past have the element representing the injury assigned to −1.
4.3.3 Structure of the transition matrix
The row order of the transition matrix for each year is as follows:
1. The Well state is listed first, followed by the initial primary cancer only (no second
cancers or injuries) state.
2. All Unwell states are listed with the exception of the states where an injury has
been recovered from. These states are listed in lexicographical order. For example,
the order of the first states (represented by S) are: [0 0 0 0] (well), [0 0 0 1], [0 0 0
2], [0 0 0 3], [0 0 1 0], etc.
3. These Unwell states are followed by the Unwell states that are duplicated for the
cases where there has been a history for one or more injuries. For a given number
of absent injuries, there is a duplicate for every possible combination of histories
of the absent injuries. For example, if there are two absent injuries, Injuries 1
and 2, then there are four states with only these injuries absent (all other factors
constant, including the presence or absence of cancers and other injuries). If the
cancers are absent, then there is the state for where both have never been present,
represented by S = [0 0 0 0], a state for where both have been present (S =
Chapter 4. Analytic Evaluation 82
[−1 − 1 0 0]) and two states for the cases where one has been present in the
past (S = [0 − 1 0 0] and S = [−1 0 0 0]). Of these four, the first is listed
with the non-recovered Unwell states in the previous item.
4. The order of the recovered Unwell states follows the order of the non-recovered Un-
well states, that is, all duplicates of a given non-recovered state are listed together.
The order of these follows a binary pattern, with a 1 being replaced with a -1 to
denote the history of an injury. For example, consider the simple case where there
are no cancers present and two injuries. The order of the states are demonstrated
as follows for the case where the cancers are absent, along with a description of
each of the states:
[0 0 0 0]→Well, no injury history,
[0 1 0 0]→Injury 2, no history of Injury 1,
[1 0 0 0]→Injury 1, no history of Injury 2,
[1 1 0 0]→Injuries 1 and 2,
[0 -1 0 0]→Well, history of Injury 2,
[-1 0 0 0]→Well, history of Injury 1,
[-1 -1 0 0]→Well, history of both injuries,
[1 -1 0 0]→Injury 1, history of injury 2,
[-1 1 0 0]→Injury 2, history of injury 1.
5. Finally, the Deceased states are listed, one for each injury, followed by the second
cancer Deceased state, the initial primary cancer Deceased state and the background
Deceased state.
4.3.4 Calculation of transition probabilities
The elements of the transition matrix are calculated in the AE model using a similar
method to the MCE model (see Section 3.3.3.2). Development of different injuries and
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SPCs are independent (with the exception of differing grades of the same injury). There-
fore, the probability of transitioning from state i to state j at year x after treatment is
given by
pij(x) = (1−Pr(Die, i, x))
M+2∏
`=1
Pr(E`, i, j, x), i = 1, ..., n−nd, j = 1, ..., n−nd, (4.12)
where Pr(E`) is the probability of event E` occurring and nd = M − 3 is the number
of Deceased states. The events associated with a given transition are determined by
comparing the state at the beginning of the cycle, represented by Si, to the state at the
end of the cycle, represented by Sj. The values of each of the ` elements of Si and Sj
are determined by the events that occur in the transition. The events include injury or





NTCP`,r(x) if ` ≤M, Si,` = 0, Sj,` = r, r ≥ 1,
SPCIP(x) if ` = M + 1, Si,` = 0, Sj,` = 1,
1−∑ur=1 NTCP`,r(x) if ` ≤M, Si,` = 0, Sj,` = 0,
1− SPCIP(x) if ` = M + 1, Si,` = 0, Sj,` = 0,
P r(EIR,`,r) if ` ≤M, Si,` = r, r ≥ 1, Sj,` = 0,
1− Pr(EIR,`,r) if ` ≤M, Si,` = Sj,v ≥ 1,
P r(ESI,s, is, js) if ` = M + 1, Si,` ≥ 1, is < js,
1− Pr(ESI,s, is, js) if ` = M + 1, Si,` = Sj,` ≥ 1, is < js,
P r(ESI,p, is, js) if ` = M + 2, Si,` ≥ 1, is < js,
1− Pr(ESI,p, is, js) if ` = M + 2, Si,` = Sj,` ≥ 1, is < js,
(4.13)
where Pr(ESI,s, is, js) is the time-independent probability of the stage of second cancer
increasing from stage is to stage js, Pr(ESI,p, is, js) is the time-independent probability
of the stage of initial primary cancer increasing from stage is to stage js, NTCP`,r is the
probability of developing grade r of injury `, Pr(EIR,`,r) is the probability of recovering
from grade r of injury `, and u is the total number of grades of injury `. The probability
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of the stage of cancer increasing can be unique for a given pair of stages. Note that the
injury recovery is time-independent.
Many of the transitions from Si to Sj are impossible, including:
 Si,` = −1, Sj,` > 0, ` ≤M : developing an injury again once recovered from,
 Si,` 6= 0, Sj,` = 0, ` ≤M : erasing a history of injury,
 Si,` = 0, Sj,` = −1, ` ≤M : recovering from an injury before obtaining it,
 Si,` > 0, Sj,` > 0, Si,` 6= Sj,`, ` ≤ M : transitioning between different grades of the
same injury,
 Si,` > 0, Sj,` = 0, ` > M + 1: cancer recovery,
 Si,` = 0, Sj,` > 1, ` = M + 1: developing a higher stage of cancer before the lowest
stage,
 Si,` = 0, Sj,` > 1, ` = M + 2: recurrence of the initial primary cancer.
4.4 Computational efficiency methods
With a state for every possible combination of injury grades, cancer stages and also
the recovered states, a challenge exists in storing the entirety of the transition matrix
simultaneously. As explained in Section 4.3.4, the transition matrix is a sparse matrix
as many elements are zero. This property was utilised to allow for more efficient storage
and computation time without compromising the model predictions. This is particularly
important as the intended purpose of the model is to provide decision support in the
clinic with minimal computation time. Furthermore, it is likely that many clinics would
rely on standard desktop computers due to a limited access to supercomputer clusters.
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4.4.1 Method of matrix condensation
Each matrix element is calculated in order of increasing row, then increasing column. The
method of matrix storage involves storing only the non-zero values of the transition matrix
as they are calculated. These values are stored sequentially in a single one-dimensional
array in order of increasing row then increasing column (the order in which they are
calculated). As a number of probabilities are time-dependent, the length of this array is
not necessarily constant for each year after treatment. The array is accompanied by two
other arrays of equal length: one stores the row index of each non-zero element and the
other stores the column index of each non-zero element. The indices are important as
they allow successive transition matrices to be multiplied together.
4.4.2 Filling of the transition matrix in blocks
The slowest component of the model evaluation is the process of determining which
events contribute to each probability in the transition matrix (see Section 4.3.4). It is
not possible to know which transitions are impossible until the events that contribute
to the transition have been assessed. As the matrix is sparse, there are many elements
that are calculated but not stored as they evaluate to zero. This represents unnecessary
computation time.
Fortunately, the structure of the matrix has a pattern due to the lexicographical ordering
of the states (see Section 4.3.3). This property was exploited to decrease the computation
time required to construct the transition matrix for each year. For example, consider the
case where there are three injuries and no cancers. The state where the first injury is
present and the others are not is represented by Si = [1 0 0 0 0]. Suppose the elements of
the row corresponding to this state are being calculated. The first transition considered
is from this state to the Well state, represented by Sj = [0 0 0 0 0]. This transition is im-
possible as recovery from the first injury would mean a transition to the state represented
by [−1 0 0 0 0]. Hence, once the first element of Si in this case is compared with the first
element of Sj, the transition matrix element will evaluate to zero regardless of any events
associated with the other injuries present. Therefore, it is not necessary to consider these
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events. Similarly, it is impossible to transition to all other states where Sj,1 = 0 if Si,1 = 1
and these probabilities are not stored as a result. Recall that, due to the lexicographical
order, all states where Sj,1 = 0 (or where Sj,1 = 1) are listed consecutively due to the
order of the states. States where Sj,2 = 0 or where Sj,2 = 1 are not necessarily listed
together but are listed in sub-blocks. The sizes of the blocks decrease with increasing
index value of the element of Sj. Hence, the largest computation savings correspond to
elements of Sj with the smaller indices.
In general, the process of filling the matrix in blocks is as follows:
1. Each row is considered separately (i is kept constant), that is, the probabilities of
transitioning from a given state to all other states. The rows representing Deceased
states are not included in the algorithm as all elements of these rows will be zeros
(except the diagonal elements, i = j > n−nd, which are equal to 1 as it is impossible
to leave a Deceased state). Once rows i ≤ n−nd have been filled, nd elements with
the value 1 are appended to the end of the array that contains the values of the
transition matrix (see Section 4.4.1).
2. The events corresponding to the first transition probability in the row are deter-
mined by considering elements of Si,` and Sj,` for ` = 1, ...,M + 2.
3. If a forbidden event is encountered for a given i and j, then the transition probability
is assigned a value of 0 regardless of whether all possible values of ` have been
considered. This is because each transition consists of several events and if at least
one event is forbidden, then the transition is not possible. Thus, it is not necessary
to check all possible values of `, thereby saving computation time.
4. A check is then carried out to determine whether the same forbidden event E` exists
for a transition to be made from state i to the next state in the row, j + 1 (before
checking if other events exist by keeping ` constant). If it does occur, then the
transition is also forbidden and the state j + 1 is skipped without being stored.
No other calculations are necessary to determine that transition probability. The
reduced number of calculations results in a reduced computation time.
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5. Each of the following states are skipped (j + 1 is incremented while keeping `
constant) until a state is encountered where the forbidden event does not occur.
Then Step 2 is repeated for the next probability in the row i.
6. The process is repeated until j = n− nd + 1 and the absorbing states are reached.
These are appended to the list of transition matrix values. If the row represents a
state where an injury or cancer is not present, then the corresponding element is
set to zero and not stored in the condensed representation of the transition matrix
(recall that only the non-zero elements are stored).
7. The process is repeated for the next row of the transition matrix.
4.5 Model output
Evaluating the AE model analytically involves making calculations based on the distri-
bution of the cohort among Markov states at each cycle. From here, it is possible to
calculate both the raw and quality-adjusted life expectancy.
4.5.1 Raw life expectancy
Both mean and median raw life expectancy can be calculated from the fraction of the
cohort that moved to a Deceased state each year. This fraction for a given year is the
difference between the surviving fractions of two consecutive years. Initially, at τ = 0, the
surviving fraction is 1 by default as it is not possible to die at this time in the model. In
a discrete-time Markov model, the time to death, τ , is a discrete random variable. Hence
it is only possible for a member of the cohort to die at τ = 1, 2, 3..... If death occurs at
τ = 1 for example, then the life expectancy is 1.
The mean life expectancy is equivalent to the expected time until death, E[τ ], plus the
patient’s age at treatment, a. The expected time to death is determined by finding the
mean of the distribution of yearly deaths, which depends on the probability of dying in
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kPr(τ = k), (4.14)
where m = 100− a, Pr(τ = m) = 1−∑m−1k=1 Pr(τ = k) and Pr(τ > m) = 0, that is, the
surviving fraction of the cohort is absorbed after the final year of the Markov chain. If a
patient does not die before 100−a, then it is assumed that they are deceased after 100−a,
as it is not possible to live beyond the age of 100 in the model. This assumption allows
comparison of the output with that of the MCE model, where each Sim is considered
individually.
The probability of dying at a given year can be calculated as






where πA0 contains the initial fraction of the cohort in each living state, the square matrix
P
(i)
A is the upper left quadrant of the transition matrix at year i that represents the proba-
bilities of transitioning between the living states, and d contains each of the probabilities
of moving from a living state to a Deceased state. The sum of the numbers of elements
of d and πA0 is equal to the number of Markov states, n.














It is also possible to calculate the mean “on the fly” with a less computationally expensive
































where n is the number of Markov states. This is essentially the sum of the surviving
fraction at each year.
In reality, the distribution of the time until death is a skewed distribution, as typically the
death probability increases with time due to the effect of background death. Therefore,
it is more appropriate to report the median life expectancy instead of the mean, as
it generally is not distorted by skewed data. It is possible that two treatment plans
could have equal mean life expectancies but unequal medians and therefore the median
can provide additional information. By definition, half of the cohort will die before the
median life expectancy. This quantity may therefore be calculated by finding the age
corresponding to half of the area contained within the distribution of time until death.
4.5.2 Quality-adjusted life expectancy
The calculation of the QALE is more complicated than the raw life expectancy. Unlike
the MCE model, it is not possible to track individual members of the cohort and it is
therefore not straightforward to obtain a distribution of QALEs for the calculation of the
mean and median QALE. For example, if a certain fraction moves to the Deceased state
in a given year, each member in that fraction would not necessarily have had the same
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injuries or cancers for the same amount of time and hence may not have had the same
quality of life.
Equation (4.17) calculates the mean survival each year, and then sums over all years.
The result is the mean life expectancy. A similar method can be used to obtain the mean
QALE, by multiplying the fraction of the cohort in a given state by the utility of the






(πj)i · ui (4.18)
where U = [u1 u2 ... us] is a vector of the quality of life utilities for each state. While
the mean QALE is straightforward to obtain, this is not the case for the median QALE.
Therefore, the median QALE was not considered in the AE model.
4.5.3 Other metrics
The proportion of the cohort that died of particular causes (discussed in Chapter 3) is
evaluated by the AE model. This is achieved by having several Deceased states, one for
each possible cause of death (as explained in Section 3.3.2.4), and considering the fraction
of the cohort in each of these states when the time horizon is reached.
The yearly fraction of the surviving cohort that suffered an injury or second cancer after
treatment is also evaluated by the model. This is calculated as the sum of the fractions of
the cohort in each injured or cancer state, respectively (some states are both injured and
cancer states). The fraction with an injury or second cancer is divided by the surviving
fraction to give the surviving fraction in an unwell state.
4.6 Comparison with the MCE model
It was necessary to compare the output of the two models to ensure that the AE model
was developed correctly. The output of the MCE model was verified to ensure that the
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model was behaving as expected (see Section 3.4). Therefore, if the two model outputs
agree, then it could be inferred that the AE model is also behaving as expected.
The fundamental difference between the evaluation of the two models is that the entirety
of the hypothetical cohort is considered simultaneously in the AE model, whereas individ-
ual cohort members are considered separately in the MCE model. However, this should
not affect the predictions of the model.
Another important difference between the evaluation of each model is the alternative
methods used to prevent injury redevelopment. While this should not result in differing
predictions, it does increase the number of states in the AE model compared with the
Monte Carlo simulation. This is important to consider when comparing the computation
time of the two models.
The death and recovery probabilities are time-independent in the AE model (with the
exception of the background death probabilities), as described in Section 4.2.3. However,
for the purposes of comparing the output between the two models, the death probabilities
in the MCE model were manually set to time-independent values that were equal to those
used in the AE model. Furthermore, for the purposes of comparing with the MCE output,
injury grades and cancer stages were not included in the AE model as these were not
originally considered in the MCE model.
The SPCIPs are combined for all organs in the AE model. Therefore, only a single organ
was considered in the comparison to remove the effect of the alternative processing of
these probabilities on the comparison. Negligible probabilities were not removed.
The data from a proton plan for a four-year-old female base of skull chordoma patient
was considered for the test. This data was the input to both models. A cohort size of 106
was selected for all tests of the Monte Carlo simulation as this gave results consistent to
3 significant figures. The yearly primary cancer death probability was set to 0.9 and the
yearly second cancer death probability was set to 0.1. The injury death probability was
set to 0. The results are summarised in Table 4.1. The two models produce the same
result to within 3 significant figures, and also agreed to within the statistical error of the
MCE model. This is the same level of accuracy that can be obtained when comparing
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different outputs of the Monte Carlo simulation calculated with the same input data. A
comparison of the graphical output is given in Figures 4.3-4.5. These compare at each
year after treatment the surviving fraction of the cohort, the fraction injured, and the
fraction with a second cancer, respectively. Good agreement was achieved for all cases
tested.
Monte Carlo Analytic
Mean raw LE (years) 67.43±0.08 67.42
Mean QALE (years) 41.05 ±0.32 41.00
Table 4.1: The results of each model given equivalent input data. The TCP resulting
from the input treatment plan was 0.83 and the NCTP was 0.99. The Monte Carlo
cohort size was 106 and the statistical uncertainty associated with the life expectancies
is shown.
Figure 4.3: The fraction of the cohort surviving for each year after treatment. The
cancer death probability was set at 0.9 which results in the initial sharp decrease in
survival. The possibility of death due to injury was disabled. The background death
accounts for the large decrease in survival in the later years after treatment. A good
agreement between the two models is apparent.
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Figure 4.4: The fraction of the cohort with an injury for each year after treatment.
The probability of injury recovery was set to 0.05. A good agreement between the two
models is apparent.
Figure 4.5: The fraction of the cohort with a second cancer at each year after treat-
ment. The small discrepancy apparent is a result of the relatively small probability of
developing a second cancer (differences are more easy to detect compared to Figure 4.4,
due to the difference in vertical scale).
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The computation time was also compared between the two models. For the Monte Carlo
simulation, this time is a function of both the hypothetical cohort size (number of itera-
tions) and the number of states. In contrast, the analytic computation time is function
of the number of states only. The same patient data was used (proton treatment plan
for the four-year-old female patient with base of skull chordoma). As stated above, the
AE model combines all organs to give a single estimate of the SPCIP. Hence, only the
length of the list of injuries was increased sequentially to determine the computational
efficiency for an increasing number of states. It is unlikely that more than 6 OARs would
receive a significant dose, so this was the maximum considered. The results are tabulated
in Table 4.2, and graphed in Figure 4.6. Recall that additional states are required in the
AE model (see Section 4.2.6).
MCE model AE model
# Injuries # States Time (s) # States Time (s)
1 8 78.2 16 0.052
2 13 93.3 41 0.13
3 22 123.0 114 0.4
4 39 193.8 331 1.5
5 72 365.8 980 10.3
6 137 748.1 2925 125.1
Table 4.2: The results of the computation time comparison.
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Figure 4.6: The computation time for each model, as a function of the number of
Markov states (left) and organs at risk (right). For an equivalent number of states/or-
gans at risk, the AE model clearly offers an advantage over the MCE model in terms
of computation time.
The AE model offers a significantly reduced computation time compared with the Monte
Carlo simulation. For six OARs, the runtime is six times faster even though the number
of states is at least 20 times greater. When the number of states are approximately equal,
the AE model is approximately 1,800 times faster.
It should be noted that it can be difficult to compare the two models fairly in terms of
computation speed for several reasons. Firstly, the entire matrix is calculated each year
in the AE model whereas only a single row is calculated each year in the MCE model.
Secondly, a number of computational efficiency techniques were implemented in the AE
model.
4.7 Discussion and conclusion
The AE model has been implemented successfully and produces predictions with a signif-
icantly reduced computation time compared with the MCE model. A major contributor
to this is the efficiency of matrix multiplications compared with Monte Carlo simulations.
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Furthermore, these results do not have the statistical uncertainty that is present in the
results of the Monte Carlo simulation. However, like the MCE model, the AE model has
limitations. Some of these are unique to the latter but many also apply to the former.
A key enhancement of the model is that the injury and cancer death probabilities depend
on the grade or stage rather than time. While it is more realistic for death probabilities
to depend on severity rather than time, a difficulty exists in sourcing appropriate death
probabilities, particularly for different stages of cancer. Furthermore, there is a time-
and dose-independent probability of transitioning to higher stages of cancer to allow for
more realistic quality of life estimates for the fraction of the cohort being affected by
each cancer. However, it can be difficult to source reliable estimates of these parameters.
In the absence of reliable estimates, a single representative quality of life utility can be
applied to the lowest stage while omitting the probabilities of transitioning to higher
grades.
In other models developed for patient selection for proton therapy, patient-specific vari-
ables other than dose are included [66, 68, 69]. In this thesis (both the MCE and AE
models), the only patient-specific variables are dose, age and gender. There is no consid-
eration of concurrent chemotherapy, pre-radiotherapy patient history, or genetics, all of
which may influence patient outcome after receiving radiotherapy. However, due to the
structure of the model, it would be difficult to include these factors without having an
unacceptably large number of Markov states.
In both models, there is uncertainty inherent in the application of the NTCP model
parameters, as they have been determined in studies based on populations treated with
photons only. As a result, they may not be able to produce reliable predictions for a
patient when treated with proton therapy. In future work, the model parameters should
be validated using populations treated with both photon therapy and proton therapy.
Finally, it is important to consider the quality of the input data. In both models, uncer-
tainty associated with the input data is not taken into consideration. The methods used




The publication P2 forms the basis of this chapter:
Austin, A.M., Douglass, M.J.J., Nguyen, G.T. & Penfold, SN. Patient selection for pro-
ton therapy: A radiobiological fuzzy Markov model incorporating robust plan analysis.
Mathematical Medicine and Biology. 2019 (Submitted May 2019).
5.1 Introduction and motivation
The AE model presented in Chapter 4 was developed to improve computational efficiency
and to include the effects of higher injury grades and cancer stages on patient quality
of life. In addition, it facilitated the development of the model presented in this chap-
ter, which forms the basis of the publication P2. This model incorporates the effects
of uncertainties in the radiobiological model parameters and the dose delivery into its
predictions.
Where different treatment modalities are being considered, there may be significant differ-
ences in uncertainties that could arise due to patient set up and changes to the treatment
volume over the course of treatment. Internal organ motion/displacement and breathing
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may exacerbate these effects. In addition, due to the prominence of the Bragg peak in the
proton therapy dose deposition, the range uncertainty for proton therapy can be signifi-
cantly larger than that of X-ray therapy. This is because a small shift in the Bragg peak
can have a much more significant effect on the tumour and healthy tissue than changes
in the X-ray therapy dose distribution. These effects are not taken into account in the
AE model. It is important to consider these uncertainties as they can affect whether a
patient is selected for proton therapy.
The aims of this publication were to present the model that incorporated these uncer-
tainties into its predictions, and to demonstrate the output with an example patient.
The model is based on a fuzzy Markov model, which is a Markov model with uncertain
transition probabilities.
This chapter details features and technical aspects that were not included in the publica-
tion (Section 5.3), including the uncertainties in the quality of life utilities (Section 5.3.3).
A discussion and conclusion are given in Section 5.4.
5.2 Statement of contribution
5.2.1 Conception
The idea to incorporate the effect of uncertainties into the model was first conceptualised
by Scott Penfold. All authors contributed to the development of ideas and methods.
5.2.2 Realisation
The writing of the code and analysis was performed by Annabelle Austin, with advice
provided by Scott Penfold, Michael Douglass and Giang Nguyen.
5.2.3 Documentation




Title of Paper Patient selection for proton therapy: A radiobiological fuzzy Markov model incorporating robust 
plan analysis.  
Publication Status Published Accepted for Publication
 
Submitted for Publication
Unpublished and Unsubmitted w ork w ritten in 
manuscript style  
Publication Details Austin, A.M., Douglass, M.J.J., Nguyen, G.T. & Penfold, SN. Patient selection for proton 
therapy: A radiobiological fuzzy Markov model incorporating robust plan analysis. Mathematical 
Medicine and Biology. 2019 (Submitted May 2019) 
Principal Author 
Name of Principal Author (Candidate) Annabelle Austin 
Contribution to the Paper 
 
 
Developed methods and code, sourced input model parameters from literature performed 
simulations and analysis, wrote manuscript and acted as corresponding author.  
Overall percentage (%) 85% 
Certification: This paper reports on original research I conducted during the period of my Higher Degree by 
Research candidature and is not subject to any obligations or contractual agreements with a 
third party that would constrain its inclusion in this thesis. I am the primary author of this paper. 
Signature Date  
Co-Author Contributions 
By signing the Statement of Authorship, each author certifies that: 
i. the candidate’s stated contribution to the publication is accurate (as detailed above); 
ii. permission is granted for the candidate in include the publication in the thesis; and 
iii. the sum of all co-author contributions is equal to 100% less the candidate’s stated contribution.  
 
Name of Co-Author Scott Penfold 
Contribution to the Paper Provided supervision, advice, and assisted in manuscript evaluation.  
 
Signature Date  
 
Name of Co-Author Michael Douglass 
Contribution to the Paper Provided supervision, advice, and assisted in manuscript evaluation.  
 

















Name of Co-Author Giang Nguyen 
Contribution to the Paper Provided supervision, advice, and assisted in manuscript evaluation.  
 
Signature  Date  
 
Patient selection for proton therapy:
A radiobiological fuzzy Markov model
incorporating robust plan analysis
Annabelle M. Austina,d, Michael J. J. Douglassa,b,e, Giang T. Nguyenc,f ,
Scott N. Penfolda,b,g
aDepartment of Physics, University of Adelaide,
Adelaide, SA 5005, Australia
bDepartment of Medical Physics, Royal Adelaide Hospital
Adelaide, SA 5000, Australia
cSchool of Mathematical Sciences, University of Adelaide,
Adelaide, SA 5005, Australia
d Corresponding author email: annabelle.austin@adelaide.edu.au
Phone: +61 8 8313 5996





Purpose: While proton therapy can offer increased sparing of healthy tissue
compared with X-ray therapy, it can be difficult to predict whether a benefit
can be expected for an individual patient. Predictive modelling may aid in
this respect. However, the predictions of these models can be affected by un-
certainties in radiobiological model parameters and in planned dose. The aim
of this work is to present a Markov model that incorporates these uncertain-
ties to compare clinical outcomes for individualised proton and X-ray therapy
treatments.
Methods: A time-inhomogeneous fuzzy Markov model was developed which
estimates the response of a patient to a given treatment plan in terms of quality
adjusted life years. These are calculated using the dose-dependent probabili-
ties of tumour control and toxicities as transition probabilities in the model.
Dose-volume data representing multiple isotropic patient set-up uncertainties
and range uncertainties (for proton therapy) are included to model dose deliv-
ery uncertainties.
Results: The model was retrospectively applied to an example patient as a
demonstration. When uncertainty in the radiobiological model parameter was
considered, the model predicted that proton therapy would result in an im-
proved clinical outcome compared with X-ray therapy. However, when dose
delivery uncertainty was included, there was no difference between the two
treatments.
Conclusion: By incorporating uncertainties in the predictive modelling cal-
culations, the fuzzy Markov concept was found to be well suited to providing a
more holistic comparison of individualised treatment outcomes for proton and
1
X-ray therapy. This may prove to be useful in model-based patient selection
strategies.




As proton therapy becomes increasingly available, a greater number of clinics will
need to decide which patients to treat with proton therapy instead of X-ray therapy.
While a reduction in normal tissue complications can generally be expected with
proton therapy, the expense and limited availability of the treatment suggests that
the patients with the greatest need should be prioritised. Randomised Phase III
clinical trial data comparing novel and standard treatments can become outdated
in the rapidly evolving environment of radiation oncology. Hence this data may not
always provide an adequate reference to determine which patients can expect the
greatest benefit from receiving proton therapy. Alternatively, a modelling study in
the form of an in-silico clinical trial [1] can be used to predict the patient outcome.
There has been a growing interest in the clinical use of model-based methods to
select patients for proton therapy [2, 3].
In previous work, a Markov model was developed which used dosimetric data from
a given treatment plan to determine probabilities of tumour control, second primary
cancer induction, and multiple normal tissue complications [4]. The model com-
bines these probabilities to give a single metric, the quality adjusted life expectancy
(QALE), which allows a quantification of the effect of a treatment on a patient’s
quality of life. The result is a quantitative comparison of the clinical outcomes of
two treatments on an individual patient basis. However, the limitation of the model
was that the nominal planned dose was used in the comparison and there was no
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consideration of the effect of dose and radiobiological model parameter uncertainties
on the prediction.
The delivered dose can be different from the planned dose due to patient set-up
errors or anatomical changes over the course of treatment. It has been suggested
that these can have a significant impact on the accuracy of model-based selection of
oropharyngeal cancer patients for proton therapy [5]. Range uncertainties are also
an important consideration for proton therapy, where the distribution of dose with
depth increases sharply at the end of the proton range. This feature is known as
the Bragg peak and if this is misplaced, the result can be unacceptably high doses
being delivered in normal tissue or an under-dosage of the clinical target volume
(CTV). Furthermore, the parameters used in the radiobiological models are typically
obtained with regression methods and are also subject to uncertainty. The combined
impact of these uncertainties on the predictions of patient selection models warrants
further investigation.
The aim of this work is to present an evolution of the patient selection model
developed by Austin et al. [4], which includes a quantification of the effect of treat-
ment and model uncertainties during model-based patient selection for proton ther-
apy. The new model accounts for these sources of uncertainty using a fuzzy Markov
model. Fuzzy Markov models are an extension of conventional Markov models where
the transition probabilities are not known precisely [6]. The technical details of the
model are presented in Section 2 with a description of the Markov states, transition
probabilities and uncertainties. The model is demonstrated with a clinical example
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(base of skull chordoma) in Section 3, and a discussion and conclusion are given in
Section 4.
2 Methods
2.1 The Markov model
With a discrete-time inhomogeneous (time-dependent) Markov chain, the response
of a patient to a particular treatment is modelled. Here, a revised version of the
model developed by Austin et al. [4] is presented that takes the uncertainty of the
input parameters into account. The reader is referred to Austin et al. [4] for the
underlying details and motivation for the development of this model.
2.1.1 Markov states
A patient can occupy only a single Markov state at a given time. These states
describe the health status of a patient and include Well, Deceased and the Unwell
group of states. Figure 1 shows the Markov states for the simple case where only one
injury with one grade is considered and multiple stages of cancer are not considered.
In this figure, each state is represented by a node and allowed transitions are indicated
by arrows between the relevant states.
In this work, the Unwell group contains states that represent varying numbers
and forms of complications arising as a result of treatment. These states include the
cases in which a patient:
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• still has their initial primary cancer due to unsuccessful treatment, represented
by the Cancer node;
• develops one or more normal tissue complications as a result of treatment,
represented by the Inj node;
• develops one or more second primary cancers (SPCs) as a result of treatment,
represented by the SPC node.
There are also other states representing every possible combination of the above:
• Unwell (primary cancer and injury): Cancer & Inj node;
• Unwell (primary and second cancer): Cancer & SPC node;
• Unwell (second cancer and injury): SPC & Inj node;
• Unwell (primary and second cancer and injury): Cancer & SPC & Inj node.
If there are multiple injuries being considered in the model, then a state exists for
every possible combination of injuries. In addition, a patient can have any number of
injuries as well as the primary cancer (if remaining after an unsuccessful treatment)
and/or a second radiation-induced cancer.
The states with no injury present are duplicated and denoted by * in Figure 1.
These are the states that a patient moves to after recovering from a particular injury.
For each injury, there is a zero probability of moving from a recovered state back to
the injured state, however a patient can develop a different injury from the recovered
state. For example, if a patient develops only injury 1 and subsequently recovers,
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they will be in the (Well, Injury 1*) state, where the star denotes a history of injury 1.
From here it is possible to develop injury 2, but not injury 1. If injury 2 is developed
and recovered from, then the patient will move to the (Well, Injury 1*, Injury 2*)
state where the stars denote a history of both injuries. The recovered states were
implemented to avoid a contradiction that would arise when a patient moved back
to the Well state after recovering from an injury, only to develop it again some time
later.
2.1.2 State transition probabilities
The time period modelled is the interval between the completion of the treatment
and the death of the patient. The Markov chain consists of discrete time intervals,
or cycles. Markov models in medical applications assume that a patient remains
in a state for the duration of a cycle. The cycle length for this Markov chain was
chosen to be one year, as this provided computational efficiency while maintaining
sufficient temporal resolution. As a result, only toxicities occurring after one year
are considered in the model. At the end of each cycle, it is possible for a patient to
transition to another state. The time-dependent transition probabilities determine
the likelihood of transitioning between particular state pairs at a given year of the
Markov chain.
Many of the transition probabilities are derived from radiobiological models that
take the planned dose to a structure as an input. These include:
• The tumour control probability (TCP), which is a single probability calculated


















Figure 1: The Markov state transition diagram showing the allowed transitions between
states. For simplicity, this describes the case where there is only one injury and one
second primary cancer being considered in the model. ‘Well’ represents perfect health.
‘Cancer’ represents the situation where the patient still has the initial primary cancer
‘SPC’ represents a state with a second primary cancer, and ‘Inj’ represents an injury state.
The starred states denote a history of an injury. Unwell states are represented by pale grey
nodes and the Deceased state is represented by a dark grey node.
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Depending on the value of the TCP, the patient can begin the Markov chain in
either the Well state or the Primary cancer state. Therefore, once the Markov
chain has begun, it is not possible to transition between these two states, as
depicted in Figure 1. The probability of beginning in the Well state is equal
to the value of the TCP. The probability of beginning in the Primary cancer
state is equal to the probability of the complement event, that is, 1 - TCP. It
is not possible to begin the chain in any other state.
• The normal tissue complication probability (NTCP), which is the probabil-
ity of developing a radiation-induced injury and is calculated using the DVH
associated with a particular organ and the Lyman-Kutcher-Burman (LKB)























where TD50 is the uniform dose given to the entire organ that results in 50%
complication risk, m is an organ specific parameter that is related to dNTCP
dD
, n
is a parameter that characterises the volume dependence of the organ’s response
to radiation, Deff is the effective dose, and ` is the number of voxels. This is
a time-dependent probability and the reader is referred to Austin et al. [4] for
the details of the time-dependent probability calculation. Injury recovery was
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not considered in this work. The injuries considered here include brainstem
necrosis, tinnitus, blindness and endocrine dysfunction.
• The second primary cancer induction probability (SPCIP), which is the prob-
ability of developing a radiation-induced cancer as a result of the treatment.
This is also a dose- and time-dependent quantity and was calculated using
the model developed by Schneider et al. [11]. In this work, a single SPCIP is
calculated using all contoured non-tumour volumes that represents the overall
probability of having a second primary cancer in any structure.
The events of developing different injuries or a second cancer are assumed to
be independent. Consequently, for the transitions that involve the development of
several injuries and/or a second cancer simultaneously, the transition probability was
assumed to be the multiplication of the relevant individual probabilities.
In addition to the dose-dependent transition probabilities, there are the prob-
abilities of transitioning to the Deceased state. While these quantities are dose-
independent and are not directly related to the treatment plan that is being com-
pared, they allow for a more realistic estimate of the length and quality of life a
patient can expect after receiving a given treatment. Uncertainties in these proba-
bilities were not considered in this work. The probabilities of dying as a result of
various causes include:
• Death from the primary cancer (with yearly probability 0.4, derived from 5-year
survival rates after relapse of base of skull chordoma [12]) or a second primary
cancer (with yearly probability 0.08 derived from cancer survival data [13]).
These are time-independent quantities.
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• Death from injury. This is also a time-independent quantity. In this work, it
was assumed that it was not possible to die as a result of any injury, with the
exception of brainstem necrosis which was assumed to be fatal.
• Unrelated death. This time-dependent probability is based on data from life
tables obtained from the Australian Bureau of Statistics [14].
2.1.3 Quality of life utilities
Each state is assigned a quality of life (QoL) utility which represents the quality
of life associated with the state, relative to perfect health. These utilities are used
to calculate the QALE, which is the number of QALYs that are lived by a patient
until they move to the absorbing Deceased state. A time horizon of 100 years was
selected for the Markov model as the survival probability is negligible beyond this
point. The QALE can be thought of as the number of years with a quality of
life equivalent to perfect health lived by a patient after treatment. This is the
primary metric used to evaluate and compare treatment plans in the proposed patient
selection approach, as it incorporates both the probabilities of tumour control and
of developing complications.
The QoL utilities applied in the Markov model are listed in Table 1. For Unwell
states where there is more than one injury or cancer, the assigned utility is a multi-
plication of the utilities corresponding to the states where only one of each injury or
cancer is present. The states representing the cases of second primary cancers were
all assigned a value of 0.8 in accordance with the Eastern Cooperative Oncology
Group (ECOG) performance status [15], as their definition of a grade 1 complication
11
QUALITY OF LIFE UTILITIES
State Utility Source Comments
Skull base chordoma 0.72 [16]
Brainstem necrosis 0.6 [15]
Endocrine dysfunction 0.6 [15]
Tinnitus 0.58 [17] Evaluated after visit-
ing a tinnitus clinic
Blindness 0.33 [18] Complete blindness
Second primary cancer 0.8 [15]
Table 1: Estimates for the quality of life (QoL) utilities for states in the Markov model.
(with utility 0.8) gives a reasonable description of these states. Where it was not
possible to source an appropriate QoL utility for a particular injury, a default value
of 0.6 was assigned as the ECOG definition of a grade 2 complication (which has a
utility of 0.6) gives a reasonable description of these states.
2.1.4 Model evaluation
In the previous version of the model [4], the Markov chain was evaluated using a
Monte Carlo approach. This involved simulating the Markov process many times
with each simulation representing a different member of a hypothetical patient co-
hort. The disadvantage of this approach is that a large cohort is required for accurate
results, corresponding to a significant computation time.
As an alternative, an analytical solution was implemented in this work. This
enables the exact solution to be obtained with a significantly reduced computation
time compared with the Monte Carlo method. Using the analytical approach, the
distribution of a hypothetical cohort of patients – which are each an identical copy
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of the real patient under consideration – amongst all Markov states, π, is calculated.
This is achieved with the use of a transition matrix, P, which stores the probability
of transitioning from each Markov state to all other Markov states. As this Markov
model is time-dependent, the values of P vary at each Markov cycle. Matrix multipli-
cation is carried out to determine the distribution at a given time. The distribution





where Pk is the transition matrix corresponding to cycle k and π0 is the initial
distribution of the cohort immediately after treatment (before any Markov cycles
have taken place). Each element of the vector π gives the fraction of the cohort in
a given state. Hence, all elements of π0 are zero except the elements representing
the fraction of cohort who are well (equal to the TCP) and the fraction who did not
have a successful treatment and still have the cancer (equal to 1 - TCP).
The expectation value (or mean) of the life expectancy (LE), denoted L̂E, can be







for n states and i years after treatment where the maximum value of i, m = 100−a,
corresponds to the year in which the patient (with age a at the time of treatment)
is 100 years old. The Deceased state represented by the final element of π is not
included in the summation.
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To calculate the mean QALE, denoted Q̂ALE, each fraction is multiplied by the






(πk)j · uj (4)
where U = [u1, ..., un−1] is a vector of the utilities for each state.
2.2 Uncertainties
2.2.1 Radiobiological model parameters
The uncertainties in the radiobiological parameters manifest as uncertainties in the
dose-dependent transition probabilities. The parameters in these models are usually
determined with regression methods. In this work, uncertainties were only considered
in the TD50 parameters for the pituitary dysfunction NTCP [19] and tinnitus [20],
as the NTCPs associated with brainstem necrosis and blindness are typically small.
The uncertainty was set to zero for other model parameters, but the framework exists
to allow for non-zero uncertainties in these parameters.
2.2.2 Dose
The uncertainty related to the delivered dose was considered by performing analysis
with the fuzzy numbers constructed from uncertainty in the radiobiological model
parameters, for multiple scenarios of dose delivery variability. DVH curves corre-
sponding to each scenario were calculated using the Varian Eclipse treatment plan-
ning system 13.7 (TPS) (Varian (Palo Alto, CA, USA)) and the relevant DVHs were
14
exported for use in the Markov chain. The result is a set of DVHs, one for each
organ at risk (OAR) and the tumour volume for each scenario. Survival curves and
QALEs were obtained for each scenario using the Markov chain.
2.3 The fuzzy Markov model
A ‘crisp’ Markov chain [6] can be thought of as a Markov chain where the values of
the transition probabilities are known precisely. A fuzzy Markov chain does not have
precisely known transition probabilities [6]: rather than a single probability X, each
element of the transition matrix is an interval, [X,X], where X is the lower bound
on the estimate of the value of X and X is the upper bound. The upper and lower
bounds are not necessarily symmetric about the crisp value in this model. In order to
multiply fuzzy matrices, interval arithmetic must be applied. Matrix multiplication
involves both multiplication and addition when considering elements; the rules for
intervals are outlined as follows (following the notation of Moore et al. [21]):
• Addition
X + Y =
[




X · Y = [minS,maxS] , whereS = {XY ,XY ,XY ,XY }. (6)
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The result is a confidence interval for each element of π, with lower and upper
bounds given by π and π, which serves as a quantification of the uncertainty in the
model output.
2.3.1 Optimization of the QALE uncertainty
Let the quality adjusted surviving fraction of the hypothetical cohort at a given time,
F (k), be defined as F (k) =
∑n−nA
j=0 (πk)j · uj, k = [0, 1, 2, ...,m], where there are nA
absorbing states. While
∑n




j=0 πj may not
necessarily be 1 for a given scenario of dose delivery accuracy. Therefore, a situation
could arise where
∑n
j=0 πj > 1, and therefore F (k) and F (k) cannot be defined as
F (k) =
∑n−1
j=0 (πk)j and F (k) =
∑n−1
j=0 (πk)j, respectively. As a result, defining QALE
and QALE as QALE =
∑m
k=0 F (k) and QALE =
∑m
k=0 F (k), respectively, would be
invalid.
As an alternative, the uncertainty in the QALE was determined through mathe-
matical optimization. Using (2), it can be shown that the quality adjusted survival
at a given year is a function of all the elements of the transition matrix P, some of
which are functions of the various NTCPs. Therefore, the QALE defined in (4) can
be written as a function of the parameters in the radiobiological models as
f(λ) = f(p11(λ,m), ..., p1n(λ,m), p21(λ,m), ..., pnn(λ, x),
p11(λ,m− 1), ..., p1n(λ,m− 1), p21(λ,m− 1), ..., pnn(λ,m− 1), ...,
p11(λ, 1), ..., p1n(λ, 1), p21(λ, 1), ..., pnn(λ, 1),U),
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where m is the total number of Markov cycles, λ = [λ1, λ2] = [TD50t, TD50e], TD50t
is used to calculate the probability of tinnitus, and TD50e is used to calculate the
probability of endocrine dysfunction. Let λ1 and λ1 be the lower and upper bounds
for TD50t and λ2 and λ2 be the lower and upper bounds for TD50e. The two opti-
mization problems used to find the upper and lower bounds on the uncertainty have







pij(k) = 1, for i = 1, ..., n and k = 1, ...,m,
λ1 ∈ [λ1, λ1],









pij(k) = 1, for i = 1, ..., n and k = 1, ...,m,
λ1 ∈ [λ1, λ1],
λ2 ∈ [λ2, λ2].
(8)
The constraints in the optimization problems ensure that each row of the tran-
sition matrix at each year must sum to 1. The objective function also depends on
the quality of life utilities U, which were not allowed to vary in the optimization
problems.
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The objective function and constraints were used with MATLAB’s fmincon()
routine for non-linear constrained optimization to determine the uncertainty bounds.
To determine the uncertainty in the QALE as a result of radiobiological model pa-
rameter uncertainty only, the optimization routine was performed using the dose data
for the nominal scenario. When considering dose delivery uncertainty in addition to
the radiobiological model parameter uncertainty, the optimization was carried out
for each dose delivery scenario d, and the upper and lower bounds are defined as:
QALE = min{QALE1,QALE2, ...,QALED},
and
QALE = max{QALE1,QALE2, ...,QALED}.
3 Demonstration patient
A four-year-old female presenting with base of skull chordoma was considered for
the purposes of demonstrating the functionality of the model. Treatment plans for
the delivery of 70 Gy in 35 fractions to the tumour with both protons (intensity
modulated pencil beam scanning) and X-rays (volumetric modulated arc therapy
(VMAT)) were retrospectively generated using the Varian Eclipse 13.7 TPS. In each
treatment plan for this patient, each critical structure (healthy tissue) and the target
volume corresponding to the tumour were contoured by a clinician. The VMAT plan
was created on a planning target volume (PTV) with a 4 mm expansion of the CTV.




TCP 0.83 [0.64, 0.84] 0.74 [0.50, 0.83]
SPCIP <0.01 0.020 [0.019, 0.076]
Brainstem necrosis NTCP <0.01 <0.01
Tinnitus NTCP 0.05 [0.02, 0.12] 0.14 [0.08, 0.24]
Blindness NTCP 0.01 [<0.01, 0.05] 0.01 [<0.01, 0.05]
Endocrine dysfunction NTCP 0.99 [0.91, 1.0] 0.93 [0.56, 1.0]
Table 2: The values for the transition probabilities that were calculated and used as
input for the Markov model, for each treatment modality. The SPCIPs listed represent the
probability of a second cancer in the 25 years after treatment. Each probability calculated
without considering uncertainties is listed along with its upper and lower bounds in square
brackets when uncertainty is considered. TCP=tumour control probability.
range uncertainty and a 3 mm set-up uncertainty. A differential DVH was generated
for each of the OARs and the CTV for both the nominal plan and the set of scenarios
of dose delivery. These scenarios were produced in a robust plan analysis of both the
VMAT and proton plan taking into account patient setup uncertainties and include
+/- shifts of 3 mm in the (x, y, z) position of the patient with respect to isocentre
(giving a total of 6 uncertainty scenarios). For proton therapy, there is an additional
+/- beam range uncertainty of 3%, resulting in 12 scenarios.
The TCP was calculated based on dose to the CTV for both the proton and
X-ray plans. The TCP, NTCPs and SPCIP that were calculated for each treatment
plan for this patient are listed in Table 2.
The model returned the expectation value of the patient life expectancy along
with the expectation value of the QALE. The results for this clinical example are
listed in Table 3. The NTCP model parameter uncertainties do not contribute to




Raw LE 66.6 [53.4, 68.7] 57.9 [40.8, 65.7]
QALE
(model uncertainties only)
39.5 [39.2, 40.0] 34.4 [33.0, 36.1]
QALE
(model and dose uncertainties)
39.5 [31.4, 41.5] 34.4 [24.5, 45.8]
Table 3: The estimates of the mean raw life expectancies (LE) and the mean quality
adjusted life expectancies (QALE) in years for each treatment modality. The results cal-
culated without considering uncertainties are listed along with their respective upper and
lower bounds in square brackets. The uncertainties in the QALE are listed with and
without the inclusion of dose uncertainties.
Therefore, the uncertainties in the raw life expectancy arise from dose uncertainties
only. The estimates of the life expectancy and QALE for the nominal proton plan are
greater than the X-ray plan. When uncertainties in the radiobiological parameters
only are considered, there would be a clear benefit for the patient if treated with
proton therapy. However, when the uncertainties associated with treatment delivery
are accounted for, the proton plan does not have a significantly increased benefit
compared with the X-ray plan. The survival curves are given in Figures 2 and 3.
The uncertainty in the quality adjusted survival curve was calculated with (2) and
the maximum and minimum values of TD50 that satisfied the constraints of the
optimization problem. It is apparent that uncertainty in the NTCP parameters has
a smaller effect than the set-up and range uncertainties, and that the uncertainty
associated with proton therapy is smaller than that of VMAT.
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Figure 2: Raw survival curves for both the proton plan and VMAT plan.
4 Discussion
For the presented example, the uncertainty associated with proton therapy was pre-
dicted to be smaller than the uncertainty associated with VMAT. This is the case for
both the dose and radiobiological model parameter uncertainties. The later is due
to the differences in the effective dose, Deff between the two treatments, resulting in
different t parameters. The implication of a t parameter corresponding to a steeper
part of the dose response curve will be a greater magnitude in NTCP uncertainty
if t is varied within a certain range. The difference in the magnitude of the dose
uncertainty is likely a result of the proton plan being robustly optimized to the CTV
and the photon plan being robustly optimized to the PTV.
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Figure 3: Quality adjusted survival curves for both the proton plan and the VMAT plan.
The top right figure corresponds to a situation in which only uncertainty in NTCP model
parameters is considered. The bottom left figure corresponds to a situation in which only
uncertainty in dose is considered. The bottom right figure corresponds to the situation in
which both dose and NTCP model parameter uncertainties are included.
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The presented model improves on the existing model [4] by considering the effects
of dose delivery and radiobiological model parameter uncertainties associated with a
radiotherapy treatment on whether an individual patient would be selected for pro-
ton therapy. However, the model has several limitations. It should be stressed that
not all transition probabilities and quality of life utilities in the presented example
were clinically founded, as it was not always possible to obtain representative values
in the literature. As in any predictive model, the usefulness of the results is directly
dependent on the accuracy of the input parameters. At this stage, the functional-
ity of the model has been demonstrated with an example patient and appropriate
validation of all radiobiological model parameters must be conducted before clinical
implementation of this model-based patient selection approach. In-silico clinical tri-
als could potentially be used to gradually refine the accuracy of the input data over
time through a feedback system [1].
However, in some cases, it is not possible to know the true transition probability
for a given state pair. This is particularly true for patient death in the cases where
there are multiple possible causes of death. For example, for the fraction of the
cohort in a state where there are multiple cancers or fatal injuries, there are different
ways of transitioning to the absorbing state. However, the death probabilities used in
the model correspond to the probability of transitioning from a state representing a
given complication to the Deceased state, and do not reflect the probability of dying
when multiple complications are present. In these cases, it was assumed that the
probability of death was the maximum death probability out of all possible causes.
The result is that patients with multiple complications have the same probability
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of dying compared to patients with a single complication. This is a reasonable
approximation, as there is usually a single dominant death probability and it is
unlikely that a patient could have a fatal cancer or injury while simultaneously
having an equally high background death probability.
Several of the parameters in the radiobiological models used in this study were de-
termined in studies based on adult populations. However, the output of the Markov
model is demonstrated using a paediatric patient in this work. It is possible that
this assumption contributed to uncertainty in the results, as it is likely that younger
cell populations have differing radiobiological properties compared with older popu-
lations.
The estimated SPCIPs for the example patient were lower compared with ob-
servations of second malignancy incidences. These have been found to be 7.5% for
photons and 5.3% for protons (median follow up of 6.7 years) [22]. The model used
to calculate the SPCIP in this work is yet to be validated, and this is the likely
reason for the discrepancy between this work and the observations.
The dose uncertainty included in the model is derived from multiple scenarios of
treatment delivery accounting for variations in delivered dose as a result of patient
positioning and range uncertainties. These include worst case scenarios modelled
with a systematic set-up uncertainty applied throughout the treatment course, which
is unlikely to occur in reality. The result is an overestimation of the magnitude of
the uncertainty in the final results. In future applications of the model, the robust
analysis will be refined to allow the generation of more realistic scenarios through
the incorporation of fractionation effects of random set-up uncertainties [23].
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As the dose distribution will influence tumour control rates and complication
rates, it is entirely possible that uncertainties in the radiobiological parameters nat-
urally incorporate the effect of uncertainties in the dose delivery. As we consider dose
uncertainties in addition to uncertainties in these parameters, there is the possibility
that the quoted uncertainties in the QALE are overestimated due to the doubling
of the dose uncertainty. However, the advantage of considering the dose uncertain-
ties separately is that it allows the contribution of these uncertainties to be directly
assessed and isolated.
4.1 Conclusion
The presented model could serve as a valuable tool for patient selection for proton
therapy. The effects of radiobiological model parameter and dose uncertainties have
been included to aid decision making in the referral process. In this work, the
functionality of the model has been demonstrated. The inclusion of the uncertainties
demonstrated the need for validated and precise radiobiological model parameters in
model-based patient selection strategies.
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5.3 Fuzzy Markov model details
The development of the Fuzzy model involved assigning uncertainties to the transition
probabilities in the Markov model. The only probabilities that did not have uncertainty
were the background death probabilities. Error bounds were assumed to be asymmetric.
The uncertainties in the radiobiological model parameters and the input dose data have
been discussed in the publication P2. There are additional uncertainties included in the
model that were not considered in the publication. The primary reason for this was due
to a lack of available data on uncertainties. The quality of life utilities have a significant
influence on the QALE predicted for a given patient and treatment plan. Uncertainties
in these weights were incorporated into the Fuzzy model. In addition, while the publi-
cation P2 focussed on uncertainties in the dose-dependent transition probabilities, there
was no consideration of dose-independent transition probabilities. These include death
probabilities, injury recovery probabilities and the probabilities of transitioning to higher
stages of cancer. The Fuzzy model includes uncertainties in these probabilities, with the
uncertainties being easily modifiable by the user if reliable parameters become available.
5.3.1 NTCP calculation
The NTCP was calculated for each injury using (2.8) (Section 2.3.2). The parameters
used in the NTCP calculations are listed in Table 5.1.
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Table 5.1: Parameters used for the calculation of the all-time NTCP for each injury using
the LKB model. Burman et al. [62] was used as the source of the parameters unless otherwise
stated. Estimates of the mean (x̄) and standard deviation (σx) of the time taken for each
injury to develop after treatment are also listed in months. Where it was not possible to find
an estimate of the mean or standard deviation, it was assumed to be 12 months or 6 months,
respectively. Confidence intervals are indicated in square brackets for the TD50 parameters
where applicable.
Tissue α/β (Gy) Endpoint n m TD50 (Gy) x̄ σx
Brainstem 2.5 1 Necrosis 0.16 0.14 65 17 2 6 3
Ear 3.0 4 Tinnitus 0.01 0.35 5 46.5 [41.9, 53.4] 5 12 3 6 3
Optic
chiasm
3.0 4 Blindness 0.25 0.14 65 18 6 6 3
Pituitary 3.0 4 Endocrine
dysfunction
0.156 7 0.08 7 60.6 [59.1, 62.0] 7 12 3 6 3
1 Source: [86]
2 Source: [87]
3 Not clinically founded





As discussed in the publication P2 Section 2.2, interval arithmetic is applied to evaluate
the Fuzzy model.




. Simple arithmetic operations can be carried out through applying the following
rules:
 Addition
X + Y =
[
X + Y ,X + Y
]
. (5.1)
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 Subtraction
X − Y =
[




XY = [min S,max S] , where S = {XY ,XY ,XY ,XY }. (5.3)
 Division





These operations allow fuzzy transition matrices to be multiplied.
5.3.3 Quality of life utility weights
The quality of life utility weights are a major contributor to the QALE estimated from a
given plan, which is the primary metric used to evaluate the plan quality (Section 2.2.3).
It can be difficult to quantify the impact of an illness on a patient’s quality of life,
relative to perfect health. As a result, estimates of quality of life utilities often include
an uncertainty estimate [90].
The model presented in this chapter treats the quality of life utilities as fuzzy numbers.
The interval arithmetic rules defined in Section 5.3.2 are applied when multiplying the
vector of utilities U with π (in (3) of the publication P2) to calculate the bounds on the
QALE. While it was not possible to source uncertainties for utilities for the injuries and
cancers considered in P2, the framework exists in the model to include uncertainties if
required. The utilities and associated uncertainties may be modified by the user in this
instance.
The lower bounds on the utilities for states where there are more than one injury or
cancer present is the multiplication of the lower bounds on the utilities of the individual
injuries or cancers. This method is also applied to calculate the upper bounds.
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5.3.4 Transition matrix
Once all of the individual transition probability confidence intervals (CIs) are calculated,
they are used to calculate the upper and lower bounds on each element of the transition
matrix P. The CIs of all matrix elements are calculated using the lower bounds on the
CIs of the each of the relevant NTCPs, SPCIPs, death and recovery probabilities. The
same is true for the upper bounds. An important implication is that the lower bounds on
the CIs of all elements of a given row will not necessarily sum to one. This also applies
to the upper bounds.
Organs with negligible NTCPs are not considered in the model (see Section 4.2.4). How-
ever, an organ may have a negligible NTCP in one scenario of dose delivery accuracy,
while having a non-negligible NTCP in another. It was therefore necessary to recalculate
the number of injuries and the number of states for each scenario. This process allows
the model to run faster for some scenarios, and hence the model as a whole can be more
efficient.
For the transitions between absorbing states, the diagonal elements are [1, 1] and the
off-diagonal elements are [0, 0], as there are no uncertainties associated with these.
5.4 Discussion and conclusion
The Fuzzy model has been developed to include the effect of several sources of uncertainty
on the model predictions. Optimizing the QALE uncertainty demonstrated that the
patient considered could expect a clinical benefit as a result of proton therapy (in the
presence of NTCP model parameter uncertainty only). Including more realistic scenarios
of dose delivery accuracy in treatment planning systems could reduce the magnitude
of uncertainties in dose delivery. A challenge in developing this model was sourcing
appropriate input uncertainties, particularly for the quality of life utility weights. The
model presented in this chapter contains the framework to analyse these uncertainties,
once they become available. Ultimately, comparing the model predictions with patient
outcomes through clinical validation will allow the estimated uncertainties to be assessed.
Chapter 6
Cost-effectiveness Model
The publication P3 forms the basis of this chapter:
Austin, A.M., Douglass, M.J.J., Nguyen, G.T., Dalfsen, R., Le, H., Gorayski, P., Tee,
H., Penniment, M. & Penfold, S.N.. Cost-effectiveness of proton therapy in treating base
of skull chordoma. Australasian Physical and Engineering Sciences in Medicine. 2019
(Submitted May 2019).
6.1 Introduction and motivation
In Chapter 5, the incorporation of model parameter uncertainties into the AE model is
described. However, this model did not consider the effects of treatment cost-effectiveness.
This is particularly important when considering proton therapy, where treatment costs
are significantly greater when compared with X-ray therapy. Treatment costs are also an
important consideration when developing health policy more generally.
In this chapter, the method of incorporating cost-effectiveness into the AE model (at the
stage before uncertainties were incorporated) is described. The motivation of this work
was to develop the functionality of the patient selection model to make decisions based on
treatment cost-effectiveness. In some cases where there is an elevated risk of treatment
failure or radiation-induced injury or cancer associated with an X-ray treatment, the
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larger initial cost of proton therapy may be justified if it is less than the combined cost
of X-ray therapy and of treating complications.
The aim of the publication that is the basis of this chapter was to present the model with
cost-effectiveness incorporated and utilise a cohort of base of skull chordoma patients to
determine whether this indication may be treated with proton therapy cost-effectively.
The advantage of presenting a cohort rather than an individual patient is that it enables
a more powerful conclusion to be drawn regarding the cost-effectiveness of the treatment.
6.2 Statement of contribution
6.2.1 Conception
The idea of incorporating cost-effectiveness into the model was first conceptualised by
Scott Penfold. Annabelle Austin developed the approach of incorporating cost-effectiveness.
6.2.2 Realisation
The writing of the code, analysis, and sourcing of parameters was performed by Annabelle
Austin. The organs on the CT scans were contoured by Hien Le, Peter Gorayski, Hui
Tee and Michael Penniment. The radiotherapy treatment plans used in the analysis were
created by Raymond Dalfsen.
6.2.3 Documentation
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Introduction: While proton beam therapy (PBT) can offer increased sparing of healthy 
tissue, it is associated with large capital costs and as such, has limited availability. 
Furthermore, it has not been well established whether PBT has significant clinical 
advantages over conventional volumetric modulated arc therapy (VMAT) for all tumour 
types. PBT can potentially offer improved clinical outcomes for base of skull chordoma 
(BOSCh) patients compared with photon (X-ray) therapy, however the cost-effectiveness of 
these treatments is unclear. In this study, the cost-effectiveness of PBT in the treatment of 
BOSCh patients is assessed, based on an analysis of comparative radiotherapy treatment 
plans using a radiobiological Markov model.     
Methods: Seven BOSCh patients had treatment plans for the delivery of intensity modulated 
proton therapy (IMPT) and VMAT retrospectively analysed. The patient outcome (in terms 
of tumour local control and normal tissue complications) after receiving each treatment was 
estimated with a radiobiological Markov model. In addition, the model estimated the cost of 
both the primary treatment and treating any resultant adverse events. The incremental 
cost-effectiveness ratio (ICER) was obtained for each patient. 
Results: PBT was found to be cost-effective for 6 patients and cost-saving for 1. The mean 
ICER was AUD$3,220 per quality adjusted life year (QALY) gained. Variation of model 
parameters resulted in the proton treatments remaining cost-effective for these patients. 
Conclusion: Based on this cohort, PBT is a cost-effective treatment for patients with BOSCh. 


































Medicare support for proton beam therapy (PBT) in Australia is currently being considered 
as part of the Medicare Services Advisory Committee (MSAC) 1455 application. MSAC 1455 
considers PBT for a specific list of cancer types and has included a review of clinical evidence 
for PBT for these cancers. The assessment identified a lack of Level 1 evidence for PBT 
across multiple tumour types. Due to issues regarding equipoise, funding and availability, 
there have not been any Phase III randomized clinical trials comparing PBT to conventional 
photon (X-ray) therapy for the cancer types listed in MSAC 1455. In this case, a lack of 
evidence does not equate to non-superiority. Therefore, it is important that other 
approaches are considered when assessing whether new technologies should be supported 
for funding through the public health system. 
Markov models were adopted by the Assessment of New Radiation Oncology Technology 
and Treatments (ANROTAT) project1, undertaken by the Trans-Tasman Radiation Oncology 
Group (TROG) and funded by the Australian Federal Government Department of Health and 
Aging. The group recommends that Markov models be adopted for economic assessments 
of new health technologies. In the current work, we propose the use of Markov models for 
assessing the cost-effectiveness of PBT relative to conventional X-ray therapy.  
One of the most common indications making use of the Medical Treatment Overseas 
Program (funded by the Australian Government Department of Health) for PBT is base of 
skull chordoma (BOSCh). Chordoma is a very rare form of bone tumour, accounting for 1–4% 
of all primary malignant bone tumours2 with base of skull cases representing approximately 
one third of presentations3. Achieving complete surgical removal can be limited by the 
critical anatomical location. Similarly, postoperative radiotherapy with X-rays can also be 
limited by the presence of nearby critical organs. 
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Mailhot Vega et al.4 have proposed a method of selecting paediatric brain cancer patients to 
receive PBT based on treatment cost-effectiveness. PBT was found to be cost-effective or 
even cost-saving, depending on the degree to which the hypothalamus could be spared with 
protons compared with photons. Peeters et al.5 have carried out a cost analysis of treating 
various indications with particle therapies compared with photon therapy, based on 
construction and operational costs. Treatment costs for various tumour types were sourced 
through a review of cost-effectiveness studies. Cost differences between particle and 
photon therapy were found to be larger for BOSCh treatments compared with lung and 
prostate treatments. The cost-effectiveness of carbon ion therapy in the treatment of 
BOSCh has been analysed by Jäkel et al.6 , based on studies of local control improvement 
compared with photon therapy. Primary treatment costs and costs for recurrent tumours 
were estimated. It was found that if local control exceeds 70% with carbon ion therapy, then 
the overall treatment costs of carbon ion therapy are lower than that of conventional 
radiotherapy (assuming a local control rate of 50%). The limitation of their approach is that 
costs associated with toxicities and productivity losses were not considered. Therefore, it 
may be possible that carbon ion therapy is cost-effective at a smaller difference in local 
control. Lundkvist et al.7 have included the effects of adverse events to evaluate the cost-
effectiveness of PBT in the treatment of childhood medulloblastoma. A Markov simulation 
model was used to combine risks of a wide range of toxicities including hearing loss, 
intelligence quotient (IQ) loss, hypothyroidism, growth hormone deficiency (GHD), 
osteoporosis, cardiac disease, and second malignancies. PBT was found to be cost-effective 
and cost-saving compared with conventional radiation therapy for patients with a high risk 
of IQ loss or developing GHD. However, in this approach variations in the dosimetry 
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between individual patient treatment plans was not considered directly (population-based 
risks were applied). 
In previous work by our group, a Markov model was developed with the ability to identify 
patients who would receive the most improved clinical outcome if treated with PBT 
compared with X-ray therapy8. The model predicts the radiobiological effect of a given 
treatment plan on an individual patient basis. This effect includes contributions from 
locoregional control, treatment toxicities and radiation-induced malignancies. The inclusion 
of second radiation-induced cancer risk is particularly important when considering younger 
patients (who comprise the majority of BOSCh patients) as they have a longer remaining 
life-time over which to develop second cancers. The output of the Markov model was the 
quality-adjusted life expectancy (QALE), or the number of quality adjusted life years (QALYs) 
associated with a radiotherapy treatment plan. This output allows quantitative comparisons 
of treatment modalities.  
In the current work, the previously developed Markov model is extended to include a cost-
effectiveness analysis, with the output being the cost of a treatment per QALY gained, also 
known as the incremental cost-effectiveness ratio (ICER). This work builds on that of Mailhot 
Vega et al.4 with the inclusion of second cancer risk, locoregional control and a wider range 
of potential radiation-induced injuries. The aim of this work was to determine whether 
BOSCh patients can be treated with PBT cost-effectively, based on individual patient 





2.1 Patient cohort and treatment planning 
The cohort consisted of 7 female BOSCh patients with a wide range of ages at the time of 
treatment. The size and characteristics of the cohort was limited by availability as BOSCh is 
particularly rare. The ages and prescription doses are summarised in Table 1. Each patient 
had volumetric modulated arc therapy (VMAT) and intensity modulated proton therapy 
(IMPT) treatment plans generated in the Varian Eclipse treatment planning system. VMAT 
plans consisted of 2 co-planar arcs using a 6 MV Varian TrueBeam HD MLC beam model 
clinically commissioned at the Royal Adelaide Hospital (RAH). Plans were optimized to a 
planning target volume (PTV) which was generated from a 3 mm expansion of the CTV. IMPT 
plans consisted of 2-4 beams with pencil beam weights obtained through robust multi-field 
optimization (MFO) to the clinical target volume (CTV). Beam range uncertainty of 3% and 
set-up uncertainties of +/-3mm were included in the robust optimization. The proton beam 
model was based on a Varian ProBeam accelerator.  
 
Table 1: The patient ages at the time of treatment and prescription doses. 
Patient ID Age (years) Treatment schedule 
(Gy/fraction #) 
Comments 
1 6 78/39  
2 12 78/39  
3 8 78/39  
4 46 70/35  
5 27 74/37  
6 51 74/37 Pituitary not discernible 
7 4 70/35 CT scan did not extent to parotids 
 
2.2 Markov model 
A discrete-time Markov chain model developed previously8 was extended in this work to 
model the clinical outcome of each patient. The model consists of several Markov states, 
with each representing a unique status of health. These include the Well state (or 
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complication-free control), the Deceased state, and the states representing various 
treatment complications. These are detailed in Sections 2.4 and 2.5. In addition, there are 
states representing an unsuccessful treatment.  
 
It is assumed that a patient occupies a single state at a given time. In each cycle (defined to 
be one year in this work), it is possible for the patient to transition to another state based 
on certain probabilities. For example, the probability of transitioning from the Well state to 
an injured state is given by the calculated normal tissue complication probability (NTCP) 
corresponding to the injury for the patient being considered. 
 
The transition probabilities in the model can be either dose-dependent or dose-
independent. The probabilities of locoregional control, second cancer induction and normal 
tissue complication are dose-dependent and are calculated using the dose-volume 
histogram (DVH) data from a given treatment plan. Death and recovery probabilities were 
assumed to be dose-independent in this work. 
 
2.3 Locoregional control  
The DVH data for the tumour volume for each patient was used to determine a tumour 
control probability (TCP) that was unique for each patient (details described by Austin et 
al.8). In the event of treatment failure, it is assumed the patients cannot return to the well 
state (i.e. no retreatments). While this is a simplification of the disease progression, the 
clinical outcome of the two alternate primary treatments are the subjects of comparison in 




The yearly death probability (due to treatment failure), denoted Pr(Die), applied in this 
analysis was 0.4. This was derived from 5-year survival rates after relapse (local or distant) 
of base of skull chordoma9 (7%), by evaluating 𝑆 = (1 − Pr(𝐷𝑖𝑒))𝑛,  where n=5 and S=0.07. 
Solving for the death probability gives 0.4. There is an additional risk of death each year due 
to unrelated causes. The annual probability of this was derived using Life Tables published 
by the Australian Bureau of Statistics10. 
 
2.4 Second primary cancers 
The volumes used to calculate the time-dependent second primary cancer induction 
probability (SPCIP) for each patient included the brain and the whole body (with the brain 
and tumour volumes subtracted). The SPCIP was then calculated for both of these volumes 
using the parameters determined by Schneider et al.11. The yearly SPCIP derived for each 
volume was combined into a single probability for each year x after treatment as follows: 
𝑆𝑃𝐶𝐼𝑃(𝑥) = 1 − (1 − 𝑆𝑃𝐶𝐼𝑃𝐵𝑜𝑑𝑦(𝑥)) (1 − 𝑆𝑃𝐶𝐼𝑃𝐵𝑟𝑎𝑖𝑛(𝑥)). 
Treatment of second primary cancer was not considered. The yearly second cancer death 




Several injuries were considered in this analysis. These included brainstem necrosis, spinal 
cord myelitis, tinnitus (damage to the cochlea), blindness (damage in either optic nerve or 
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the optic chiasm), xerostomia (damage to the parotid glands), cataracts (damage to the 
lens), and endocrine dysfunction (damage to the pituitary gland). The model determined by 
Lee et al.13 was used to estimate the NTCP for tinnitus. The model determined by De Marzi 
et al.14 was used to estimate the NTCP for endocrine dysfunction. The models used for all 
other injuries have been described in previous work8. 
It was assumed that all injuries were non-fatal, with the exception of brainstem necrosis, 
which was assumed to be fatal within one year for all patients affected.  
All injuries were assumed to be chronic, with the exception of cataracts (which can usually 
be treated with surgery) and spinal cord myelitis due to a lack of data on long-term costs for 
this complication. 
 
2.6 Estimation of costs and utilities   
Costs associated with both the primary radiation treatment and treatment of side effects 
were incorporated into this model. Each state of health was assigned both a yearly cost and 
a quality of life utility. By default, the Well state has a utility of 1 and the Deceased state has 
a utility of 0. All other states have utilities within this interval depending on the impact of 
the corresponding complication on patient quality of life. The utilities used in this work are 
listed in Table 2, and are used to calculate the QALE. Second cancers were assumed to have 







Table 2: Estimates for the quality of life utilities for states in the Markov model. 
State Utility Comments 
Base of skull chordoma  0.7215  
Second primary cancer 0.8 Not clinically founded 
Brainstem necrosis     0.6 Not clinically founded 
Spinal cord myelitis 0.716 Utility for spinal cord stenosis taken as an 
approximation for myelitis  
Tinnitus 0.5817 Evaluated after visiting a tinnitus clinic 
Blindness 0.3316 Complete blindness 
Xerostomia 0.8315  
Cataracts 0.616 Advanced lens opacity 
Endocrine dysfunction 0.7318 Utility of adult females with growth hormone 
deficiency. Average of values derived from 
Belgian and Dutch cohorts. 
 
 
No costs were assumed for death, only loss of QALYs. Costs and utilities were discounted by 
3% annually, to adjust for differences in timing of costs and effects. All costs are listed in 
Australian dollars. The costs applied in the model are as follows: 
 Radiation therapy: The cost of a photon treatment was assumed to be $11,87719 and 
the cost of PBT to be conservatively 2.5 times greater19. 
 Chordoma and second cancers: Re-treatments are not incorporated into the model and 
hence the only assumed cost associated with cancers was due to lost productivity. The 
reduction in Australia's GDP has been found to be $1,738 million due to 108,900 cancer 
patients not participating in the work force20, or approximately $15,960 per patient per 
year. The same estimate was applied for the chordoma state, due to a lack of data 
specific to this rare cancer. In this model, it is likely that the majority of patients in 
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cancer states will move to the Deceased state before they reach the typical retirement 
age or shortly after. To reduce bias however, the estimated cost of lost productivity was 
not applied to patients when they were older than 65 years, which is the minimum age 
to be eligible for the aged pension in Australia. In addition, costs due to lost productivity 
were not applied when the patient age was less than 18. 
 Spinal cord myelitis: The cost of an episode of myelitis was assumed to be $43,76421. 
This cost was only applied once, rather than annually. 
 Tinnitus: The treatment and societal costs of tinnitus have been analysed by Maes et 
al.22 On average, the annual cost of tinnitus per patient was estimated as €11,949 
(AUD$18,918), representing a significant economic burden. Productivity losses were 
included in this estimate.  
 Blindness: It has been estimated that vision impairment cost $9.85 billion in Australia in 
2004, corresponding to 480,000 vision-impaired people23. This implies that on average, a 
vision-impaired person costs $20,520 annually. This cost estimate includes both direct 
healthcare expenditure and indirect costs such as carer costs, lost earnings and welfare 
payments. 
 Xerostomia: The annual cost of xerostomia was assumed to be US$2,14424 (AUD$2,950), 
including oral saline rinses, pilocarpine, dental and nutritionist visits and fluoride gel.   
 Cataracts: Cataracts was assumed to be treatable with surgery involving lens extraction 
and insertion of an intraocular lens. The cost of this was estimated at $760 based on the 
Medicare Benefits Schedule25.   
 Endocrine dysfunction: The cost of the medicine required to treat GHD is on average 
$5,478 per patient annually19. This cost was only applied to patients aged 18 years and 
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under as treatment is usually not necessary beyond this age. However, it was assumed 
that it was not possible to recover from this injury. 
 
3 Results 
The dose-dependent transition probabilities calculated for each plan and for each patient 
are summarised in Table 3. No patients had a significant risk of brainstem necrosis, spinal 
cord myelitis, or blindness from any treatment. This is most likely due to these organs being 
particularly critical and being weighted accordingly during plan optimisation. IMPT was able 
to provide a much greater probability of locoregional control in some patients (the greatest 
difference was 0.2 for Patient 1). Tinnitus and endocrine dysfunction were the most 
common injuries in the cohort, although the probabilities of these complications were 
negligible in some patients, regardless of the treatment. The risk of xerostomia was 10 times 
greater for Patient 2 if treated with VMAT (10% compared with 1%). Patient 1 had a 25% 
chance of developing cataracts if treated with VMAT compared with a negligible probability 
(<1%) if treated with IMPT. 
The Markov model took the dose-dependent transition probabilities as input to calculate an 
ICER for each patient (Table 4). In accordance with NICE guidelines26, an IMPT treatment 
was classified as cost-effective if it could be provided at a cost of £20,000-30,000 
(AUD$36,000-54,000) per QALY gained or less compared with VMAT. Table 4 demonstrates 
that all patients could be treated with PBT cost-effectively. The mean ICER was AUD$3,220 
per QALY gained. Of particular interest was Patient 5, who had an improved predicted 
clinical outcome if treated with IMPT. However, this also corresponded to a lower cost 
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compared with VMAT when complication costs were considered. This is likely a result of the 
elevated dose received by the ear with VMAT.  
One-way sensitivity analyses were conducted to test the sensitivity of the results to 
estimated model parameters. The results are summarised in Table 5. Only the parameters 
associated with cancers, tinnitus, and endocrine dysfunction were considered in the 
sensitivity analysis, as these were the most common injuries. As the most likely driver of the 
treatment cost ratio is the PBT cost, this cost was varied in the sensitivity analysis. The 
fraction of the cohort that could be treated cost-effectively remained stable with all 





















Table 3: Dose-dependent transition probabilities for each patient. The second primary cancer 
induction probabilities (SPCIPs) listed represents the probability of a second primary cancer 
within 25 years after treatment. The normal tissue complication probabilities (NTCPs) 




















































































1 IMPT 0.88 <0.01 <0.01 0.98 0.01 <0.01 <0.01 1.00 0.01 
 VMAT 0.68 <0.01 <0.01 0.98 <0.01 <0.01 0.24 1.00 0.02 
2 IMPT 0.89 <0.01 <0.01 0.01 <0.01 0.01 <0.01 <0.01 0.01 
 VMAT 0.82 <0.01 <0.01 0.01 <0.01 0.10 <0.01 <0.01 0.02 
3 IMPT 0.94 0.02 0.02 0.01 <0.01 <0.01 <0.01 0.82 <0.01 
 VMAT 0.75 <0.01 <0.01 0.13 <0.01 <0.01 <0.01 0.25 0.01 
4 IMPT 0.86 0.01 <0.01 0.02 <0.01 <0.01 <0.01 0.39 0.01 
 VMAT 0.78 <0.01 <0.01 0.04 <0.01 <0.01 <0.01 0.79 0.03 
5 IMPT 0.83 0.01 0.01 0.48 <0.01 <0.01 <0.01 0.99 0.02 
 VMAT 0.79 <0.01 <0.01 0.67 <0.01 <0.01 0.02 0.84 0.03 
6 IMPT 0.62 <0.01 <0.01 0.01 <0.01 <0.01 <0.01 - <0.01 
 VMAT 0.61 <0.01 <0.01 0.03 0.01 <0.01 0.01 - 0.01 
7 IMPT 0.83 <0.01 <0.01 0.05 <0.01 - <0.01 0.97 0.01 












Table 4: Predicted life expectancies, costs and ICERs for each patient. QALE = quality 































Patient ID Treatment Raw LE (years) QALE (QALYs) Cost ($) ICER ($/QALY) 
1 IMPT 68.4 29.8 358,320 13,620 
 VMAT 52.8 23.1 266,440  
2 IMPT 63.8 63.2 35,320 2,230 
 VMAT 58.7 57.2 21,860  
3 IMPT 71.2 55.3 72,350 4,220 
 VMAT 57.8 51.0 54,020  
4 IMPT 34.1 30.3 37,790 2,110 
 VMAT 31.3 24.4 25,390  
5 IMPT 47.6 28.5 189,990 -15,800 
 VMAT 45.3 26.0 229,800  
6 IMPT 22.9 22.6 39,390 14,250 
 VMAT 22.3 21.7 26,270  
7 IMPT 66.2 47.9 98,590 1,910 
 VMAT 57.4 41.9 87,100  
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Table 5: The effect of model parameter variation on the percentage of the cohort that could be 
treated with IMPT cost-effectively. The treatment cost ratios were altered by altering the proton 
treatment cost. This cost is more likely to vary compared with the photon treatment cost. 
Scenario Percentage cost-effective 
No parameter variation                         100 
Decreased proton/photon cost ratio to 1.5  100 
Increased proton/photon cost ratio to 3.5 100 
Primary cancer state  
Decreased cost to 75% 100 
Increased cost to 125% 100 
Decreased utility by 0.1 100 
Increased utility by 0.1 100 
Second primary cancer state  
Decreased cost to 75% 100 
Increased cost to 125% 100 
Decreased utility by 0.1 100 
Increased utility by 0.1 100 
Tinnitus state  
Decreased cost to 75% 100 
Increased cost to 125% 100 
Decreased utility by 0.1 100 
Increased utility by 0.1 100 
Endocrine dysfunction state  
Decreased cost to 75% 100 
Increased cost to 125% 100 
Decreased utility by 0.1 100 
Increased utility by 0.1 100 
 
4 Discussion 
For all of the cases presented, it was found that the initial cost of the proton treatment was 
justifiable if the costs associated with the greater risk of radiation-induced toxicity arising 
from photon treatments are considered. This was predominantly due to reduced risks of 
tinnitus and endocrine dysfunction, as well as improved tumour control probabilities 
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associated with the IMPT treatments. It was predicted that the proton treatment for one of 
the patients was cost-saving, that is, the treatment of both the tumour and treatment side 
effects were both less expensive and resulted in an improved clinical outcome compared 
with VMAT.  
The results presented here are consistent with those of Mailhot Vega et al.4, in that PBT has 
been found to be a cost-effective treatment in cases where critical structures can be spared 
(typically the pituitary and cochlea in this case). While Peeters et al.5 found a larger cost 
difference between proton and photon treatments for BOSCh (AUD$26,070) compared with 
other indications, here proton treatments were found to be cost-effective for BOSCh 
patients with a mean cost difference of AUD$17,200. The discrepancy between the results 
presented here and those of Peeters et al. is possibly due to different healthcare systems, as 
well as our inclusion of costs associated with additional treatment complications.  
This work has limitations that should be considered when interpreting the results. The 
quality of life utility associated with the endocrine dysfunction state was derived from an 
adult population and may not be representative of the quality of life experienced by a 
paediatric patient, which may influence the ICER calculated for certain patients in the cohort 
considered here. Furthermore, it is possible that endocrine dysfunction could be associated 
with costs other than that of treating GHD, and the cost assumed in this work could be 
underestimated as a result. However, the results were stable with variations in the costs 
associated with this injury. The assumed cost of spinal cord myelitis could also be 
underestimated as it did not include treatment of additional complications associated with 
the condition. However, the NTCP calculated for this injury was <0.01 for most patients and 
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did not exceed 0.02 for any patient or treatment, so it is unlikely that this assumption 
impacted the results. 
No costs were assumed for premature death. Due to the large TCP difference between IMPT 
and VMAT treatments for many patients, this assumption likely underestimates the costs 
associated with VMAT. There was also difficulty in sourcing accurate injury development 
times, resulting in a degree of uncertainty in the costs and QALYs. 
Model validation is an important step in the process of developing individualised patient 
selection strategies27. The estimated SPCIPs for several patients in the cohort were 
comparatively low considering observations of second malignancy incidences in all 
treatment sites. These have been found to be 7.5% for photons and 5.3% for protons 
(median follow up of 6.7 years)28. The model used to calculate the SPCIP in this work is yet 




Markov modelling provides a means for timely assessment of new technologies in radiation 
oncology. This concept has been applied in the current work on an individual patient 
dosimetry basis for the assessment of cost-effectiveness of PBT for BOSCh. The model 
suggested all patients could be treated cost-effectively with PBT when compared to VMAT. 
Sensitivity analyses demonstrated the robustness of these results. This form of assessment 
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6.3 Discussion and conclusion
The publication presented in this chapter demonstrates that a consideration of treatment
cost-effectiveness has been successfully added to the patient selection tool. This will
increase the utility of the model in future applications.
The results suggest that base of skull chordoma is not only a standard indication for
proton therapy, but also a cost-effective one. As proton therapy becomes an available
treatment option in Australia, such evidence could be used as a means of justifying the




The publication P4 forms the basis of this chapter:
Austin, A.M., Douglass, M.J.J., Nguyen, G.T., Cunningham, L., Le, H., Hu, Y. & Pen-
fold, S.N.. Individualised selection of left-sided breast cancer patients for proton therapy
based on cost-effectiveness. International Journal of Particle Therapy. 2019 (Submitted
May 2019).
7.1 Introduction and motivation
The method of incorporating treatment cost-effectiveness into the patient selection tool
has been presented in Chapter 6. The output was demonstrated with a small cohort of
base of skull chordoma patients. This disease is relatively rare and is most common in
paediatric patients. In contrast, breast cancer is more prevalent. However, unlike base
of skull chordoma, breast cancer is not considered to be a standard indication for proton
therapy.
While the costs of construction and operation of proton therapy treatment facilities is
significant, they become increasingly viable if more patients are expected to benefit from
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the treatment. Therefore, the cost-effectiveness of treating common indications with
proton therapy warrants further investigation.
The aim of the publication that forms the basis of this chapter was to apply the method
of patient selection for proton therapy that had been developed in this work to a non-
standard indication. In this case, the indication considered was left-sided breast cancer.
Patients with this diagnosis that receive radiation therapy have an elevated risk of com-
plications related to the heart, lungs and the contralateral breast. The possibility of a
reduced dose to these organs offered by proton therapy suggests that left-sided breast
cancer patients could benefit from the treatment. Another key difference between this
cohort and the cohort considered in Chapter 6 is that no patients received proton ther-
apy. All treatment plans were created for the purposes of retrospective analysis as part
of research.
This chapter details additional data and technical aspects that were not included in the
publication, including probability calculations (Section 7.3) and the estimation of costs
(Section 7.4). A discussion and conclusion are given in Section 7.7.
7.2 Statement of contribution
7.2.1 Conception
The idea to apply the Markov model to a cohort of breast cancer patients first concep-
tualised by Scott Penfold. The method by which to implement this was developed by
Annabelle Austin.
7.2.2 Realisation
The writing of the code, analysis, and sourcing of parameters was performed by Annabelle
Austin. The organs on the CT scans were contoured by Hien Le and Yvonne Hu. The
radiotherapy treatment plans used in the analysis were created by Lisa Cunningham.
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7.2.3 Documentation
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Introduction: The significantly greater cost of proton therapy compared with X-ray therapy 
is frequently justified by the expected reduction in normal tissue toxicity. This is often true 
for indications such as paediatric and skull base cancers. However, the benefit is less clear 
for other more common indications such as breast cancer. This is due to uncertainty 
regarding the effect of a reduced dose in the chest region on clinical outcome. The aim of 
this work is to demonstrate an individualised selection method for proton therapy of left-
sided breast cancer patients based on cost-effectiveness of treatment.   
Patients and Methods: 16 left-sided breast cancer patients had a treatment plan generated 
for the delivery of intensity modulated proton therapy (IMPT) and of intensity modulated 
photon therapy (IMRT) with the deep inspiration breath hold (DIBH) technique. The 
resulting dosimetric data was used to predict probabilities of tumour control and toxicities. 
These probabilities were used in a Markov model to predict costs and the number of quality 
adjusted life years expected as a result of each of the two treatments.  
Results: IMPT was not cost-effective for the majority of patients, but was cost-effective 
where there was a greater risk reduction of second malignancies with IMPT.  
Conclusion: The Markov model predicted that IMPT with DIBH can only be cost-effective for 
selected left-sided breast cancer patients where IMRT would result in a significantly greater 
dose to normal tissue. The presented model may serve as a means of evaluating the cost-
effectiveness of IMPT on an individual patient basis. 
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Comparative planning studies have suggested that proton therapy has the potential to 
increase sparing of critical structures in the treatment of breast cancers for certain 
patients1,2. However, Weber et al.2 noted that the issues of treatment cost and availability 
for a common disease could limit the routine clinical use of protons in the post-operative 
treatment of breast cancer. 
While proton therapy is a more expensive treatment than conventional X-ray therapy, it 
may be justified when costs other than that of the initial treatment are considered over the 
lifetime of a patient. For some patients, savings may be made if they are treated with 
proton therapy, even if the initial cost is greater. Lundkvist et al.3 have investigated whether 
improved outcomes for breast cancer patients who receive proton therapy are sufficient to 
justify a greater treatment cost. They found the treatment to be cost-effective for patients 
who had a high risk of developing a cardiac complication as a result of the radiation. Mailhot 
Vega et al.4 have developed an approach of selecting breast cancer patients to receive 
proton therapy based on risk of radiation-induced cardiac toxicity and proton treatment 
cost-effectiveness. Proton therapy was found to be cost-effective for cases where a woman 
had a cardiac risk factor and would receive a mean heart dose of greater than 5 Gy if treated 
with photons. 
Deep inspiration breath hold (DIBH) with X-rays is becoming increasingly common for the 
treatment of left-sided breast cancer5. This technique can increase the distance between 
the breast and the heart, reducing heart dose and thereby the risk of radiation induced 
heart complications. For patients capable of the breath hold technique, the reduction in risk 
of radiation induced toxicity may be negligible with proton therapy. Proton therapy still has 
the potential to reduce dose to the lung and contralateral breast compared with DIBH with 
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X-rays, however6, 7. These organs are particularly sensitive to radiation induced second 
primary cancers8. It is important these organs at risk are included in an analysis of cost-
effectiveness of proton therapy compared to state-of-the-art X-ray therapy. 
The objective of the current work was to assess cost-effectiveness of proton therapy for a 
cohort of 16 DIBH-capable early stage breast cancer patients. In addition to cardiac toxicity, 
pneumonitis and second primary cancer induction were included in a Markov chain cost-
effective analysis comparing intensity modulated proton therapy (IMPT) with hybrid three 
dimensional conformal radiotherapy (3DCRT)/intensity modulated radiotherapy (IMRT) X-
ray radiotherapy. The transition probabilities of the Markov model were based on 
radiobiological models of tumour control probability (TCP), normal tissue complication 
probability (NTCP) and second primary cancer induction probability (SPCIP). These 
probabilities were derived on an individual basis from their comparative proton/X-ray 
radiotherapy treatment plans. The model was used to predict the likely outcome after a 
given treatment for each of the patients in the cohort in terms of life expectancy and quality 
adjusted life expectancy (QALE). Costs of primary and subsequent treatment were also 
included to determine the cost per quality adjusted life year (QALY) gained for protons 
compared to X-rays, also known as the incremental cost-effectiveness ratio (ICER). 
2 Patients and Methods 
2.1 Patient cohort and treatment planning 
The cohort of patients considered in this retrospective study consisted of 16 female left-
sided breast cancer patients treated at the Royal Adelaide Hospital with X-ray radiotherapy. 
The median age was 56 years (range 36-74). 50% of diagnoses were invasive ductal 
carcinoma, but diagnoses also included invasive lobular carcinoma, papillary carcinoma, 
ductal carcinoma in situ, and apocrine carcinoma.  A majority (68%) of patients were stage 
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T1 and N0 (87.5%). As patients with metastatic disease were excluded from the study, most 
patients were M0, with one patient Mx (unable to be assessed for distant metastases). All 
patients had breasts intact and the whole breast was modelled in treatment planning.  
Each patient had a computed tomography (CT) scan acquired with DIBH. The clinical target 
volume (CTV) included apparent CT glandular breast tissue and lumpectomy CTV. In this 
retrospective analysis, each patient had two new treatment plans created. The prescribed 
dose was 40 GyRBE (the RBE weighted dose) in 15 fractions. Planning objectives for the heart 
were Dmean < 3 Gy and V21.5Gy < 10%, for the left lung V18Gy < 15% and as low as reasonably 
achievable doses to the left anterior descending artery, right lung, and right breast. 
The X-ray treatment plan made use of the 3DCRT/IMRT hybrid technique (h-IMRT). The 
plans consisted of opposing tangential fields with 70% and 30% weighting of the 3DCRT 
(open tangent field) and IMRT beams (inversely optimized IMRT field) in each tangent 
respectively. This weighting was used to ensure planning consistency. 6 MV beams were 
used unless the size of the breast required the use of 10 MV beams in the 3DCRT beam to 
reduce lateral hotspots and improve target coverage. IMRT beams were optimized to a 
planning target volume, defined as the CTV with a 5 mm margin limited to within the 
exterior of the patient minus 5 mm and excluding the left lung. Treatment plans were 
created to achieve 98% coverage of the planning target volume (PTV) with 95% of the 
prescribed dose. 
IMPT plans were created with a single en-face beam. A range-shifter was used to allow the 
placement of Bragg peaks close to the patient surface. A beam specific PTV was generated 
with an expansion of 5 mm laterally and 3% of the beam range distally. Two patients were 
duplicated and re-planned to test planning consistency. 
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2.2 Markov model 
A discrete-time Markov chain model was applied in this work9. The time period modelled 
begins immediately after the final fraction of radiotherapy treatment and ends when the 
patient is deceased. The cycle length was chosen to be one year. 
A patient can occupy only a single Markov state at a given time. These states are 
summarised in Figure 1. The toxicities considered included pneumonitis and heart disease. 
The possibility of developing a second primary cancer (SPC) as a result of the initial radiation 
treatment was also included. 
The following assumptions were made when determining the Markov states to be used in 
the model: 
 Pneumonitis, if developed, is likely to resolve many years prior to the induction of a 
second primary cancer. Therefore there are no states for the situations where a patient 
is affected by both pneumonitis and a second primary cancer. 
 If a treatment is unsuccessful, it is assumed that it is highly unlikely that the patient will 
still be alive when the probability of developing a second malignancy is significant. 
Therefore there are no states where the initial cancer and a second cancer coexist. 
2.3 Markov state transition probabilities  
Markov models in medical applications assume that a patient occupies a single state for the 
duration of a cycle. At the end of each cycle, it is possible for a patient to transition to 
another state. The allowed transitions are summarised in Figure 1. 
The following assumptions were made when determining the allowed transitions in the 
model: 
 It is not possible to recover from heart disease or a second cancer once it has developed. 
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 It is not possible to transition from the Cancer state to the Well state once the first 
Markov cycle has begun. The patient may begin in the Well state as a result of a 
successful treatment. 
 There is a large difference in the time point after treatment at which the second primary 
cancer induction probability (SPCIP) becomes significant compared to the time point 
where the NTCP is significant for the toxicities considered. Therefore, the probability of 
simultaneously developing an injury and second cancer is negligible. Similarly, the 
probability of developing an injury after a second cancer is also negligible. 
 Once pneumonitis has been recovered from, the model ensures that it is not possible to 
relapse. 
The transition probabilities are explained in more detail in Sections 2.3.1 – 2.3.4.  
2.3.1 Locoregional control 
The probability of the patient beginning in the Well state is equal to the dose-dependent 
TCP (defined in the Supplementary Material), while the probability of beginning in the 
Cancer state is the complement of the TCP. Re-treatments are not directly included in the 
model. This is assumed as the outcome of the initial treatment is the focus of this selection 
tool. Similarly, while there were no explicit states for metastases, the cancer death 
probabilities incorporate this implicitly in the model.   
2.3.2 Normal tissue complications 
The probability of pneumonitis is calculated using the radiation dose to both lungs. The 
probability of heart disease is calculated with the dose to the heart. These transition 
probabilities are time-dependent to allow for a more realistic estimation of costs and QALYs. 
The details of the calculations are described in the Supplementary Material. 
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The majority of patients with pneumonitis recover10. It was assumed that recovery would 
occur after 1 year as all estimated costs associated with treating this injury applied within 
the first year only. It was assumed that heart disease was chronic and the possibility of 
recovery was neglected in this work. 
2.3.3 Second primary cancer induction 
The SPCIP is the probability of developing a radiation induced cancer as a result of the 
treatment. This is an important consideration due to the expected difference in integral 
dose between a proton and photon plan. This is also a dose- and time-dependent quantity 
and was calculated using the model developed by Schneider et al.11. The relevant formula 
and input data are described in the Supplementary Material. 
2.3.4 Death Probabilities  
Unlike the other transition probabilities described in this section, the probability of 
transitioning to the Deceased state is dose-independent. The purpose of this study was to 
evaluate the cost-effectiveness from a dosimetric point of view and while the death 
probabilities are not dosimetric quantities, they allow for a more realistic estimate of the 
number of QALYs gained as a result of a given treatment. Depending on the Markov state of 
a patient, there are a number of possible transitions that can be made to the Deceased 
state: 
 Death due to breast cancer as a result of an unsuccessful treatment. Survival of breast 
cancer patients was found to be 55% at 10 years for the case of local failure12. A 
constant yearly death probability, denoted 𝑃𝑟(𝐷𝑖𝑒), was derived from this data, where 
𝑆 = (1 − Pr(𝐷𝑖𝑒))𝑛, 𝑛 = 10  is the number of years after treatment, and S=0.55 is the 
surviving fraction. Solving for the death probability gives 0.06. 
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 Death due to a second malignancy. The 5-year survival for all cancers combined is 68%13. 
Using the same method for the breast cancer death described above, a yearly death 
probability of 0.08 was derived. 
 Death due to heart disease. The probability was assumed to be 0.01 per year which was 
estimated using 2007 prevalence (3.5 million) and death rates (48, 456) associated with 
cardiovascular disease in Australia14. 
 Unrelated death. This time-dependent probability is based on data from life tables 
obtained from the Australian Bureau of Statistics (ABS)15. 
Note that as recovery from pneumonitis is highly likely, it was assumed that this injury was 
non-fatal. 
2.4 Estimation of quality of life utilities   
The quality of life (QoL) utility value of each Markov state represents the quality of life 
associated with the state relative to perfect health (with QoL=1). By default, the quality of 
life associated with death is 0. The utilities used in the current work are listed in Table 1.  
For states where there is more than one injury or cancer, the assigned utility is a 
multiplication of the utilities of the states where there is only one of each injury or cancer. 
The state representing the cases of second primary cancers were assigned a value of 0.8 in 
accordance with the Eastern Cooperative Oncology Group (ECOG) performance status16 as 
their definition of a grade 1 complication gives the most accurate description of this state.  
2.5 Estimation of costs 
In addition to the cost of the breast cancer treatment, costs of side-effect treatments were 
also incorporated into the model to allow for a more realistic representation of the costs 
associated with a given treatment. The costs of re-treatments and treatments of second 
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cancers were not included. No costs were assumed for fatal events, only loss of QALYs. For 
states where several injuries or cancers affect a patient, the cost applied was the sum of the 
costs for the individual injuries. Costs and QALYs were discounted by 3% annually, to adjust 
for differences in timing of costs and effects. Where possible, Australian costs were applied 
for consistency and all costs are in Australian dollars (AUD). These are summarised in Table 
1. The details of the cost estimation are given in the Supplementary Material. 
3 Results 
The ICER was calculated for each patient in the cohort. The results are given in Table 2. In 
accordance with the NICE guidelines17, IMPT was considered cost-effective if it cost £20,000 
($36,000) per QALY gained or less compared with h-IMRT.   
Proton therapy was cost-effective for one patient in the cohort and cost-ineffective for 15 
patients. Both members of both sets of the duplicated patients were classified as cost-
ineffective. The difference in the ICER calculated for patient 3 and the ICER calculated for its 
re-planned duplicate was approximately $8,000. For patient 8, the difference between the 
ICER and the ICER of the duplicate was $6,000. These differences are due to small 
differences (up to 0.1 years) in the number of QALYs in the denominators. 
3.1 Sensitivity analysis 
Variation of selected parameters altered the fraction of the cohort that could be treated 
with IMPT cost-effectively. 
Parameters related to second cancers were varied as these had a large impact on whether a 
patient was classified as cost-effective. These included costs, the utility and the death 
probability. In contrast, the TCP difference between the treatments did not exceed 0.01 for 
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any of the patients. Therefore, it is unlikely that variation of related parameters would 
impact the results. 
Due to the relatively small NTCP for pneumonitis (see Supplementary Material), no 
parameters relevant to pneumonitis were considered to have a significant effect on the 
results. Even if the NTCP difference were larger between the two treatments, the relatively 
small cost and duration of pneumonitis would result in a minimal effect on the results. The 
exception was the possibility of this injury becoming chronic in a fraction of patients. 
There was not a significant difference in the heart disease NTCP between IMPT and h-IMRT 
for any of the patients (see Supplementary Material). The only parameter related to heart 
disease that was varied was the baseline risk. This parameter was doubled in the analysis to 
investigate whether high risk groups could be treated with protons cost-effectively. 
Treatment cost ratios were varied by varying the proton treatment cost, as this was 
considered to have the greatest uncertainty. 
After selecting parameters that were most likely to influence the results, a sensitivity 
analysis was performed for each. The results are presented in Table 3. As expected, if IMPT 
could be delivered at a lower cost (1.5 times that of IMRT), then a significantly greater 
proportion of the cohort could be treated with IMPT cost-effectively. Proton therapy was 
also less likely to be cost-effective where there was a reduced probability of death due to 
second cancer induction. The results were stable with variation of other model parameters. 
4 Discussion 
The Markov model predicted that IMPT could not be delivered cost-effectively to the 
majority of patients in the cohort investigated. The patient that could be treated cost-
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effectively had a comparatively high lung dose (see Supplementary material) which 
increased the second cancer risk. The higher lung dose was necessary to spare breast tissue 
in this patient who had relatively larger breasts. This was also a younger patient (less than 
the assumed retirement age at the time of treatment) and hence in the model they had the 
potential to be less productive in society as a result of second malignancies. Alternatively, 
the difference in normal tissue doses between treatments was smaller for the remainder of 
the cohort.  
The sensitivity analysis indicated that, as expected, the initial cost of the proton treatment 
had the largest impact on whether a patient could be treated cost-effectively. However, it is 
anticipated that the cost of proton therapy will decrease over time as it is a newer 
treatment. Furthermore, it is likely that the initial cost of building a proton clinic would have 
a large contribution to this cost. This cost can be increasingly justifiable with an increasing 
number of patients who are expected to benefit from the treatment. If breast cancer 
patients could be included in this category, then proton clinics may be more viable as 
current standard indications are predominantly relatively rare or paediatric cases. 
Lung cancer was found to be the most likely second cancer in this work, agreeing with a 
study of second cancer incidences after X-ray therapy for breast cancer18. In a planning 
study of various X-ray treatment techniques for breast cancer, Santos et al.8 also found the 
lungs to have the highest second cancer risk.  
The mean heart dose did not exceed 4 Gy for any treatment for any of the patients (see 
Supplementary material). This is likely a result of the DIBH technique, which is designed to 
reduce exposure to the heart. Mailhot Vega et al.4 found that for a proton treatment of 
breast cancer to be cost-effective, it was necessary for the mean dose to the heart from 
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photons to be greater than 5 Gy. Hence, the results presented here are consistent with this 
finding.  
The average predicted ICER of $84,600 was smaller than the average predicted by Lundkvist 
et al. of €67,000 ($105,000)3. Our estimation of the ratio of proton therapy to photon 
therapy costs is similar (2.5 in this work compared with 2.6). Their estimation of the 
probability of death due to breast cancer was lower than ours, but it is unlikely that this 
alone would influence our results significantly due to the relatively small difference in the 
expected TCP between IMPT and IMRT for the patients in our cohort. Therefore, the 
discrepancy is likely due to our inclusion of costs associated with the possibility of radiation-
induced cancers. 
While an ICER of £20,000 was assumed to be the threshold for a treatment to be cost-
effective in this work, according to the NICE guidelines17 the threshold can be as large as 
£30,000 ($54,000) if advisory bodies can make a strong case in support of the intervention. 
If this threshold were to be assumed here, an additional 4 patients would have a cost-
effective proton treatment (31% of the cohort in total). These patients had relatively large 
lung dose differences between the two modalities, corresponding to larger SPCIP 
differences. 
There are several assumptions in the Markov model that may have influenced the results. 
For example, re-treatments were omitted as the alternate treatments of the initial cancer 
are the subject of comparison in the model. However, the results may be less realistic as a 
consequence of this assumption. In reality re-treatments would likely occur and this would 
contribute to costs. In addition, loss of life is assumed to have no cost. Including each of 
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these factors would increase the likelihood of a proton treatment being cost-effective, 
assuming it resulted in improved tumour control and reduced second cancer rates.     
The radiobiological models that are built into the Markov model also have limitations. For 
example, the model used to estimate the probability of developing heart disease was 
developed using data from both left and right-sided breast cancer patients. The effect of this 
is that the true NTCP may be underestimated, which could have contributed to the relatively 
small probabilities that were obtained for each of the patients despite a wide variation in 
mean heart dose.  
It is worth noting that the patients considered in this study represent a subset of breast 
cancer patients who are able to hold their breath during treatment. This is not the case for 
all breast cancer patients, particularly those who are elderly. It may be possible to treat 
patients cost-effectively if they are not able to hold their breath or have suspected nodal 
involvement and therefore would experience a higher risk of cardiac toxicity if treated with 
X-rays. 
5 Conclusion 
The cost-effectiveness of proton therapy for a cohort of left-sided breast cancer patients 
capable of being treated with DIBH has been assessed with a Markov model. It was found 
that proton therapy was not a cost-effective treatment for the majority of the cohort. 
However, patients that would have an elevated risk of second malignancy if treated with X-
rays could be treated with IMPT cost-effectively. The presented model has the potential to 
evaluate the cost-effectiveness of treatments on a case-by-case basis, facilitating the 
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Figure 1: The Markov state transition diagram showing the allowed transitions between states. 
`Well' represents perfect health. `Cancer' represents the situation where the patient still has the 
initial primary breast cancer, `SPC' represents a second primary cancer, `Pneum.' refers to 











Table 1: Estimates for the yearly costs and quality of life utilities for states in the Markov model. 
Details of the cost estimations are given in the supplementary material. 
State Utility Cost ($) 
Breast cancer 0.8919 15,960 
Heart disease 0.820 13,658 
Pneumonitis 0.820 4,037 




































Table 2: Predicted life expectancies and costs for each patient. The cost of protons per QALY 
gained is listed. Duplicated patients are denoted by an asterisk. QALY = quality adjusted life year. 
QALE = quality adjusted life expectancy=number of QALYs lived. 
Patient ID Treatment Raw LE (y) QALE (QALYs) Costs ($) ICER ($/y) 
1 IMPT 48.2 25.48 39,040 73,950 
 IMRT 47.6 25.26 22,470  
2 IMPT 19.0 14.38 31,430 107,130 
 IMRT 18.8 14.21 13,650  
3 IMPT 38.9 22.91 38,040 122,700 
 IMRT 38.6 22.77 20,740  
3* IMPT 38.9 22.88 38,160 128,640 
 IMRT 38.6 22.75 21,050  
4 IMPT 22.3 16.16 31,720 49,610 
 IMRT 21.9 15.80 13,960  
5 IMPT 19.0 14.40 31,430 79,660 
 IMRT 18.8 14.17 13,660  
6 IMPT 33.4 21.02 37,000 89,980 
 IMRT 33.1 20.83 20,000  
7 IMPT 25.6 17.78 33,760 46,640 
 IMRT 25.2 17.41 16,450  
8 IMPT 33.5 21.07 36,490 54,730 
 IMRT 33.0 20.77 20,180  
8* IMPT 33.4 21.01 37,050 60,910 
 IMRT 33.0 20.74 20,550  
9 IMPT 18.2 13.94 31,360 67,800 
 IMRT 18.0 13.67 13,600  
10 IMPT 21.4 15.69 31,650 87,370 
 IMRT 21.2 15.48 13,910  
11 IMPT 36.2 22.00 37,660 237,110 
 IMRT 36.0 21.92 20,110  
12 IMPT 15.0 12.03 31,040 99,620 
 IMRT 14.9 11.85 13,410  
13 IMPT 18.1 13.92 31,360 90,840 
 IMRT 18.0 13.73 13,920  
14 IMPT 30.7 19.96 36,450 26,750 
 IMRT 29.9 19.38 20,780  
15 IMPT 40.6 23.42 38,660 52,680 
 IMRT 40.0 23.12 22,540  
16 IMPT 29.0 19.26 35,480 45,820 






Table 3: The effect of model parameter variation on the percentage of the cohort that could be 
treated with IMPT cost-effectively. The ratio of the treatment costs was varied by varying the 
proton treatment cost. 
Scenario Percentage cost-effective 
No parameter variation 6 
Decreased proton/photon cost ratio to 1.5 88 
Increased proton/photon cost ratio to 3.5 0 
Decreased recovery rate of pneumonitis to 80% 6 
Decreased second cancer death probability by  50% 0 
Increased second cancer death probability by 50% 6 
Decreased second cancer cost to 75% 6 
Increased second cancer cost to 125% 6 
Decreased second cancer utility by 10% 6 
Increased second cancer utility by 10% 6 
Doubled baseline risk of heart disease 6 
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7.3 Calculation of transition probabilities from DVH
data
7.3.1 Tumour control probability (TCP) calculation















where there are a total of M voxels, each having a fractional volume vi (of the total
tumour) that receives dose Di as part of a treatment delivered in n fractions (nfrac), and
α and β are the linear and quadratic coefficients of the LQ model, respectively. For breast
cancer, α/β = 2.88 and α = 0.08 [91]. The dose was converted to an equivalent dose in
2 Gy fractions.
The parameter γ is the normalised dose-response gradient evaluated at D = D50, the
dose at which 50% of tumours are controlled. This value was taken as 1.46 [92].
7.3.2 Normal tissue complication probabilities
7.3.2.1 Pneumonitis
The Lyman-Kutcher-Burman (LKB) NTCP formalism was used to determine the prob-
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where TD50 is the uniform dose in Gy given to the entire organ that results in 50%
complication risk, m is an organ-specific parameter that represents the gradient of the
dose-response curve (analogous to γ in the TCP calculation), and n is a parameter that
characterises the volume dependence of the organ’s response to radiation, and ` is the
number of voxels. The values determined by Seppenwoolde et al. [93] (TD50 = 30.8 Gy,
m = 0.37, n = 0.99) were used in this model. An α/β of 3.0 was assumed for the lung to
convert the dose to an equivalent dose in 2 Gy fractions.
To calculate a time-dependent NTCP, a time-dependent normal distribution was defined
that was normalised such that the integral was equal to the NTCP defined in (7.3). The
mean of the distribution was the mean time taken for pneumonitis to develop. This was
assumed to be 6 months with a standard deviation of 2 months as most cases are expected
to develop within a year [94]. The result is a discretised normal distribution with a NTCP
for each year after treatment.
7.3.2.2 Heart disease
The probability of a major coronary event was calculated using the model developed by
Darby et al. [27]:
NTCP (heart disease) = B(1 +KD), (7.5)
where K = 0.074 Gy, D is the mean dose to the heart, calculated from the individual
patient’s DVH for the heart associated with a particular plan, and B is the risk of a
cardiac event without radiation therapy. This was estimated to be 1.5% based on a
review of the prevalence of heart failure in Australia [95], which was found to be 1-2%.
An α/β of 3.0 was assumed for the heart to convert the dose to an equivalent dose in 2
Gy fractions.
Once the NTCP for cardiac events was calculated, time-dependent probabilities were
derived using the same method described for pneumonitis. The mean time taken for a
cardiac event to occur after treatment was estimated to be based on data presented by
Darby et al.[27] on the percentage increase of events per Gy for given time periods after
radiotherapy. The overall average of the mean dose to the heart in their population study
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was 4.9 Gy. The largest increase was within 4 years of radiotherapy, and hence the mean
was assumed to be 4 years. A standard deviation of 2 year was assumed in this model,
but this was not clinically founded.
7.3.3 Second primary cancer induction probabilities
The excess absolute risk (EAR) of developing a cancer in a particular organ at a particular
time after treatment due to radiation exposure is given by (7.6) and was taken as an







Here, ageX is the age of the patient at the time of treatment (the time of exposure to
radiation), age is the age of the patient after treatment at the year of interest, VT is
the total volume of the organ, βEAR is the initial slope, ` is the number of voxels, and
µ(ageX, age) is the modifying function,
µ(ageX, age) = exp
[





with γe and γa being the age modifying parameters.
Equation (7.8) gives the risk equivalent dose (RED) mechanistic model which accounts











where R is the repopulation/repair parameter, α′ is given by
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and DT and dT represent the prescribed dose to the target volume and the corresponding
dose per fraction, respectively. The values used for these parameters are listed in Table
7.1.
It was assumed that it was possible to develop a second cancer in any of the following:
the left lung, the right breast, and all regions in the body that were not contoured. The
parameters used for the SPCIP calculation are listed in Table 7.1 [84].
Table 7.1: Parameters used for the calculation of the SPCIP for each year after
treatment. Data was not provided for the heart.
SPCIP PARAMETERS
Tissue βEAR α R γe γa
Lung 8.0 0.042 0.83 0.002 4.23
Body 74.0 0.089 0.17 -0.024 2.38
Breast 8.2 0.044 0.15 -0.037 1.7
Once the SPCIP for each year had been calculated for the two tissues being considered,
they were combined into a single probability of developing any second cancer (SC) in a
given year, P(SC 1 ∪ SC 2), assuming the two events were independent.
7.4 Estimation of costs
7.4.1 Radiation therapy
The cost of IMRT was assumed to be $11,877 [14] and the cost of proton therapy to be
conservatively 2.5 times greater [14].
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7.4.2 Cancer
The estimate of the cost associated with an unsuccessful treatment (resulting in the
patient being in a state associated with cancer) was based on lost productivity (see
Section 2.6 of the publication P3, Chapter 6). The model does not incorporate the effect
of re-treatments and hence the costs associated with this were not included. In reality, it
is likely that re-treatments would occur resulting in the true cost being higher. However,
the original treatment (either proton or photon) is the subject of comparison in this study.
7.4.3 Heart disease
In the 2004-2005 financial year, $5,942 million was spent on approximately 685,000 car-
diovascular disease patients in Australia, corresponding to an average cost per year per
person of $8,674. This estimate includes hospital admissions, prescription pharmaceu-
ticals (including the contribution from the PBS (pharmaceutical benefits scheme) and
patient contributions), and out-of-hospital medical services [97]. The expenditure on
lipid-lowering medicines was not included which may lead to a significant underestima-
tion of costs. The annual expenditure on research ($164 million) was subtracted for this
study as it is not necessarily case specific.
To estimate costs associated with lowered productivity and workforce participation, the
cost of heart disease-related absenteeism in 2004 obtained for a study in productivity
loss [98] was applied. Applying a prevalence of 355,600 in 2004 [99], the total cost of
$31.7 million was translated to $89 per person. Similarly to cancer, costs associated with
workforce participation were applied only when the patients were below the retirement
age.
7.4.4 Pneumonitis
The costs associated with pneumonitis were estimated based on management strategies
described by Ghafoori et al. [100]. These included a chest X-ray and a course of oral
prednisone (a corticosteroid). The cost of the X-ray was estimated to be $47, based on
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Medicare Benefits Schedule (MBS) data [101]. The medication cost was estimated at $63,
based on the Pharmaceutical Benefits Scheme (PBS) dispensed price [102].
In the estimations of Lundkvist et al. [40], one month of leave was assumed for 75% of
patients with the injury. This corresponded to a total average leave cost of $3,927 after
applying data relevant to Australia. A patient recovers from pneumonitis after a single
cycle and hence the cost is applied for one year only.
7.5 Dose-dependent transition probabilities by pa-
tient
The transition probabilities that were calculated based on the dose received by each
patient are summarised in Table 7.2. The NTCPs and SPCIP are time-dependent proba-
bilities. The total NTCP integrated from the starting age of the patient to the maximum
possible age in the model (100) and the average yearly SPCIP is listed.
TRANSITION PROBABILITIES
Patient ID Treatment TCP Pneumonitis NTCP Heart NTCP SPCIP
1 IMPT 0.971 <0.01 0.02 0.053
IMRT 0.973 0.01 0.02 0.130
2 IMPT 0.971 <0.01 0.02 0.044
IMRT 0.974 0.01 0.02 0.110
3 IMPT 0.971 <0.01 0.02 0.055
IMRT 0.975 0.01 0.02 0.110
3 * IMPT 0.972 <0.01 0.02 0.065
IMRT 0.972 0.01 0.02 0.100
4 IMPT 0.971 <0.01 0.02 0.044
IMRT 0.975 0.02 0.02 0.160
5 IMPT 0.971 <0.01 0.02 0.040
IMRT 0.971 0.01 0.02 0.110
6 IMPT 0.973 <0.01 0.02 0.069
Chapter 7. Cost-Effectiveness of Breast Cancer 192
IMRT 0.971 0.01 0.02 0.120
7 IMPT 0.971 <0.01 0.02 0.057
IMRT 0.973 0.02 0.02 0.170
8 IMPT 0.976 <0.01 0.02 0.067
IMRT 0.972 0.01 0.02 0.130
8 * IMPT 0.971 <0.01 0.02 0.069
IMRT 0.969 0.01 0.02 0.140
9 IMPT 0.971 <0.01 0.02 0.036
IMRT 0.972 0.02 0.02 0.130
10 IMPT 0.967 <0.01 0.02 0.050
IMRT 0.973 0.01 0.02 0.120
11 IMPT 0.971 <0.01 0.02 0.060
IMRT 0.972 0.01 0.02 0.080
12 IMPT 0.971 <0.01 0.02 0.036
IMRT 0.972 0.02 0.02 0.100
13 IMPT 0.971 <0.01 0.02 0.042
IMRT 0.971 0.01 0.02 0.110
14 IMPT 0.969 <0.01 0.02 0.069
IMRT 0.972 0.03 0.02 0.230
15 IMPT 0.971 <0.01 0.02 0.068
IMRT 0.971 0.01 0.02 0.150
16 IMPT 0.972 <0.01 0.02 0.073
IMRT 0.97 0.02 0.02 0.170
Table 7.2: Transition probabilities calculated based on the dose to each patient.
Duplicates are indicated by an asterisk.
7.6 Mean organ doses by patient
The mean radiation doses that would be received by each organ as a result of each
treatment are summarised in Table 7.3. The difference in dose for each modality is listed
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for each patient.
ORGAN DOSES
Patient ID Lung Heart
IMPT (Gy) IMRT (Gy) ∆(Gy) IMPT (Gy) IMRT (Gy) ∆(Gy)
1 0.74 3.00 2.26 0.05 0.25 0.20
2 0.94 4.54 3.60 0.08 0.44 0.37
3 0.92 3.11 2.20 0.04 0.34 0.30
3* 1.29 2.92 1.63 0.06 0.34 0.28
4 0.89 7.95 7.06 0.03 0.64 0.62
5 0.91 5.24 4.34 0.03 0.58 0.55
6 1.41 3.83 2.42 0.20 0.34 0.14
7 1.16 6.83 5.67 0.06 1.23 1.17
8 1.32 4.66 3.34 0.06 0.47 0.41
8* 1.38 4.67 3.28 0.08 0.48 0.40
9 0.89 6.45 5.56 0.07 0.69 0.61
10 1.14 4.82 3.68 0.02 0.71 0.69
11 1.02 1.86 0.84 0.10 0.32 0.22
12 1.35 7.80 6.46 0.10 2.04 1.95
13 1.15 5.58 4.42 0.10 3.31 3.21
14 1.19 10.00 8.81 0.14 2.68 2.54
15 1.18 3.70 2.52 0.06 0.39 0.33
16 1.36 6.32 4.96 0.07 0.54 0.47
Table 7.3: Mean doses to the heart and lung for each patient and treatment modality.
Duplicates are indicated by an asterisk.
7.7 Discussion and conclusion
The proton treatment cost-effectiveness was predicted for each member of the left-sided
breast cancer patients in the cohort. However, the presented approach has limitations
that should be considered when interpreting the results.
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The estimation of costs of adverse events is inherently challenging and can be signifi-
cantly more complex compared with the estimations employed here. For example, the
cost of drugs is highly variable with time. In addition, productivity loss was estimated
considering paid work only and work such as caring and volunteering was omitted. This
could be particularly relevant for older patients who were assumed to have no potential
for productivity loss and were predicted as having predominantly cost-ineffective proton
treatments.
Another limitation is the uncertainty associated with the time for toxicities to develop.
This may have resulted in uncertainties in the estimated cost and QALYs. Uncertainties
in the dose were not considered as it was not possible to perform a robust analysis in the
treatment planning system used to develop the plans used in this work. Furthermore,
there was a lack of data available on the uncertainties associated with the radiobiological
model parameters.
The publication presented in this chapter demonstrates the developed model as a potential
tool for selecting patients for proton therapy. This is particularly important for cancer
types that would not normally be considered as standard indications for the treatment.
Chapter 8
Conclusions and Future Work
8.1 Conclusions
The model developed in this work provides a prediction of the clinical outcome associated
with a given radiotherapy treatment plan. Specifically, the difference in dose distribu-
tion evident in a comparison of treatment plans is translated to a difference in clinical
outcome. As a result, it has the ability to estimate the relative benefit of a proton treat-
ment compared to conventional X-ray radiotherapy on an individual patient basis. This
prediction is of great value in the absence of data from clinical trials of proton therapy
and allows the patients who are expected to receive the greatest benefit from this limited
resource to be identified.
Several stages of model development have been detailed in this work. These included:
1. The initial model, which was evaluated with a Monte Carlo simulation. While this
model was functional, it was limited by large computational times.
2. The model that was evaluated analytically, giving the exact solution with a signifi-
cantly reduced computation time. This model also assumed that the probability of
death due to cancer or injury was determined by the stage/grade rather than the
time the cancer/injury had been present.
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3. Incorporation of the effects of dose and radiobiological model parameter uncertain-
ties on the model predictions. It was found that uncertainties in dose delivery made
it difficult to conclude whether proton therapy would improve the clinical outcome
of the base of skull chordoma (BOSCh) demonstration patient. However, when
considering NTCP model parameter uncertainty only, a clear benefit was predicted
for the demonstration patient if they were to be treated with protons. A framework
for considering the effect of uncertainty in the quality of life utility weights was also
developed. These weights are particularly important drivers of outcomes.
4. Incorporation of the effect of treatment cost-effectiveness to allow the model to
select patients for proton therapy through balancing treatment cost and patient
quality of life.
5. An investigation of the patients selected by the model to receive proton therapy,
based on proton treatment cost-effectiveness. Two distinct cohorts were considered,
one consisting of BOSCh patients and the other consisting of left-sided breast cancer
patients (treated with the deep inspiration breath hold technique (DIBH)). The
former is considered to be a standard indication for proton therapy, while the latter
is not. It was found that all BOSCh patients could be treated with proton therapy
cost-effectively. In contrast, the majority of the breast cancer patient cohort could
not be treated cost-effectively. This was largely due to the greater risk of toxicity
associated with the radiation treatment of BOSCh, while the toxicity rate associated
with DIBH (particularly cardiovascular disease) was found to be low for both proton
and photon treatments. However, it was also evident that the breast cancer patients
who could be treated cost-effectively had an elevated lung dose associated with the
planned photon treatment. Therefore, individualised approaches to patient selection
may prove useful for this indication. Conversely, the results are supportive of proton
therapy being adopted as a standard treatment for BOSCh.
The developed toolkit has the potential to serve as the basis of a patient selection system
for proton therapy in clinical environments. This is particularly relevant in Australia as
proton therapy facilities commence construction. Patient selection systems are valuable
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in ensuring the efficient and equitable delivery of healthcare, both of which are high
priorities in any society.
8.2 Future work
The prediction offered by the presented model provides a valuable approach to patient
selection for proton therapy. However, there remains significant potential for further de-
velopment of the model both before and after clinical implementation. Recommendations
for future work are as follows:
 External model validation. This is an essential requirement before this type of
model can be implemented clinically, as it allows the clinical utility to be evaluated
and the accuracy of the predictions to be tested.
 The inclusion of additional predictors. Currently, the model input variables are the
dose distributions for each organ and the tumour, along with the patient gender
and age at the time of treatment. Demographic specific toxicity models, which
could give information on baseline risks or histories of certain complications, are
not included. In addition, further information regarding the tumour stage at the
time of treatment and the presence or absence of concurrent treatment could lead
to more informed predictions.
 Individualised medicine and precision medicine have been gaining increased atten-
tion in recent years [103]. These approaches involve individual-specific treatments
where individual variability is taken into account. While the model developed in this
work aims to achieve this goal, there remains the potential for future development
as advances are made in the field of genomics and as biomarkers are identified.
 Several of the parameters used in the model were not clinically founded due to a lack
of appropriate data. However, as an increasing number of patients receive proton
therapy treatment, and their treatment outcomes are recorded in multi-institutional
data registries, it will be possible to gather observations of clinical outcomes and to
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adjust the prediction through a mechanism of gradual feedback. This is also true
for the quality of life utility weights. Therefore, it is possible to continuously refine
the parameters in the toxicity models [28].
 A major limitation of the proposed style of patient selection system is that two
treatment plans are required as input for the model to produce a comparison. This
corresponds to a greater time investment from clinic staff. Automated planning has
been proposed to address this issue [104] by facilitating the automatic generation
of robust proton plans with a dose mimicking algorithm. Combining similar work
with the model presented here would assist in addressing this practical aspect of
clinical implementation.
 As proposed by Langendijk et al. [28], a possible future application of the model that
has been developed is to investigate the efficacy of proton therapy in the treatment
of certain indications. For example, while the model predicted that the majority
of patients in the cohort considered in the publication P3 would receive a clear
benefit from proton therapy, not all patients were treated with proton therapy for
various reasons. Observations of the clinical outcomes of these patients would make
for an interesting comparison with the outcomes of those patients who did receive
proton therapy. As the two groups were predicted to have similar outcomes, any
differences in observations could potentially be attributed to the proton treatment.
Similar studies could be conducted in the future to investigate the efficacy of proton
therapy.
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